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CHAPTER 1. 
INTRODUCTION 
1 . 1 SCOPE OF THE STUDY 
In this thesis the history, biosynthetic pathways and biological 
activities of leukotrienes is being reviewed. Their contractile effects 
on lung parenchymal strips and their formation by macrophages are 
investigated. In addition the action of specific synthesis inhibitors is 
determined. These two approaches were chosen , firstly to investigate the 
mechanism of action of these potent bronchoconstrictive agents and 
secondly to determine the capacity of cells to generate the whole cascade 
of arachidonic acid products, to which leukotrienes belong. Leukotrienes 
belong to the so-called eicosanoids , which also comprise the group of 
prostaglandins and mono-hydroxy eicosatetraenoic acids. The results 
presented in chapters ~ and 4, show that the three main groups of 
eicosanoids have different biological effects and are able to interact 
with each other. 
1.1.1 ~ode of action of leukotrienes on lung parenchymal strips 
It has been shown that the guinea pig lung parenchyma is particularly 
sensitive to the bronchoconstrictive effect of leukotrienes. During 
contractions induced by these compounds, another eicosanoid , thromboxane 
A2 , is formed. This substance has been shown to be both a potent 
vasoconstrictor and bronchoconstrictor. The decrease in contractile 
activity induced by specific synthesis inhibitors and beta adrenergic 
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agents was investigated and the effects of their antagonists were 
determined. The release of thromboxane A2 following to contractions with 
phospholipase A2 was studied in guinea pig lung and compared with the 
effects on human and porcine parenchyma. In addition, it was the aim of 
these studies to further investigate the mechanisms of action of the 
leukotrienes, in particular in so far as their role in respiratory 
diseases is concerned. 
1.1.2 Formation oF leukotrienes and other eicosanoids by chopped tissue and 
macrophages 
The next step was to further define the role of the formation of 
arachidonic acid metabolites as measured in chopped human lung tissue. 
The development of chromatographic methods made it possible to separate a 
number of structurally closely related compounds in tissue extracts and 
incubation media. Starting-point of this part of the investigations was 
the idea that a relationship existed between the biological response and 
the formation in the tissue of one or more compounds belonging to the 
group of the eicosanoids. 
Subsequently, a number of experiments are described in which the 
production of leukotrienes and other eicosanoids by particularly human 
macrophages, obtained from ascites of patients with liver cirrhosis, was 
determined. 
Arachidonic acid derived products play an important role in the 
regulation of the inflammatory process. Finally therefore the use of 
specific synthesis inhibitors in relation to the participation of 
leukotrienes in the pathogenesis of asthma and related inflammatory 
diseases was investigated. 
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CHAPTER 2 
EICOSANOIDS 
2.1 INTRODUCTION 
The voluminous literature on prostaglandin and leukotriene research 
explains the growing interest in the biological activity of compounds of 
the family of eicosanoids. These substances are generated from 
unsaturated fatty acids by tissues and cells. Their discovery and the 
development of their chemistry has led to advances in pharmacology and 
clinical medicine. Although the structure and chemistry of eicosanoids 
are now well established, it is still difficult to assign specific 
biological functions to each of these substances. The lack of a clear-cut 
functional definition is attributable to several factors. 
Firstly, tissues can synthesize several eicosanoids or respond to more 
than one. Secondly the response of a tissue to eicosanoids may reflect 
the type and number of receptors that it contains for only one specific 
prostaglandin or leukotriene. Thirdly, because a number of biological 
active eicosanoids are inactivated rapidly after they are synthesized, 
they cannot always be detected by the physiological parameters used as 
indicators of their effect. Finally eicosanoids are involved in many cell 
to cell interactions as mediators, in which other derivatives of 
arachidonic acid can cause opposite effects. 
The properties and potencies of biologically active eicosanoids on a 
specific tissue prove to be wide ranging. Since the elucidation of the 
structure of leukotrienes, a large number of different actions has 
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been found at physiological concentrations. This suggests that 
leukotrienes, like prostaglandins, may be of important biological 
significance in most tissues of the body. 
Eicosanoids as potent naturally occurring biological modulators are 
becoming prominent in cardiovascular diseases [Moncada,1982; Berkowitz et 
al., 1984], dermatology [Kragballe and Voorhees,1983], cancer [Hohn et 
al., 1983], asthma [Weiss et a1.,1982] and inflammatory diseases [Bonta 
and Farnham, 1982]. In this chapter current knowledge of the biochemistry 
and physiology of eicosanoids will be discussed, with particular emphasis 
on the role of leukotrienes on lung parenchyma and their formation by 
macrophages. 
2.2 HISTORY 
In 1930 Kurzok and Lieb, two New York gynecologists, discovered the 
muscle-stimulating actions of seminal fluid on the human uterus. 
Subsequently, Goldblatt in England [1935] and Von Euler in Sweden [1936] 
independently described some of the actions of seminal plasma on smooth 
muscle. Von Euler, who believed that the myometrial-contracting activity 
originated from the prostate, called the active substance -prostaglandin-. 
Bergstrom and Sj5vall [1957] established that prostaglandin was a mixture 
of biologically active compounds. It was not until 1959, however, that 
Eliassen discovered that the seminal vesicles were the origin of 
prostaglandins. 
Working with acidified lipid extracts from sheep seminal vesicular 
glands, Bergstrom [1964] demonstrated that the active principle was 
present in a fraction containing unsaturated hydroxy acids. Monitoring of 
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these products was until then performed by biological assay systems. 
Independently of each other, Bergstr5m [1964] and Van Dorp [1964] 
performed studies, in which 3H-labelled arachidonic acid was incubated 
with homogenates from sheep seminal vesicles, which led to the new and 
important concept that prostaglandins are derived from essential fatty 
acids, constituents of membrane phopholipids. 
The next significant biological step was the demonstration by Vane et 
al., [1971], that aspirin and other nonsteroidal anti-inflammatory 
compounds inhibited cycle-oxygenase, the enzyme that catalyzes the 
transformation of arachidonate to prostaglandins. Just before this 
finding, Piper and Vane [1969] observed the release of a substance during 
anaphylaxis on guinea pig lung, which had a contractile effect on rabbit 
aorta. This rabbit aorta contracting substance (RCS) was not a classical 
prostaglandin such as E2 , although aspirin and indomethacin inhibited its 
formation. Shortly thereafter [1973] Vargaftig and Zirinis reported RCS 
formation by platelets during aggregation, after addition of arachidonic 
acid. It has taken another two years before this substance was named as 
thromboxane A2 , at that time believed to be the most potent 
vasoconstrictor and platelet aggregator known [Hamberg et al.,1975]. This 
short-lived intermediate is formed via biologically active, unstable 
endoperoxides, which are intermediates in the transformation of 
arachidonic acid to prostagl.andins [Hamberg and Samuelsson,1973]. 
The next breakthrough in prostanoid research was published in 1976 by 
Moncada and co-workers. They observed that prostacyclin (the so-called 
PGX), formed by endothelial cells, prevented platelet aggregation and had 
strong vasodilator properties. 
The discovery of leukotrienes and related compounds goes parallel to this 
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50-years history of prostaglandin research. 
Spasmogenic substances in the plasma of patients suffering from asthma 
were discovered in 1922. They were also described in 1930 by Harkavy in a 
study performed with ethanol extracts of sputum of patients before, during 
and after an asthmatic attack. The dissolved residue from patients during 
an attack caused contractions of both the cat jejunum and the rabbit 
duodenum. 
Some years after this finding Feldberg and Kellaway [1938] investigated 
the spasmogenic substances released after cobra venom infusion into guinea 
pig lungs, and compared their effects to those of histamine. Shortly 
thereafter Kellaway and Trethewie [1940] discovered the presence of a slow 
reacting smooth muscle stimulating substance (SRS-C) during anaphylaxis. 
The name slow-reacting substance of anaphylaxis (SRS-A) was introduced by 
Brocklehurst in 1960. Orange and Austen described in the late sixties a 
number of characteristics of SRS-A. The first experiments in which SRS-A 
preparations were administered to asthmatic subjects by aerosol date from 
1966 by Herxheimer and Stresemann. 
Pharmacological investigations proved that mast cells were responsible 
for the release of histamine, whereas SRS-A was predominantly produced by 
leucocytes [Orange and Austen,1968]. In 1974 Back and Brasher discovered 
that challenge of rat peritoneal cells with the calcium ionophore A23187, 
in the presence of calcium, resulted in the generation of SRS. 
Incorporation of large amounts of cysteine increased the SRS production. 
This observation led to structural work, using new methods such as mass 
spectrometry, to obtain highly purified SRS-A from biological extracts 
[Blackwell et a1.,1980]. Although it became clear that SRS-A did not 
belong to the group of prostaglandins, it still was believed that 
arachidonic acid could be the precursor of SRS-A [Jakschik et a1.,1977]. 
It was the group of Samuelsson who finally, in collaboration with Borgeat, 
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suggested that dihydroxy acids, with functional groups on the 5 and 12 
positions, were derived from a hypothetical epoxy-eicosatetraenoic acid 
intermediate, which they named leukotriene [Borgeat and 
Samuelsson,1979]. 
This was the first step leading to the discovery of a whole cascade of 
biologically active substances, called leukotrienes [Samuelsson et 
al. ,1980]. Subsequent work showed that SRS-A was in fact a combination of 
at least 2 of these leukotrienes (LTs). In 1984 Serhan et al. isolated 
another class of metabolites of arachidonic acid, the trihydroxy 
eicosatetraenoic acids or lipoxins. These are not derived from the same 
intermediate as leukotrienes, but through a different lipoxygenase 
pathway. The biological importance of these group of substances is still 
unknown. During the last few years a number of LT-derivatives have been 
introduced, which will be discussed later in the section Biosynthesis of 
leukotrienes. 
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2.3 PRECURSORS OF EICOBANOIDB 
Eicosanoids are formed from essential fatty acids and are present 
throughout the body. The prostaglandins (PGs), leukotrienes (LTs) and 
related compounds are called eicosanoids, because they are derived from 
20-carbon containing essential fatty acids that include three, four or 
five double bonds. The substrate for the biosynthesis of eicosanoids, 
arachidonic acid (AA), is structarally a part of phospholipid, 
triglyceride and cholesterol (Fig.1.). The essentiality of unsaturated 
dietary fatty acids was first observed by Burr and Burr in 1929. The 
clinical and biochemical consequences of deficiences of these fatty acids, 
could be reversed by feeding linoleic acid to mammals. In figure 2 the 
conversion of linoleic acid to the precursor of the eicosanoids is shown. 
In this thesis only the formation of metabolites derived from AA and their 
effects were investigated, and for that reason, only the pathways involved 
will be discussed in detail. Linoleic acid is desaturated and elongated 
via gamma-linolenic acid and dihomogammalinolenic acid to AA. The 
structure of each essential fatty acid (EFA) is fully described by three 
distinguishing marks in the generally accepted nomenclature. 
PLA1---------,~ II 
0 CH2 - 0 - C - R1 
II I 
R2 - C - 0 - C o- CH3 t I I I 
::' ________ C_H_2_.t 0 -I r OCH,cH, - t CH, 
PLD ------------------------~-
Fig.1 Differential action of phospholipases 
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The notation of AA is C20 4 w 6, in which 20 is the number of carbon 
atoms in the chain, 4 is the number of the double bonds and w 6 means the 
number of carbon atoms between the terminal unsaturated bond and the final 
methyl group of the EFA. 
Linoleic acid is the major dietary EFA in humans [Burr and Burr,1929], 
and is present in vegetable seed oils and milk products. Linoleic acid 
cannot be synthesized by man and has to be present in the daily food 
intake [Vincent et al.,1975]. Gamma-linolenic acid is found in evening 
primrose oil. The minimum daily intake of AA in rats needed to obtain 
sufficient prostaglandin formation by cells, is 1 mg/day [Horrobin,1983]. 
_ COOH ~ linoleicacid 
! C18:2, w 6 
~ rlinolenic acid 
! C18:3, w 6 
~OH 
-- - dihomo rlinolenic acid 
! C20:3, w 6 
~OH 
-- -- arachidonic acid 
C20:4, w 6 
Fig.2 Conversion of linoleic acid to arachidonic acid, 
the precursor of eicosanoids 
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The amount of linoleic acid in the diet is correlated with the 
concentration of AA metabolites, the PGs, in the urine [Nugteren et 
a1.,1980]. Much work has been done with EFA deficient diets in 
experimental models [Kort,1987], rat blood platelets [Vincent and 
Zijlstra, 1976, 1978] and man to investigate the significance of EFA in 
disease [Yamanaka,1981]. Pitfalls of the use of EFA deficient rats for 
the study of the role of prostaglandins in pathophysiology was reviewed by 
Farnham et al. [1979]. 
Slight increases in the linoleic acid content of the diet led to the 
production of appreciable amounts of endogenous PGs in platelets. In 
conclusion it was found that, when a triene I tetraene ( 20:3(n-9) I 
20:4(n-6) ) -ratio of 6 or more was achieved, a high level of deficiency 
was present. EFA deficiency exerted an anti-inflammatory effect in both 
acute and chronic inflammation [Bonta and Parnham,1982]. 
Recently, macrophage fatty acid metabolism and function in EFA deficient 
mice were described [Lefkowith et a1.,1987]. EFA deficiency was shown to 
decrease phosphatidylinositol in peritoneal macrophages. After 
stimulation with zymosan, control macrophages synthesized LTC4 and LTB4 , 
whereas EFA deficient macrophages synthesized markedly less LTC4 and also 
metabolized 20:3(n-9) to LTC3 . EFA deficient macrophages synthesized 
minimal amounts of LTB4 . The prostaglandin production was only minimally 
affected by EFA deficiency. The lack in leukotriene formation by EFAD 
macrophages could be responsible for the anti-inflammatory and protective 
effect of the deficiency state. 
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2.4 BIOSYNTHESIS OF EICOSANOIDS 
2.4.1 Phospholipases 
Eicosanoids are synthesized in the cell membrane from AA, which is 
released from membrane phospholipid and other lipid esters by the action 
of a phospholipase. (Fig.1.) Phospholipase can be activated by a variety 
of stimuli, and its activation is evidently the initial and rate-limiting 
step in eicosanoid biosynthesis [Lands,1979]. In response to this 
stimulus, phospholipase A2 (PLA2 ) or a combination of phospholipase C 
(PLC) and diglyceride lipase, catalyze the cleavage of an esterified 
eicosanoid precursor from the 2 position of specific glycerophospholipids 
[Blackwell and Flower,1983]. Arachidonic acid can also be released either 
from diacylglycerol or from phosphatidic acid. This could be one reason 
that the so-called selective inhibitors of PLA2 , are insufficiently 
selective to discriminate between the direct PLA2-dependent pathway and 
this indirect one [Lapetina et a1.,1981; Hofmann et a1.,1982]. 
Arachidonic acid can be activated by several distinct enzyme systems. 
PLA2 activity is dependent on the availability of intracellular Ca
2+, 
intracellualar cAMP content [Van den Bosch,1980] and the activity of 
lipocortin. This has been shown in several celltypes. 
Lipocortin is a glucocorticosteroid induced polypeptide. It has been 
isolated from macrophages (M¢), neutrophile and renomedullary interstitial 
cells [Blackwell et a1.,1982; Hirata et a1.,1980; Cloix et a1.,1983]. 
Both PLA2 and PLC are inhibited by lipocortin. Enhanced eicosanoid 
production was observed in several tissues and in macrophages of 
adrenalectomized rats, probably due to a diminished formation or 
inactivation of lipocortin. [Vincent et a1.,1986]. 
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Cell activation appears to be dependent on the turnover of phosphatidyl 
inositol, mediated by PLC, which results in the elevation of ca2+ into the 
cell and activation of PLA2 and protein kinase C and consequently the 
release of eicosanoids (the indirect pathway [Lapetina et a1.,1981]). 
The inactivation of lipocortin through phosphorylation is carried out by 
a tyrosine kinase which is activated by stimulating agents. Tyrosine 
kinase itself is regulated by phosphorylation by serine kinases. The ca2+ 
dependent protein kinase C activates it and the cAMP dependent protein 
kinase A, deactivates tyrosine kinase [Hirata et a1.,1984]. Receptor 
mediated, PLC dependent reactions can be mimicked by the Ca2+ ionophore 
A23187. In fig.3 interactions between ca2+, cAMP and PLA2 are presented. 
phosphorylation 
==C> inhibition 
....... stimulation 
Fig.3 Interactions between lipocortin, Ca2+-elevation, cAMP and PLA2 . 
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In this scheme [ace. to Schenkelaars,1985], a summary is given, comprising 
the PLA2 dependent and independent AA release, the inhibition of the PLA2 
dependent AA release by l'ipocortin and the inactivation of lipocortin by 
phosphorylation through tyrosine kinase. Following this scheme both an 
increased cAMP level and an enhanced lipocortin concentration will result 
in a diminished eicosanoid production. An increased ca2+ elevation, on 
the contrary, stimulates eicosanoid formation. 
2.4.2 Prostaglandins 
Prostaglandins are cyclic fatty acids that contain 20 carbon atoms similar 
to the basic carbon skeleton of the hypothetical parent compound, 
prostanoic 
Fig.4 
acic (Figure 4.). A prostaglandin (PG) consists of a 
~ )( X ICOOH 10~9 8f'''''w w w 
. 20 
11 12 14 16 18 
13 15 17 19 
The hypothetical parent compound, prostanoic acid 
PGD PGE PGFa 
Ring structures of three primary prostaglandines. 
PGG/H 
9~ 
u 
"' R2 
cfH 
PGI 
ex:1 ' 0 2 
TXA 
The cyclic endoperoxides, prostacyclin and thromboxane A 
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cyclopentane ring and two aliphatic side chains. The synthesis of PGs 
from AA is preceded by the oxygenation and cyclization of the pentane ring 
by cyclooxygenase, leading to an unstable c 15 hydroperoxy, o9 o 11 
endoperoxide, prostaglandin G2 Endoperoxides, which are 
chemically unstable, form the intermediate substrates for tissue-specific 
synthesis of a variety of biologically active PGs [Flower,1978]. Each PG 
is designated by a letter and a subscript, indicating the nature of the 
cyclopentane substituents and the number of double bonds, being dependent 
upon the precursor. In this case, dienoic acid is synthesized from AA, 
mentioned as the 2-series (Figure 5). Another cyclooxygenase product is 
0 2 cyclooxygenase 
Fig.5 Formation of prostaglandins, prostacyclin and thromboxane 
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thromboxane A2 (TxA2 ), ~ormed by an enzyme and ~irst isolated ~rom human 
platelets. TxA2 has a·very short chemical hal~-life (T~=30 seconds at 
37•c and pH 7.5), and it breaks down non enzymatically into the stable 
thromboxane B2 (TxB2 ). Formation of thromboxane A2 is inhibited by 
aspirin and other non-steroidal anti-inflammatory compounds, via the 
inactivation of cyclooxygenase [Vane,1971]. In comparison to other 
cyclooxygenase inhibitors (indomethacin ,ibuprofen) , the inactivation by 
aspirin is markedly prolonged. 
Considerable effort has been made to discover selective inhibitors of 
thromboxane synthetase. This enzyme is inhibited by imidazole and 
imidazole derivatives such as dazoxiben [Moncada,1977] and by other 
compounds such as nicotinic acid [Vincent and Zijlstra,1978]. 
Another route of metabolism of PGG2 leads to prostacyclin (PGI2 ), which 
is also an unstable compound {T~=3 minutes at 37°C and pH 7.5), ~ormed by 
an enzyme, prostacyclin synthetase. PGI2 was first discovered in vascular 
tissue and dif~ers chemically from other PGs in that it has a double-ring 
structure, which includes a ~urane ring. It is hydrolyzed non 
enzymatically into the stable compound, 6-keto-prostaglandin F 1a (PGF1a) 
[Moncada,1976]. 
The prostaglandins of the E2 , D2 and F2a type are usually referred to as 
the primary PGs, although they are products o~ the same intermediates PGG2 
and PGH2 . These prostaglandins are the so-called stable prostaglandins. 
They are however rapidly converted into biological inactive compounds Two 
main pathways exist for the catabolism of PGs. By the enzyme 
prostaglandin 15-hydroxydehydrogenase, p~ are oxidized to the 
corresponding ketones and further reduced to obtain 13,14-dihydro,15-keto-
PGs. These metabolites are excreted via the urine [Lands,1979]. 
Recently PGD2 was found to be stereospecifically converted into the 
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compound 9~,11~-PGF2 by a human lung and liver cytosolic NADPH-dependent 
11-ketoreductase [Seibert et a1.,1987]. This substance is a potent 
bronchoconstrictor and is released into bronchoalveolar lavage fluid after 
allergen stimulation in patients with allergic asthma. 9~,11~-PGF2 is 
poorly inactivated in situ. This led to the conclusion that this 
particular compound may participate, along with other mediators, in the 
pulmonary response in humans. The biological activities of PGs and TxA2 
are summarized in table 1 . 
TABLE 1 
SOME BIOLOGICAL ACTIVITIES OF PROSTAGLANDINS 
(C =contraction; R = relaxation; +=stimulates; - = inhibits; ? = unknown) 
Effect on cell or tissue 02 E2 F2a 12 T~ 
smooth muscle vascular R R c R c 
respiratory R R c R c 
gastrointestinal ? C/R c c ? 
platelet aggregation ? + 
provoke edema ? + + + ? 
fever ? + ? ? ? 
pain ? + + ? 
chemotactic activity ? +(?) + +(?) 
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2.4.3 Leukotrienes 
As already mentioned the leukotrienes (LTs) are generated through 
mobilization o~ arachidonic acid ~rom phospholipids, mediated by a 
phospholipase. From arachidonic acid as a precursor, LTs o~ the 4-series, 
compounds with 4 double bonds are synthesized [Borgeat and 
Samuelsson,1979]. Leukotrienes are ~ormed via the enzyme 5-lipoxygenase 
through an intermediate, 
lipoxygenase generating 
the leukotriene A4 . This is the most 
these biologically active 
important 
substances 
[Samuelsson,1980]. In ~ig.6 the metabolism o~ AA via the 5-lipoxygenase 
through 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and LTA4 is shown. 
Fig.6 Formation o~ leukotrienes and other 5-lipoxygenase products 
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The enzymatic conversion of the subsequent LTs by the conjugation with 
glutathion leads to the cysteine-containing sulfidopeptide leukotrienes 
(fig. 7). 
~COOH ~ 
LT~ 
LTC4 
LTD4 
LTE4 
LTF4 
R 
Cys-Giy-Giu 
Cys-Giy 
Cys 
Cys-Giu 
Fig.? Substitution of amino acids on the 5-lipoxygenase intermediate, 
leukotriene A4 , to obtain sulfidopeptide leukotrienes 
The potencies of LTs are 100-1000 times that of histamine in the 
contractile reponse of the guinea pig ileum [Piper and Samhoun,1983]. 
Intravenous infusion of LTC4 , LTD4 and LTE4 caused a dose dependent 
bronchoconstriction in unanaesthesized mechanically ventilated guinea pigs 
[Drazen et al.,1980]. This constriction can be partly blocked by the 
cyclooxygenase inhibitor indomethacin, suggesting that bronchoconstriction 
is mediated via PGs [Leitch,1984]. This mechanism of action is described 
in detail in the results presented in chapter 3. Constriction of coronary 
arteries was observed in some cases, predominantly in experimental models 
[Feuerstein,1985]. In rat peritoneal macrophages lysosomal enzyme release 
was activated by LTC4 [Schenkelaars and Bonta,1983] and PGE2 release 
increased, whereas the formation of TxB2 was decreased dose-dependently. 
The increased release of cyclooxygenase products by LTC4 is in agreement 
with the observations with guinea pig lung parenchyma. A summary of 
biological activities is given in table 2. 
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TABLE 2 
SOME BIOLOGICAL ACTIVITIES OF LEUKOTRIENES 
(C =contraction; +=stimulates; 0 = no effect; ? = unknown) 
Effect on cell or tissue LTB4 LTC4 LTD4 LTE4 
smooth muscle vascular ? c c 0(?) 
respiratory c c c c 
chemotactic activity + 0 0 0 
vascular permeability + + + + 
>>edema 
degranulation + + + 0 
The production o~ leukotrienes o~ the C,D,E and F-type has been 
investigated with exogenous AA in human cells. Besides the 
polymorphonuclear cells [Borgeat and Samuelsson,1979], production was also 
observed in human peritoneal macrophages [Ouwendijk,1985], human alveolar 
macrophages [Fels et a1.,1982], eosinophile [Borgeat et a1,1984; Henderson 
et a1.,1984] and mast cells [Peters et a1.,1984]. LTB4 is predominantly 
generated ~rom neutrophils [Palmer and Salmon,1983] and ~urthermore by 
PMNLs, macrophages and mast cells [Bray,1984]. 
In aspirin-sensitive asthmatic patients total cell counts ~rom broncho 
alveolar lavage were increased, and the number o~ the eosinophils was 
highly increased [Godard et a1.,1982]. Increased cell activity is 
re~lected in the release o~ lysosomal enzymes, and in increased 
leukotriene production, similar to that observed during phagocytosis 
[Rouzer et a1.,1980]. By the action o~ the very potent chemotactic agent 
LTB4 , granulocytes adhere to blood vessels and leukocytes migrate to 
in~lammatory regions. 
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2.4.4 Other lipoxygenase products 
A number of enzymes has been discovered that peroxidize arachidonic acid 
in different positions. The most important of these is the 5-
lipoxygenase. The action of this enzyme results in the formation of 
leukotrienes (see 2.4.3). Hydro-peroxy eicosatetraenoic acids (HPETEs) 
are relatively unstable and are reduced enzymatically or non-enzymatically 
to the corresponding hydroxy- eicosa tetra enoic acids. HPETEs are not 
cyclic compounds; their structure consists of the parent fatty acid with a 
hydro-peroxy substituent. The position of this group is designated by a 
numerical prefix, indicating the carbon position of the substitution. The 
first enzyme was originally found in lung and platelets [Nugteren,1977], 
and is responsible for the formation of lipid peroxides, such as 12-
hydroxy- eicosatetraenoic acid (12-HETE). In figure 8 the 11-,12-, and 
the 15-lipoxygenase pathways are given. In fig.6 it was shown that 
besides the di-HETE which is LTB4 , other di-hydroxy- eicosa tetra enoic 
11·HETE 
12-HETE 
8, 9, 12-THETE 
15-HETE 
Fig.8 Formation of mono- and di-hydroxy tetraenoic acids and tri-hydroxy 
trienoic acids via other lipoxygenases 
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acids were formed. A degradation product of 15-HPETE is also a di-HETE, 
the 8,15-DHETE. Via the 12-HPETE route a hydroxy epoxy eicosa tri enoic 
acid is formed, from which two tri-HETEs proceed. 
The biological effects of (mono)HETEs on the vascular system appear not 
to be of significant importance. 5-HETE produces slow contractions of 
isolated human bronchial smooth muscle, with a potency comparable to that 
of histamine. 15-HETE is less potent than histamine, whereas 12-HETE is 
inactive. 5-HPETE and 5-HETE may be required for the release of histamine 
from basophils, and they promote the secretion of histamine and other 
substances from mast cells [Leitch,1984]. The effects of these substances 
on gastrointestinal smooth muscle have not been well studied. 
Chemotactic activities of HETEs have been established, but proved to be 
less active than LTB4 . Cunningham et al have suggested that mono hydroxy 
derivatives of AA may contribute to the inflammatory process, observed in 
psoriasis. The AA-induced aggregation of platelets and the secretion of 
cyclooxygenase products was inhibited by 12-HPETE [Aharony et al.,1982]. 
15-HETE proved to be a potent inhibitor of prostacyclin formation in human 
arterial segments [Yamaja and Stuart,1986] and also stimulates the LTB4 
and 5-HETE formation in mast cells [Vanderhoek et al.,1982]. The 12-
lipoxygenase pathway is possibly inhibited by 15-HETE [Fletcher-Cieutat et 
al.,1985]. It has been suggested that HETEs, like the LTs c4 and n4 , 
increase the mucus secretion and vasopermeability of the lungs [Johnson et 
al,1985]. 
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2.5 EICOSANOIDS AND THE LUNG 
Three criteria must be ~ollowed in order to prove that eicosanoids are 
indeed involved in allergic and other in~lammatory respiratory diseases. 
Firstly it must be shown that eicosanoids are generated in disease or 
during an asthma attack; secondly the administration o~ synthetic 
eicosanoids must cause symptoms which are comparable to those o~ the 
disease under study and ~inally intervention with selective inhibitors o~ 
the biosynthesis o~ eicosanoids must have bene~icial e~~ects. 
In vivo ~ormation. Three animal models have been developed in which an 
anaphylactic response can be associated with the production o~ 
leukotrienes, i.e. guinea pigs [Ritchie et al.,1981], greyhound dogs 
[Hirshman et al.,1982] and sheep [Abraham, 1987]. A~ter anaphylactic 
reactions, human lung tissue generates large amounts o~ leukotrienes 
[Drazen and Austen,1987]. Plasma levels o~ eicosanoids are enhanced 
during an asthma attack [Keppler et al., 1985] 
Intravenous administration 0~ and causes 
bronchoconstriction in unanaesthesized guinea pigs [Drazen et al.,1980]. 
Aerosol administration o~ LTC4 and LTD4 to normal man results in dose-
dependent bronchoconstriction [Weiss et al.,1982], with the e~~ect 
persisting ~or at least 30 min. These LTs are active as 
bronchoconstrictors at concentrations 600-9500 times lower than histamine. 
Intervention. The therapeutic implications ~or asthma are considerable, 
and competitive inhibitors or a specific 5-lipoxygenase inhibitor, 
suitable ~or administration in man, could be major additions to the 
pharmacotherapy of this disease. FPL 55712, a relatively specific 
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antagonist of SRS-A (LTs c4 and D4 ) inhibits the contractile effects of 
SRS-A in guinea-pig [Drazen ot al.,1979] and human lungs [Ghelani et 
al.,1980]. At present there have been no reports of the use of a 
leukotriene receptor antagonist useful in man. 
The SRS-A induced bronchoconstriction in guinea pigs differs from that 
seen after infusion of histamine, bradykinin or PGF2a in that SRS-A. has a 
preferential effect on the pulmonary compliance, and a prominant action in 
the pulmonary periphery, with a prolonged duration of action. 
It has been shown that injection of SRS-A into the pulmonary artery of 
isolated perfused guinea pig lungs results in the release of 
prostaglandins and thromboxane [Engineer et al.,1978]. These observations 
suggest that some of the contractile effects of SRS-A in these species may 
be due to bronchoconstrictor cycle-oxygenase products synthesized in 
response to SRS-A. 
The in vitro effects on the contractile response of superfused guinea 
pig lung strips of LTC4 , LTD4 and LTE4 are substantially inhibited by 
indomethacin [Piper and Samhoun,1981]. The enhanced plasma concentrations 
of thromboxane seen in guinea pigs after leukotriene infusion [Omini et 
al.,1981], may be generated by the lung or platelets. 
LTC4 and LTD4 have been shown to increase the release of mucus from 
human airways in vitro [Maron et al.,1982] and to induce a dose-related 
increase of glucoprotein secretion by human bronchial mucosa [Coles et 
al.,1983]. The presence of SRS-A or leukotrienes in the sputum of 
patients with chronic bronchitis and emphysema may also indicate a 
pathogenic role for these substances [Hirschman et al.,1982]. Conversion 
into the 11-trans-leukotriene occurs spontaneously with 100-fold loss of 
biological activity [Lewis et al.,1980]. 
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Implications in the pathogenesis of allergic diseases. Since 
sulphidopeptide leukotrienes can be released from human mast cells and 
alveolar macrophages, these products are likely to be implicated in the 
pathogenesis of asthma, where their properties as bronchoconstrictors, 
secretagogues and permeability-enhancing agents can make a major 
contribution to the known clinical manifestations of this disease. 
Chemotaxis of inflammatory cells by LTB4 may contribute to the late phase 
response to antigen challenge in man. 
In Chapter ~ the biological activities of LTs on lung parenchymal strips 
and the effects by antagonists and synthesis inhibitors are presented in 
detail. In Chapter 4 the formation of eicosanoids by chopped lung tissue 
and macrophages are studied; in the last paragraph the effects of a 
substance, found to inhibit specifically the 5-lipoxygenase, are 
summarized. 
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2.6 EICOSANOIDS AND THE LIVER 
The investigations on chemical structure, metabolism and biological 
actions of the leukotrienes have contributed to a better understanding of 
some liver diseases and therapeutic interventions. The liver plays an 
important role in the metabolism of eicosanoids. 
In the group of prostaglandins PGI2 is converted by the lung in the 
biologically inactive substance 6-keto-PGF 1 ~, which in turn is metabolized 
to 6-keto-PGE1 . This substance is a potent vasodilator and inhibitor of 
platelet aggregation [Wong et al., 1981; Lewis et a1.,1984]. PGD2 is 
converted stereospecifically via PGF2~ to the compound 9~,11B-PGF2 by a 
11-ketoreductase [Liston and Roberts,1985]. This substance is also a 
inhibitor of platelet aggregation, and in contrast with 6-keto-PGE1 a 
potent vasoconstrictor. 
A possible role of the liver in the degradation of biologically active 
leukotrienes was suggested by studies on its metabolism after intravenous 
administration. It was found that LTs were taken up rapidly by hepatocytes 
and that sulphidopeptide LTs were excreted in the bile [Uehara et 
a1.,1983; Hagmann et a1.,1984]. Renal failure is associated with 
insufficient degradation of cysteinyl containing LTs by the liver. 
Liver cells can also generate eicosanoids. The most important producer 
cells of leukotrienes are macrophages, monocytes, neutrophile, eosinophile 
and mast cells. Recently also Kupffer cells were shown to release LT-
material upon stimulation [Decker,1985; Ouwendijk,1985]. Hepatocytes, the 
main cell type in the liver, can generate thromboxane when stimulated with 
vasopressin [Chong et a1.,1983]. Hepatocytes and Kuppfer cells mainly 
generate PGD2 and PGF2~ [Kuiper et a1.,1987]. 
The major action of LTB4 after administration in vivo is to recruit 
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leukocytes. This chemotactic property is responsible for the effect of 
LTB4 as an important mediator of inflammatory cell infiltration. The 
immunoregulatory effects of LTB4 include inhibition of the proliferation 
of T-lymphocytes [Keppler et al., 1985] , but also stimulation of the 
activity of natural cytotoxic cells [Rola-Pleszczynski et a1.,1983] 
Endotoxin is a potent trigger for cysteinyl containing LT production in 
vivo [Hagmann et a1.,1984]. It is an example of a hepatotoxin which 
initially interacts with Kupffer cells and other mononuclear phagocytes 
and subsequently leads to inflammatory cell infiltration and 
hepatocellular necrosis. 
Drugs interfering with LT synthesis or action prevent or reduce the 
increase in 5-lipoxygenase activity in plasma, resulting from hepatocyte 
injury. Protective action was exerted by diethylcarbamazine which 
inhibits LTA4 synthesis and also by FPL 55712 which is a receptor 
antagonist for cysteinyl containing LTs [Bach,1984]. Protection was also 
achieved by pretreatment with BW 755C, which is both a lipoxygenase and a 
cyclooxygenase inhibitor [Higgs et a1.,1984]. BW 755C reduced leukocyte 
migration and edema provoked with carrageenin, whereas low-dose 
indomethacin did not prevent leukocyte migration, indicating that LTs were 
responsible. Dexamethasone, which antagonizes arachidonate liberation by 
the synthesis and release of the anti-phospholipase protein, lipocortin, 
had the same effect as BW 755C [DiRosa et a1.,1984]. Flavonoids, some of 
which are used in clinical and experimental hepatoprotection, are potent 
inhibitors of the 5-lipoxygenase pathway [Yoshimoto et a1.,1983]. 
Inhibitors of leukotriene synthesis or action, protect against lethal 
endotoxin shock in experimental models [Hagmann et a1.,1984]. The 
degradation and elimination of the LTs c 4 , D4 and E4 seems to be important 
after severe trauma and tissue injury and in pancreatitis [Keppler et 
a1.,1985]. 
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The kidney serves as an alternative organ for elimination of LTs in man, 
as well as a target organ for these LTs causing renal vasoconstriction and 
decreased glomerular filtration rate [Badr et al.,1984]. Inhibition of PG 
synthesis resulted in a hepatorenal syndrome in cirrhotic patients with 
ascites. Selective thromboxane synthetase inhibitors did not improve 
renal functions in these patients, suggesting that LTs may be the 
predominant vasoconstrictors in this syndrome [Zipser et al.,1984]. 
Stimulated peritoneal macrophages derived from ascites of experimental 
animals and patients with ascites due to liver cirrhosis, chronic 
ambulatory peritoneal dialysis and alveolar lavages can produce 
leukotrienes such as LTB4 , LTC4 and LTD4 and prostanoids 
F2~ and TxB2 [Feuerstein et al.,1981; Adolfs et al.,1985; 
6-keto-F1 ~, E2 
Ouwendijk,1985; 
Schenkelaars, 1985; Steinhauer et al., 1 985; Laviolette et al., 1 986]. 
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2. 7 EPILOGUE 
In fig.9 the structural formulas of some of the eicosanoids, of which the 
biological effects, the synthesis by cells and amounts in body fluids were 
determined, are given. 
Besides the structural differences, these stable eicosanoids have 
varying biological activities and are synthesized in different amounts in 
different organisms or following different stimuli. 
The balance of these substances and their vase- and bronchoconstrictive 
actions (TxA2 I TxB2 , PGD2 and LTC4 ), vase- and bronchodilative actions 
(PGI2 I 6kPGF1a) and chemotactive activities (LTB4 and 15-HETE), and also 
the interactions between several eicosanoids, could be of importance in 
the regulation of the diseases described above. 
HQ 
~OOH 
f ' 0 OH 
PGD2 
?H' \ I ("l· .. ···~COOH 
HA~ 
OH 
Tx9:! I Arachidonic Acid \ 
HO. 0 ~OH 
HO·""' i 
OH 
6·Keto PGF1a 
15·HETE 
OH 
COOH 
··· .. s-CH2 
fHCONHCH2COOH 
NHCOCH2CH2yHCOOH 
NH2 
Fig.9 Structural formulas of the most occurring eicosanoids, discussed in 
the next part of this thesis. 
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CHAPTER 3 
ACTIONS ON LUNG PARENCHYMA 
3. 1 INTRODUCTION 
The actions of leukotrienes have been studied on human, porcine and guinea 
pig lung parenchymal tissues. Both the direct effect of the LT and the 
secondary effect via synthesis of biologically active substances were 
investigated. 
The effects obtained were compaired with the actions of thromboxane A2 , 
generated from aggregated platelets and a thromboxane A2 -mimetic. The 
contractions induced by phospholipase A2 were compared with those obtained 
after application of LTC4 or LTD4 • 
The influence of a .B-adrenoceptor <180nist and a .e-adrenoceptor 
antagonist on the contractile activities and release reaction induced by 
LTs were studied. 
For the assessment of the effect of leukotrienes on tissue a superfusion 
cascade was used. Eicosanoid production was measured by radioimmunoassay. 
3.1.1 Superfusion method 
In an anesthesized ventilated guinea pig the in vivo effects of substances 
on bronchial smooth muscle tissue can be investigated according to the 
method of Konzett-Rossler. This method is fast, but complicated and 
poorly reproducible. 
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A very sensitive method is the in vitro superfusion cascade, in which 
lung parenchymal strips are used. This bioassay is suitable both to 
examine the contractile effects induced by unknown substances and to 
determine the concentrations of biologically active substances in samples. 
The guinea pig lung parenchymal tissue is very sensitive to leukotrienes 
in comparison to other smooth muscle contracting agents. In the 
experiments described the contraction inducing substances were added to 
the system directly, whereas antagonists and synthesis inhibitors were 
added to the superfusion buffer and preincubated before application of the 
constrictive agent under study. 
Guinea pigs (male and female, 400-600 g) were killed by a blow on the 
head and exsanguinated. Lungs, the heart and trachea were taken out and 
washed in Krebs Henseleit buffer. Piglets (male and female, 15-20 kg) 
were anaesthesized with low-dose nembutal and exsanguinated; outer parts 
of the lungs were used for experiments. Human lung parenchyma was 
obtained from lobectomy because of tumours. Strips of about 40x3x3 mm 
were prepared. 
In figure 10 the basic set-up of the superfusion cascade system is 
presented. In the upper baths lung parenchymal strips are mounted 
("donor"-strip). The release of vasoconstrictive substances from lung 
parenchymal strips by leukotrienes and other agents was measured on rabbit 
mesenteric artery ("measurement"-strip), which was mounted in a bath 
underneath. This artery is highly sensitive to thromboxane A2 [Zijlstra 
and Vincent,1981]. 
The contractile activity was standardized before and after the 
experiment with angiotensin II and/or the thromboxane A2 mimetic U-44069. 
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chart mover 
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.::!; water 37°C 
A guinea pig lung strip 
(control) 
8 guinea pig lung strip 
(treated) 
C rabbit mesenteric artery 
Krebs+ 
(B) i 
2 channel 
roller pump 
(2 ml/min) 
Krebs 
(A) 
Fig.10. Basic set-up of a two-channel superfusion cascade system. 
Contractions were registered isotonically using a Harvard smooth muscle 
transducer and employing an isotonic load of 0.5 g which stretched the 
preparations to their optimal length as found in preliminary experiments. 
The strip was superfused with Krebs-Henseleit buffer containing NaCl 
118mM, KCl 4.7mM, CaC12 2.5mM, MgS04 1.18mM, KH2Po4 1.18mM, NaHC03 25mM nd 
glucose 5.6mM. The perfusion rate was 1.6 ml/min at 37°C. The 
superfusion fluid of the cascade system was oxygenated with 95% o2 and 5% 
Initially no antagonists were added. Constriction inducing 
substances (LTs, TxA2 or PLA2 ) were added and the resulting contraction 
and release of constricting agents were measured. After contraction was 
abolished and base-line noise achieved, antagonists or synthesis 
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inhibitors were added to the superfusion system. The reduction in 
contraction and release of constricting agents w~re registered after 
application of the same concentration of constriction inducing substance. 
Data were expressed as percentages of the first application. 
3.1.2 Radioimmunoassay 
Radioimmunoassays of eicosanoids have been especially designed for 
research purposes. They combine the use of a highly specific tracer of 
eicosanoid, an antiserum which is specific for the eicosanoid under study 
and a standard. 
This provides a rapid, simple and sensitive method for the determination 
of several eicosanoids in vitro over a range of 0 -1000 pg/tube. 
The basic principle of this radioimmunoassay is competitive protein 
binding between unlabelled eicosanoid and a fixed quantity of the 
tritiated compound for a fixed number of antibody binding sites. The 
amount of radioactive antigen bound by the antibody, is inversely 
proportional to the concentration of added non-radioactive ligand. The 
measurement of antibody-bound radioactivity enables the amount of 
unlabelled eicosanoids in the sample to be determined. Separ~tion of the 
antibody-antigen complexes from free antigen is achieved by adsorption of 
the free tracer onto dextran-coated charcoal, followed by centrifugation. 
The supernatant containing the antigen-antibody complexes is decanted into 
a counting vial and a scintillation cocktail added. The radioactivity is 
measured in a beta counter. The concentration is then calculated from a 
standard (dose-response) curve. 
Samples collected after the addition'of leukotrienes or other lung 
parenchyma constricting substances were used for the determination of 
stable thromboxane B2 . Kits ready for use were obtained from New England 
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Nuclear (Boston). Antibody was purchased from l'Institut Pasteur (Paris, 
France) and 3H-TxB2 from Amersham. TxB2 was a gift of Dr Pike (Upjohn, 
Kalamazoo, USA). Cross reactivities for other cyclooxygenase products 
were all less than 0.2% at 50% displacement. Cross reactivities for 
lipoxygenase products were not determined. 
3.2.1 
THE EFFECTS OF LEUKOTRIENES, THROMBOXANE A2 AND PHOSPHOLIPASE A2 ON HUMAN, PORCINE AND GUINEA PIG LUNG PARENCHIMA 
Reproduced from Agents and Actions, 1984; 14: 88-92, with 
permission of Birkhauser Verlag, Basel, Switzerland. 
45 
46 
Agents and Actions. vol. 14. I (1984) 
The effects of leukotrienes, thromboxane A2 and 
phospholipase A2 on human, potcine and guinea pig lung 
parenchyma 
FREDERIK J. ZIJLSTRA, J. ERIC VINCENT1 and IVAI'f L. BONTA 
Department of Pharmacology, Medical Faculty, Erasmus University, Rotterdam, P.O. Box 1738. NL-3000 DR Rotterdam, 
The Netherlands 
Abstract 
A comparison was made of the contractions, induced 
by LTD4, histamine and phospholipase A2 in parenchymal 
strips of guinea pig (GPLP), porcine and human lung in a 
cascade superfusion system. The effects of LTD 4 and 
phospholipase A2 on the release of TxA2 in these tissues 
and of TxA2, 5-HT and acetylcholine on the GPLP were 
also determined. 
In the GPLP strip, the LTC4-induced contractions are 
due for ± 80% to the release of TxA2 and for ± 20% to the 
direct effect of LTC4• 
The guinea pig tissue displayed the highest sentivity 
towards all substances, except to the contraction induced by 
histamine.. which was most effective in the porcine tissue. 
Low activities were found in the human tissue in all tests. 
The reason for these effects may be a difference in activities 
or number of cell types which participate in the reactions 
leading to the contractions. 
Introduction 
It is well known that the biologically active 
leukotrienes2 induce slow contractions in smooth 
muscles. The effects of the L T on peripheral and 
central airway functions of pulmonary tissue have 
also been described [1-3]. Recently, PIPER and 
SAMHOUN [4] reported that LTC 4 and LTD4 
induced TxA 2 release from guinea pig isolated 
perfused lungs. In our experiments this finding 
was confirmed and extended. It was demon-
strated that after repeated application of LTC 4 a 
considerable tachyphylaxic occurs [5]. 
In previous work we reported that iso-
prenaline reverses the L TC 4-induced contraction 
of the G PLP and inhibits the TxA 2 release. These 
effects were inhibited by the P-adrenoceptor 
1 To whom correspondence should be sent. 
2 The following abbreviations are used: L T = leukotriene. 
TxA, = thromboxane A,. TxB, = thromboxane B,. PLA, = 
phospholipase A,. GPLP =guinea pig lung parenchyma. 
SRS-A =Slow Reacting Substance-A. 
antagonist sotalol [6]. Isoprenaline has clinical 
iiJ!portance in anaphylactic pulmonary con-
ditions. In this study a comparison is made 
between the contractile activities and TxA 2 
release of human, porcine and guinea pig lung 
parenchymal strips after the application of ~ TC 4 , 
LTD 4 , histamine and PLA2• 
Methods 
Collection of tissue samples 
Male and female guinea pigs of 400-600 g (CPB· 
TNO, Zeist, The Netherlands) were killed by a blow on the 
head and exsanguinated. The I ungs were removed and kept 
in Krebs' buffer until use. 
Male and female pigs of20-25 kg (8-10 weeks. MDF 
raised piglets, random bred. cor Lelystad, The Nether-
lands) were anaesthesized with nembutal (30 mg/kg) and 
exsanguinated. · 
Human lung parenchymal strips were obtained from 
three infants and three adults. 
Infants: All were born with an affection of the heart 
and died of a ventricle septum defect. Medication consisted 
of furosemide (Lasix®) and digoxin. 
Child I, 3.5 years, girL Child 2. 2 months. boy. Child 
3, 3 months. girl. 
Adults: Lobectomy was performed on account of 
tumours. The premedication consisted of •0.25 mg atropine 
and I 0 mg OpiaJ®. During the operation the following agents 
were administered; Fentanyl® (0.5 mg), pancuronium· 
bromide (Pavulon®, 6 mg) and thiopental (PentotaJ®, 150 
mg) and 3 g cephalothin (Keflin ®). 
Patient I, man of 72· years; medication: euphyline. 
Patient 2, man of 67 years, diabetes mellitus; 36 U insulin/d. 
Patient 3. woman of 49 years; no medication. 
Bioassay of lung parenchyma 
Strips were prepared from the largest lobes of guinea 
pig lungs (40 x 3 x 3 mm. approx. 300 mg) and from the 
outer parts of human and porcine lungs. In a superfusion 
cascade system the contractions of a strip of lung 
parenchyma were measured. A rabbit mesenteric artery 
placed under the lung strip served to bioassay the throm-
boxane A, release [7] (Fig. 1). The strips were superfused 
Figure I 
Superfusion cascade to determine the contractile effects of 
leukotrienes and other substances on the lung parenchymal 
strips and the release of TxA2 by means of a rabbit 
mesenteric artery (RbMA). Each bath is superfused with its 
own buffer; a three-way cock is used to superfuse the 
underplaced RbMA or discard the superfusion fluid. 
with oxygenated Krebs' buffer without antagonists (1.6 
ml/min at 37°C). Contractions were measured isotonically 
with a Harvard smooth muscle transducer. 
Biosynthesis ofTxA 2 
TxA2 was generated by rat blood platelets in which 
aggregation was induced by collagen. Hepinarized blood was 
taken by heart puncture, centrifuged and the supernatant 
platelet-rich plasma (PRP) was collected. 200 .ul PRP was 
preincubated at 37°C under stirring in a Payton ag-
gregometer. 10 ,ug arachidonic acid and 8 ,ug collagen 
suspension were added. The sample was collected when 50% 
aggregation occurs. A sample of 100 .ul was applied to the 
cascade after 30 seconds. This sample was collected and the 
amount of total (stable) TxB2 determined by radioimmuno-
assay. 
Materials 
All reagents used were of analytical grade (Merck 
Darmstadt). Leukotrienes C4 and D 4 were gifts of Dr J. 
Rokach (Merck Frosst Labs, Pointe Cla!re, Canada) and 
FPL 55712 of Mr Sheard (Fisons, Loughborough. UK). 
Phospholipase A, (from hog pancreas) was obtained from 
Boehringer Mannheim, histamine from Brocacef (The 
Netherlands), serotonin from Merck and acetylcholine from 
O.P.G., Utrecht, The Netherlands. Arachidonic acid and 
collagen (insoluble, from achilles tendon) were purchased 
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from Sigma Co. Radioimmunoassay of stable TxB2 was 
carried out with kits of New England Nuclear, Boston. 
Results 
In our experiments the contractile activities 
of LTC 4 and LTD 4 were of the same magnitude. 
In agreement with other observations, we found 
that the LT were 70-100 times more potent than 
histaffiine on the GPLP strip, based on the molar 
weight (Fig. 2). TxA2, generated by aggregating 
rat platelets, was slightly less potent than LTD4 • 
Figure 3 shows the effect of indomethacin on 
LTC4-induced contraction. 
Cumulative doses of LTC4 were added to 
the GPLP. Thereafter, indomethacin was super-
fused (30 min, 3 pM) and again 50 ng LTC4 was 
added. The contraction is diminished by 45%, 
which is caused by the total inhibition of TxA2 
release. However, it appears that after indo-
methacin, the dose of 50 ng LTC4 causes a 
contraction equieffective to that of 4-6 ng LTC4 
before indomethacin treatment (an inhibition of 
approx. 80%). The part of the contraction which 
is still present after indomethacin is due to the 
effect of LTC4 itself. This can be suppressed by 
the addition of the SRS-A antagonist FPL 55712 
in a dose of 10 ,ug/ml. 
Figure 4 gives a comparison of the effects of 
LTD4 and histamine added to LP strips of 
different species on both the contraction and the 
LTD4-induced release of TxA2• 50 ng had no 
effect on the human LP strip, whereas that on the 
porcine LP strip was small. This correlates with 
the TxA2 release. The effect of histamine was 
different. The porcine LP strip was more sensi-
tive to histamine than the GPLP strip, whereas 
the human LP strip was almost insensitive to high 
doses of histamine. 
In other experiments, the effect of TxA2 
either applied directly to or released from these 
tissues was determined. 
In Fig. 5 tracings of porcine and human LP 
strip are shown after the addition of LTD 4, TxA2 
and PLA2• The effect of LTD 4 is (again) very 
small. Exogenous TxA2 (expressed as ng stable 
TxB2) contracts the porcine LP strip but had less 
effect on the human LP strip even in a four times 
higher dose. 
In Table 1 a summary is given of the TxA2 
release, measured by radioimmunoassay, carried 
out in experiments comparable to those de-
scribed in Figs 4 and 5. It is clear from the table 
that irrespective of the use of LTD 4 or PLA2 , 
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50 CONTRACTION 
Figure2 
Dose-response curves of LTD 4, TxA2, 
5-hydroxytryptamine (5-HT) acetylcholine 
(AC.CHOL.) and histamine (HIST.) on 
superfused guinea pig lun$ parenchyma. 
The contractions are expressed as mg 
force. 
indom.+ FPL 10pg/ml 
lndom.+ FPL 1pg/mi~Omin. 
Indomethacin 3p M lOmln · 
,_If\ fJ' .;J"' 
... 
2.SngLTC4 
.. 
50ngL!C4 
.. 
50ngLTC4 
... .. 
SOngLTC4 
RABBIT MESENTERIC ARTERY 
Figure3 
Recordings of the contractile activity of LTC4 (50 ng) on the GPLP strip and of the TxA2 release measured by means of an 
underplaced rabbit mesenteric artery. After the cumulative additions of 2.5, 5, 10, 20 and 50 ng LTC4, indomethacin was 
superfused (final cone. 3 pM), and again 50 ng LTC4 was added. Thereafter, FPL 55712 (1 and 10 .ug/ml) was added 
followed by 50 ng LTC4• A representative experiment is shown (n = 4). 
HUMAN PIG GUINEA PIG 
~ ~! • ~ .. l . ..... "'' '" SOng S1020ng SOng lOzoS¥oo500ng LT04 hist. LTD4 hist, LTD4 hist 
t RbMA ~ RbMA "' 
Figure4 
The effects of LTD4 on the contraction of human (child 3 
years), porcine and guinea pig LP strip. compared to 
histamine. The LTD 4-induced release of TxA2 was de-
termined by means of an underplaced rabbit mesenteric 
artery (RbMA). 
both the human and porcine LP strip have a 
much smaller capacity to release TxA2 than does 
the lung tissue of guinea pigs. 
Discussion 
The results of the experiments presented here 
indicate that TxA2 released by the L T induces 
approximately 80% of the contraction of the 
GPLP strip. The remaining 20% should be 
considered as a direct effect of the LT. This 
confirms earlier data on the role of TxA2 in the 
LT-induced contraction [4]. It has also been 
shown that SRS-A, of which LTC4 and LTD4 are 
constituents, releases TxA2 from the lungs [8]. 
When exogenous TxA2 is added to the lung 
tissue contraction also occurs. Considerable 
amounts of TxA2 are formed when P LA2 is added 
-40 contr. 
PIG 
30 Smin. 
20 
10 
PLA:z110ug) 
HUMAN 
20 contr. 
10 
FigureS 
Contractile activities of LTD4 , TxA2 and PLA2 on human (patient No. 3) and porcine LP strips. Contractions are 
expressed as mg force. 
to the lung strip. These effects are, to a certain 
extent, similar to those of the LT. This may 
indicate that the LT activate a PLA2• It has 
been shown that mepacrine, which inhibits 
PLA2 , also inhibits the effects of the LT on lung 
tissue [9]. It is unlikely that the addition ofLTto 
the tissue inhibits the formation of endogenous 
LT and in this way changes the sensitivity. We 
found that after labelling of the strips with 
1-14C-arachidonic acid, no effect was observed of 
the addition of L T on the formation of lip-
oxygenase products. The formation of TxB2 was 
increased under these circumstances (unpub-
lished experiments). 
The effects of LTD4, TxA2, histamine and 
PLA2 on the different tissues are summarized as 
follows: 
Table 1 
Species 
Human 
Porcine 
Guinea pig 
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TxA2 production (ng TxBJ 
LTD4 (50ng) 
0.7 ± 0.16 (6) 
0.5 ± 0.14 (6) 
21 ± 2.1 (14) 
PLA2 (100 p.g) 
4 ± 1.0 (6) 
II± 0.6 (6) 
151 ± 9.5 (5) 
certain types of cells present in these tissues. At 
present it is not known in which type of cells 
TxA2 is formed. 
The results presented here indicate that the 
L T have only a small contractile activity on 
human lung tissue compared to that of the guinea 
pig. This raises the question of the importance of 
the guinea pig lung as a model for the in-
vestigation of human anaphylactic conditions. It 
has been shown that SRS-A is formed in human 
lung cells after immunological challenge [10]. 
This would indicate that this substance plays a 
role in human respiratory disease. 
The effect of LTD 4 is of the order of 100 
times that of histamine on the human lung. Smms 
et a!. [ 11] found that human LP strips were about 
as sensitive to L T as the guinea pig tissue. 
HEDQVIST [12] reported that the human lung is 
1000 ,times more sensitive to L T than to hista-
mine. Whether the presence of tumours has an 
effect on the sensitivity of these tissues is 
unknown. 
It is not very likely that anaesthesia or 
previous medication has an effect on the re-
sponse of the tissues, although this cannot be 
completely ruled out. We found that the con-
tractions of lung strips from guinea pigs treated in 
vivo with nembutal were not different from the 
controls. As the strips are superfused for a long 
time before the measurements are made, the 
substances used in the medications or their 
metabolites are most probably removed from the 
tissues. 
Contraction to LTD 4 
Release ofTxA2 after LTD4 
Contraction to TxA2 
Release ofTxA2 after PLA2 
Contraction to histamine 
GPLP ~porcine LP ~human LP 
GPLP ~porcine LP ~human LP 
GPLP ~porcine LP > human LP 
GPLP ~porcine LP > human LP 
porcine LP > GPLP ~human LP 
The differences may be related to a number of 
factors, such as the amounts or the activities of 
In summary, the results presented here 
indicate that considerable differences occur in the 
50 
sensitivity of lung tissue of different origin 
towards the L T and histamine. 
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-SEPARATION OF THE TWU COMPONENTS OF THE CONTRACTILE ACTIVITY OF LEU-
KOTRIENE c4 ON THE GUINEA PIG LUNG PARENCHYMAL STRIP 
F.J. Zijlstra, J.E. Vincent, and I.L. Bonta, Department of Pharmacol-
ogy, Medical Faculty, Erasmus University Rotterdam, P.O.Box 1738, 
3000 DR Rotterdam, The Netherlands 
ABSTRACT 
The contractions, induced by LTC4 in the guinea pig lung parenchymal 
strip are composed of two parts, one of which is due to the effect of 
the released TxA2 and the other one to the direct action of LTC4. Af-
ter the addition of indomethacin, the TxAz release is totally inhibit-
ed, but the contractions only partly. It 1s shown that the release of 
TxAz only occurs during the initial period of the contractions. This 
ind1cates that the direct action of LTC4 represents the slow acting 
component in the contraction. 
INTRODUCTION 
The formation of a substance in immediate type hypersensitivity re-
actions which contracts smooth muscle more slowly than histamine was 
described more than 40 years ago. This compound was called Slow Re-
acting Substance of Anaphylaxis (SRS-A). The action of this compound 
can not be blocked by a H1 antagonist (1)~ More recently, it was · 
shown that SRS-A contains a mixture of leukotrienes (LT). In SRS-A of 
the rat, LTC4, LTD4 and LTE4 are present (2). LTC4 and LTD4 induce 
long lasting contractions in the guinea pig lung parenchymal (GPLP) 
strip. During the contraction, thromboxane A2 (TxA2) is released (3). 
In the contraction induced by LTB4, the same effect occurs (4). 
The action of LTC4 and LTD4 consists of two parts, one of which re-
presents the effect of the released TxA2 and the other one the direct 
action of the LT. In the experiments described here, the contribution 
of these two components to both the rapid onset and the prolonged 
action of the LTC4 induced contraction in the GPLP strip were invest-
igated. 
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METHODS 
The contractions of the GPLP strip were measured in a superfused or-
gan cascade system. The preparation of the lung strip has been des-
cribed before (5). Under the lung strip, a rabbit mesenteric artery 
(RbMA) is placed, which is used in the bioassay of TxA2 (6). The 
strips were superfused with oxygenated Krebs buffer without antago-
nists (1.6 ml/min at 37°C). The buffer solution had the following 
ionic composition: NaCl 118, KCl 4.7, CaCl2 2.5, MgS04 1.18, KH2P04 
1.18, NaHC03 25 and glucose 5.6 mM. The contractions were measured 
isotonically with a Harvard smooth muscle transducer. 
The effluent of the GPLP strip was collected and the amount of TxB2, 
the metabolite of TxA2 measured by radioimmunoassay using a rabbit 
anti-TxB2 serum ~btained from NEN). 
RESULTS AND DISCUSSION 
A dose-response curve for the effect of LTC4 on the GPLP strip was determined. Such curves were routinely contructed at the beginning 
of every experiment. An example is shown in Fig. 1. A small decrease 
in contraction corresponds to a much larger decrease in the dose. 
When e.g. a maximal contraction is reached after 100 ng LTC4, a con-
traction of 60% is obtained after 10 ng LTC4. When indomethacin (3vM) 
is added to the superfusion fluid, the contraction induced by LTC4 is 
partly, and the TxA2 release, as measured by the RbMA, totally inhi-
bited (Fig. 2). When TxBz is determined by RIA, the same result is 
obtained. Samples of the superfusion fluid were collected from the 
baseline to the top of the peak. The release of TxA2, measured as 
TxBz was only 3.5 ± 0.8% , compared to the first addition of LTC4 be-
fore indomethacin was added (n=4). Under these circumstances, the two 
components of the contractile activity of LTC4 are separated. LTC4 
has no effect on the RbMA. After the inhibition of the TxA2 release 
by indomethacin, the contraction is diminished by± 20%, which cor-
responds to a decrease of 70% in the equieffective dose of LTC4, as 
shown in Fig. 1. This indicates that TxAz is the main component in 
the induction of the contraction. The time required by the superfusion 
fluid to reach the lower placed tissue accounts for the lag period be-
tween the two curves. After a few minutes, the TxAz release is finish-
ed, whereas the tissue continues to contract (Fig. 3). The same re~~ 
are obtained when the amount of TxB2 is determined at regular time in-
tervals in the effluent of the GPLP strip. At the end of a three minu-
te period, only a small amount of TxB2 is still present in the effluent 
(Fig. 4). 
These results indicate, that in the action of LTC4 on the GPLP strip, 
the slow reacting component is due to the direct effect of LTC4. The 
TxAz release plays a role in the onset of the contraction. 
It has not yet been investigated, whether the contractions, induced by 
LTC4 in other smooth muscles also consist of two different components. 
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Figure 1. Log dose-response curve of LTC4 on the GPLP strip. 
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Figure 2. Recordings of the contractile activity of 
50 ng LTC4 on the GPLP strip and the release 
of TxA2-measured on a RbMA. After the first 
addition of LTC4, indomethacin was superfus-
ed. (final cone. 3 ~M). 
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ng TxB 2 
3 
5 min 
Figure 3. The effect of 50 ng LTC4 on the GPLP strip and that of the 
released TxA2 on an underplaced RbMA. The lag time of the 
superfusion fluid between the two tissues is approx. 30 
seconds. 
Figure 4. The formation of TxA2, measured as TxB2, during the con-
traction induced by 50 ng LTC4 in the GPLP strip. Fractions 
of 10 seconds were collected and the TxB2 content determin-
ed. 
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Tachyphylaxis pfLeukotriene C4-Induced Release 
of Thromboxane A2 from Guinea Pig Lung 
Parenchyma and Isoproterenol Inhibition of This 
Release 
F. J. Zijlstra, I. L. Bonta, and J. E. Vincent 
Department of Pharmacology, Medical Faculty, Erasmus University Rotterdam, 3000 DR 
Rotterdam, The Netherlands 
Leukotrienes C, and D, (LTC4, LTD4) are 5-lipoxygenase-generated metabo-
lites of arachidonic acid. Furthermore, it is now an accepted view that LTC4 
and LTD, belong to constituents of slow reacting substances of anaphylaxis 
(SRS-A). Indeed, the pharmacological profiles of LTC4 and LTD4 on guinea 
pig lung parenchyma (GPLP) are strikingly similar to that of SRS-A (8). Isopro-
terenol, which yields clinical relief in anaphylactic pulmonary conditions, was 
found to reverse the LTC4-induced contraction of GPLP (4). The constricting 
activities of LTC, and LTD, on GPLP were . reported to be associated with 
the release of thromboxane A2 (TxA2), and evidence was presented that on 
GPLP the leukotriene-induced contractions are, in fact, largely mediated through 
release of TxA2 (6). We examined the influence of isoproterenol on the LTC,-
induced release of TxA2 from GPLP and observed that this event is markedly 
inhibited by isoproterenol. During these studies, we also found that the LTC,-
induced release of TxA2 is liable to marked tachyphylaxis. Our observation 
with isoproterenol has been reported in a preliminary communication (8). 
METHODS 
Male and female guinea pigs weighing 250 to 300 g were killed by a blow 
on the head and exsanguinated. The lungs were removed and kept in Krebs 
solution until use. In a superfusion cascade organ system, a strip of GPLP 
(7) measured the LTC4-induced contraction, and a rabbit mesenteric artery 
(RMA) placed under it served to bioassay the amount of TxA2 released (1). 
The contractile activity of the RMA was standardized with angiotensin II, as 
described earlier (9). The contractions were measured isotonically with a Harvard 
heart/smooth muscle transducer. Occasionally the effluent of the GPLP was 
collected to measure the stable metabolite thromboxane B2 (TxB2) by radioimmu-
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noassay using a rabbit anti-TxB2 serum (New England Nuclear, Boston)~ After 
16 hr incubation with the antiserum, the free antigen was adsorbed on charcoal, 
and, after centrifugation, the radioactivity of the supernatant was measured 
by scintillation counting. 
Two batches of LTC4 were used during this work. The batches were supplied 
as 200 ~J.g/ml in distilled water. The materials were stored at -20°C. Vnder 
such conditions, a certain decay occurs, which is reflected in diminished biologi-
cal activity. Thus, with the older batch, 50 ng was necessary to contract the 
GPLP, whereas with a fresh batch 7.5 ng was sufficient. 
RESULTS 
We did not find an appreciable difference between the contractile activities 
of LTC. and LTD. on GPLP. In agreement with other observations (4), we 
found these leukotrienes to be much more active than histamine. However, 
TxA2 proved only slightly less potent than LTC4 or LTD4 in contracting GPLP. 
A representative experiment in which LTD" was used in comparison with a 
variety of nonleukotriene mediators is shown in Fig. 1. 
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FIG. 1. Dose--response curves of leukotriene o. (L TO.), thromboxane A2 (TxA2), 5-hydroxytrypta-
mine (5-HT), acetylcholine (AC.CHOL.), and histamine (HIST.) on superfused guinea pig lung 
parenchyma. TxAz was generated from collagen-aggregated rat platelets which were preloaded 
with arachidonic acid. Immediately after the addition of collagen to the platelet-rich plasma, 
different amounts of this plasma were applied to the superfusate. TxB2 in the plasma was 
determined by radioimmunoassay, and the amounts of TxA2 added to the superfusate were 
retrospectively calculated. The contractions are expressed as millimeters (mm) on the recording 
chart 
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Mter addition of LTC4 to GPLP, a release of TxA2, measured as contraction 
ofRMA, occurs (Fig. 2). Also, the same figure shows that the contractile activity 
of GPLP slightly declines after several additions of LTC4. However, the decline 
in the amount of TxA2 released is very marked, again as apparent in Fig. 2. 
In view of the tachyphylaxis, slight with GPLP contraction but pronounced 
with TxA2 release, in the experiments that were aimed at determining the influ-
ence of isoproterenol, the effects of LTC4 have been expressed in percentages 
of the response to the initial administration ofLTC4. Table 1 shows that isopro-
terenol counteracted the LTC4-induced contraction of GPLP and markedly 
inhibited the release of TxA2 caused by LTC4. Both effects of isoproterenol 
were prevented in the presence of the ~-adrenoceptor antagonist sotalol. The 
values in Table 1 do not include the results of the experiments in which the 
bioassay of TxA2 was replaced by radioimmunoassay of TxB2. In the effi.uent 
ng All 
2 LTC 
-.. 
v v 
r rrr 
v v v v v v 
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RABBIT 
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FIG. 2. Effects of repeated additions of LTC4 (50 ng) .to the superiusate of guinea pig lung 
parenchyma (GPLP) under which a rabbit mesenteric artery (RMA) was placed in a cascade. 
Before starting the additions of LTC4 (empty triangles) to the GPLP, the contractile activity 
of the RMA was standardized with additions of angiotensin II (All, black triangles); furthermore, 
a single dose of L TC4 was added directly to the RMA. Note that RMA, which is sensitive to 
TxA2, is unresponsive to LTC •. Vertical affows indicate the magnitude of the real contractions 
of the organs. The dotted vertical line shows that the sensitivity of the recorder was increased. 
At the end of the experiment, the contractile activity of the RMA was again tested with AIL 
Note that RMA retained its sensitivity to contracting material. Accordingly, the decay in contrac-
tions following the additions of L TC4 to GPLP is caused by diminished release of TxA2. 
TABLE 1. Effects of isoproterenol and sots/of on L TC4 -induced responses of guinea 
pig lung parenchymaa 
Parameters 
measured 
and drugs in 
the perfusate 
GPLP contraction 
Vehicle 
Isoproterenol, 1 o-s M 
Isoproterenol, 1 o-s M + 
sotalol, 2 X 1 Q-6 M 
TxA. release 
Vehicle 
Isoproterenol, 1 o-s M 
Isoproterenol, 1 Q-6 M + 
sotalol 2 X 1 Q-6 M 
Responses(%) after 
additions of L TC4 
(50 ng) (response 
to first addition 
= 100%) 
Second Third 
92±2.4 (4) 86±2.4 (4) 
28±4 (7) N.T. 
N.T. 68±14 (3) 
66±6 (7) 45 ±5.3 (7) 
16 ± 5.3 (4) N.T. 
N.T. 53±9 (3) 
a TxA2 release was bioassayed on rabbit mesenteric artery which was in a cascade 
way under the guinea pig lung parenchyma. The values are means ± SE. Numbers 
of observations are shown in parentheses. N.T., not tested. The table is compiled 
from the data originally published in ref. 8. 
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of GPLP untreated with isoproterenol, after the first application of LTC4 (7.5 
ng), the amount of TxB2 was 15 ng, and following the second application of 
LTC4, the measured TxB2 was 11.5 ng. In another GPLP, the initial application 
of LTC4 caused the release of 20 ng of TxBz. In the same GPLP, but in the 
presence of isoproterenol, 10-6 M, in the superfusion fluid, the second dose of 
LTC4 caused the release of only 1.4 ng of TxBz. Following the addition of 
sotalol, 2 x w-s M, but still in the presence of iSoproterenol, the third dose 
of LTC4 induced the appearance of 5.7 ng of TxB2. Thus, the measurements 
ofTxBz confirmed the observation that LTC4-induced release ofTxA2 is inhibited 
by isoproterenol and that sotalol reverses this effect. 
DISCUSSION 
The tachyphylaxis of the LTC4-induced release ofTxA2 has not been reported 
by others who showed that the contractile effect of LTC4 on GPLP is predomi-
nantly mediated by the release of TxA2 (6). The reason for the tachyphylaxis 
could be the depletion of a pool of arachidonic acid which is used in the formation 
of cyclooxygenase products. However, the evidence for this obvious assumption 
still needs to be established. Another unanswered question is which cell popula-
tion in the LTC4-treated GPLP serves as a source of the released TxA2• Leuko-
triene C4 and LTD4 have been reported to promote the release of various products 
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of cyclooxygenase with peritoneal macrophages of rats (3), but as yet, such 
studies have not been carried out with other isolated cell populations. 
With regard to the isoproterenol inhibition of the TxA2 release caused by 
LTC4, the sotalol reversal of this effect of isoproterenol clearly shows the partici-
pation of /3-adrenoceptors in preventing the release. In several tissues, stimulation 
of /3-adrenoceptors leads to activation of adenylate cyclase. In human platelets, 
an increased activity of adenylate cyclase followed by subsequent elevation of 
intracellular cyclic AMP results in diminished availability of arachidonic acid 
to cyclooxygenase and in decreased release of TxA2 (5). Whether a similar 
sequence of events occurs in the GPLP cannot be concluded from the present 
experiments, although this possibility is quite conceivable. However, TxA2 release 
inhibition by /3-adrenoceptor agonists, at least in dog platelets, is not necessarily 
mediated through elevation of cyclic AMP (2). 
Finally, it should be kept in mind, that TxA2 release by LTC4 has not been 
shown with lung parenchyma of other species than the guinea pig (6). Therefore, 
the relevance of the present finding with isoproterenol on GPLP to inhibition 
of LTC4-induced pulmonary events in other species still needs to be established. 
ACKNOWLEDGMENT 
The LTC4 and LTD4 were obtained through the courtesy of Dr. J. Rokach 
(Merck Frosst, Pointe Claire, Canada). 
REFERENCES 
1. Bunting, S., Moncada, S., and Vane, J. R. (1976): Br. J. PharmacoL, 57:462P. 
2. Chignard, M., and Vargaftig, B. B. (1978): Biochem. Pharmacol, 27:1603-1606. 
3. Feuerstein, N., Foegh, M., and Ramwell, P. W. (1981): Br. J. PharmacoL, 72:389-391. 
4. Hedquist, P., Dahlen, S. E., Gustafsson, L., Hammarstrom, S., and Samuelsson, B. (1980): 
Acta Physiol. Scand., 110:331-333. 
5. Minkes, M., Stanford, M. M., Chi, Y., Roth, G. J., Raz, A., Needleman, P., and Majerus, 
P. W. (1977): J. Clin. Invest., 59:449-458. 
6. Piper, P. J., and Samhoun, M. W. (1981): Prostaglandins, 21:793-803. 
7. Sirois, P., Roy, S., and Borgeat, P. (1981): Prostagland. Med., 6:153-157. 
8. Zijlstra, F. J., Bonta, I. L., Adolfs, M. J. P., and Vincent, J. E. (1981): Eur. J. Pharmacol., 
76:297-298. 
9. Zijlstra, F. J., and Vincent, J. E. (1981): J. PharmacoL Methods, 6:1-4. 
3.2.4 
ISOPRENALINE INHIBITS THE LEUKOTRIENE c4-INDUCED RELEASE OF THROMBOXANE A2 FROM GUINEA PIG LUNG PARENCHYMA 
Reproduced from the European Journal of Pharmacology, 
1981; 76: 297-298, with permission of Elsevier 
Science Publishers, Amsterdam, The Netherlands. 
63 
64 
European Journal of Pharmacology, 76 (1981) 297-298 
ElsevierfNorth-Holland Biomedical Press 
Rapid communication 
ISOPRENALINE INHIBITS THE LEUKOTRIENE C4 -INDUCED RELEASE OF 
THROMBOXANE A2 FROM GUINEA PIG LUNG PARENCHYMA 
FJ. ZULSTRA. I.L. BONTA •, M.J.P. ADOLFS and J.E. VINCENT 
Department of Pharmacology, Medical Faculty, Erasmus University Rotterdam, P.O. Box '1738, 3000 DR Rotterdam. The Netherlands 
Received 28 October 1981, accepted 2 November 1981 
Leukotrienes C4 and D4 (LTC4 , LTD4 ) are en-
dogenous metabolites of arachidonic acid by the 
lipoxygenase pathway and the pharmacological 
profiles of these substances on guinea-pig lung 
parenchyma (GPLP) are strikingly similar to that 
of slow reacting substance of anaphylaxis (SRS-A) 
(Hedquist et al., 1980). Both LTC4 and LTD4 were 
shown to release thromboxane A 2 (TXA 2 ) from 
GPLP; the TXA 2 release might account for at 
least part of the contraction of GPLP upon ex-
posure to LTs (Piper and Samhoun, 1981). Isopre-
naline reverses the L TC4 -induced contraction of 
GPLP (Hedquist et al., 1980). We now report that 
isoprenaline inhibits the LTC4 -induced release of 
TXA 2 from GLP and that the ,8-adrenoceptor 
antagonist sotalol counteracts this inhibition. 
In a superfusion cascade organ system a strip of 
GPLP (Sirois et al., 1981) measured the LTC4 -
induced contraction and rabbit mesenteric artery 
placed under served to bioassay· the amount of 
TXA 2 released (Bunting et al., 1976). In a separate 
experiment the effluent of the GPLP was collected 
to measure the stable metabolite thromboxane ~ 
(TX~) by radioimmunoassay using a rabbit anti-
TX~ serum (New England Nuclear, Boston). Two 
batches of synthetic LTC4 , obtained through 
courtesy of Dr. J. Rokach (Merck Frosst, Pointe 
Claire, Canada), were used. 
Following repeated application of LTC4 to the 
superfusion fluid the contractile response of the 
GPLP became liable to slight tachyphylaxis which, 
however, was more pronounced with TXA 2 re-
lease. In the following results, obtained with 50 ng 
LTC4 , the first figure indicates the contractions of 
the GPLP, the second TXA 2 release and both 
figures are percentages (means ±S.E.M.) of the 
responses after the initial administration of LTC4 • 
Following the second application of LTC4 , these 
were 92 ± 2.4% (n = 4) and 66 ± 6% (n = 7), and 
after the third dose 86 ± 2.4% (n = 4) and 45 ± 
5.3% (n = 7), respectively. In the presence of iso-
prenaline 10 - 6 M the responses to the second dose 
of LTC4 were 28 ± 4.0 (n = 7) and 16 ± 5.3% (n = 
4). In the same experiment upon addition of sota-
lol 2 X 10-6 M, but still in the presence of isopre-
naline, the third dose of LTC4 caused 80, 82, 43% 
and 62, 44% responses (individual values). 
Fig. 1 illustrates a similar experiment in which a 
new batch of LTC4 was used and the bioassay of 
TXA 2 was replaced by radioimmunoassay of the 
stable metabolite~- The 7.5 ng dose of LTC4 
caused the GPLP to contract and to release TX~, 
the latter event being liable to tachyphylaxis. Iso-
prenaline relaxed the GPLP and markedly coun-
teracted both effects of LTC4 • Sotalol revers~ the 
effects of isoprenaline. This experiment confirms 
that TXA 2 release is inhibited by isoprenaline, as 
described above in the text. 
Sotalol reversal of the isoprenaline effect clearly 
shows the participation of ,8-adrenoceptors in the 
inhibition of TXA 2 release. In several tissues 
stimulation of ,8-adrenoceptors leads to activation 
of adenylate cyclase. In platelets, an increased 
activity of adenylate cyclase and subsequent eleva-
tion of intracellular cyclic AMP results in a de-
creased release of TXA 2 (Minkes et al., 1977). 
Whether a similar sequence of events occurs in the 
present experiments cannot be concluded, al-
though this possibility is quite conceivable. Irre-
tZ_J~ 
... 
LT~ LT~ 
... 
LT~ sotalol 2.10-&M 
Fig. l. Effect of isoprenaline and sotalol on L TC4 -induced 
TXB, release from an contractile response of GPLP. The dose 
of LTC4 added to the superfusion fluid was in each case 7.5 ng. 
Oblique arrows indicate the moment of collecting the efflUent 
in which TXB, was determined. Figures near the arrows show 
the.amount of TXB, (ng). These are mean values of triplicate 
measurements. The upper record shows the responses of a 
control GPLP, the lower record shows the responses of a GPLP 
under influence of the ,8-ad.renoceptor agonist and antagonist. 
spective of the mechanism, to our knowledge this 
report is the first which demonstrates isoprenaline 
inhibition of LTC4 -induced release of TXA 2 • 
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SRS-A is implicated in immediate hypersensitivity 
reactions leading to perturbations of pulmonary 
mechanics, furthermore SRS-A consists of L TC4 
and LTD4 , the constricting activity of which on 
lung parenchyma and bronchi is at least partially 
mediated through release of TXA 2 (Hedquist et 
al., 1980; Piper and Samhoun, 1980). Therefore 
the present finding, provided that its in vivo rele-
vance can be established, may shed new light on 
the question of the efficacy of isoprenaline in 
relieving anaphylactic pulmonary conditions. 
References 
Bunting, S., S. Moncada and J.R. Vane, 1976, The effects of 
prostaglandin endoperoxides and thromboxane A2 on strips 
of rabbit coeliac artery and certain other smooth muscle 
preparations, Br. J. Pharmacal. 57, 462P . 
Hedquist, P., S.E. Dahlen, L. Gustafsson, S. Hammarstrom and 
B. Samuelsson, 1980, Biological proftle of leukotrienes C4 
and D4 , Acta Physiol. Scand. 110, 331. 
Minkes, M., N. Stanford, M.M.-Y. Chi, G.J. Roth, A. Raz, Ph. 
Needleman and Ph.W. Majerus, 1977, Cyclic adenosine 
3',5' -monophosphate inhibits the availability of arachidonate 
t'? prostaglandin synthetase in human platelet suspensions, 
J. Clin. Invest. 59, 449. 
Piper, PJ. and M.N. Sarnhoun, 1981, The mechanism of action 
of leukotrienes C4 and D4 in guinea pig isolated perfused 
· lung and parenchymal strips of guinea pig, rabbit and rat, 
Prostaglandins 21, 793. 
Sirois, P., S. Roy and P. Borgeat, 1981, The lung parenchymal 
strip as a sensitive assay for leukotriene B4 , Prostagl. Med. 
6, 153. 

SOTALOL POTENTIATES THE LEUKOTRIENE c4-IHDUCED CONTRACTIONS AND THROMBOXANE A2 RELEASE OF GUINEA PIG LUNG PARENCHYMAL STRIPS 
Reproduced from General Pharmacology, 1986; 17: 585-588, 
with permission of Pergamon Press, Oxford, U.K. 
67 
68 
Gen. Pharmac. Vol. 17, No. 5, pp. 585--588, 1986 
Printed in Great Britain 
SOTALOL POTENTIATES THE LEUKOTRIENE C4-INDUCED 
CONTRACTIONS AND THROMBOXANE A2 RELEASE 
OF GUINEA PIG LUNG PARENCHYMAL STRIPS 
FREDERIK J. ZUI.STRA and J. ERIC VINCENT 
Department of Pharmacology, Faculty of Medicine, Erasmus University Rotterdam, P.O. Box 1738, 
The Netherlands 
(Received 27 January 1986) 
Abstract-!. The leukotriene C4 (LTC.J-induced contraction and thromboxane A2 (TxAJ release of 
the guinea pig lung parenchymal (GPLP) strip are both inhibited by the P2-adrenergic agent salbutamol. 
The effect of LTC4 is restored to nearly normal by the P-adrenergic antagonist sotalol. 
2. The latter substance alone also induces a contraction in the GPLP strip and potentiates the 
contractions and the TxA2 release of LTC4• During the sotalol-induced contractions, no TxA2 release 
occurs. An antihistaminic, mepyrarnine had no effect on the sotalol-induced contraction. 
3. When sotalol is added repeatedly to a GPLP strip, only the first time a contraction occurs. 
INTRODUCTION 
The leukotrienes {LTs) are a group of substances 
with several biological activities, which are formed 
from arachidonic acid by the lipoxygenase pathway. 
Some of these compounds have a potent broncho-
constrictor action. It has been shown that the guinea 
pig lung parenchyma (GPLP) is particularly sensitive 
to this effect (Piper and Samhoun, 1982; "Sirois et a/., 
1981). During the contractions, induced by LTC4 
and LTD4, thromboxane A2 (TxA2) is formed. This 
accounts for a part of the contraction, whereas 
another part is due to a direct effect of the L T (Piper 
and Samhoun, 1982; Zijlstra et al., 1983a). Both the 
LTC4-induced contraction and the TxA2 release are 
inhibited by isoproterenol (Zijlstra et al., 1981). This 
action is possibly related to the increase in cyclic 
AMP, induced by the ,8-adrenergic agent. An inhi-
bition is also observed after the addition of IBMX 
(3-isobutyl-1-methyl-xanthine), a phosphodiesterase 
inhibitor to the system (Zijlstra et a!., 1983c). 
In the experiments presented here, the effect of a 
substance with ,8,-adrenergic activity, salbutamol 
was determined on the LTC4-induced contraction 
and TxA2 release in the GPLP strip. This action is in-
hibited by sotalol, a ,B -adrenergic antagonist. Sotalol 
also induces a contraction itself and potentiates the 
effects of LTC4• A relationship may exist between 
these results and the induction, by ,B -adrenergic an-
tagonists of bronchospasms in asthmatic and normal 
subjects (McLagen and Ney, 1979). 
METHODS 
Male and female guinea pigs of 250-300 g were used. The 
animals were killed by a blow on the head and exsanguin-
ated. The lungs were removed and kept in Krebs' solution 
(ionic composition: NaCl 118, KC14.7, CaCI2 2.5, MgS04 
1.18, K.H,P()4 1.18, NaHC03 25 and glucose 5.6 mM). The 
strips of lung parenchyma were prepared from the largest 
lobes as has been described before (Zijlstra et a/., 1984). 
Strips of tissues were superfused with oxygenated (95% 
0 2 + 5% COJ Krebs solution. The contractions were 
measured isotonically with a Harvard heart/smooth muscle 
transducer. The perfusion rate was 2 ml/min at 37°C. 
Samples were collected after the addition of the substances 
to the GPLP strip. The amount of TxB, formed was 
measured by radioimmunoassay (Zijlstra et a/., 1984). 
The Student's T-test was used in the statistical analysis. 
MATERIALS 
The leukotrienes C4 and D4 were a gift of Dr J. Rokach, 
Merck Frosst Labs, Pointe Claire, Quebec, Canada. 
Salbutamol was a gift of Glaxo. Sotalol was obtained from 
Bristol. In the radioimmunoassay of TxB,, the antibody 
used was obtained from l'Institut Pasteur, Paris and 
PHJTxBz from New England Nuclear, Boston. All chemicals 
used were analytical grade. 
RESULTS 
The contraction, induced by 200 ng LTC4 is nearly 
totally inhibited when the system is perfused with 
111M salbutarnol. When the perfusion is continued 
with both salbutamol and 611M sotalol, this effect is 
reversed. The amounts of TxA2 released (determined 
as TxB:z) follow the same tendency (Fig. I and Table 
1). In some of these experiments, it was found that 
the LTC4-induced contraction was larger after the 
administration of both salbutarnol and sotalol than 
when LTC4 was added alone. For this reason, the 
effect of sotalol on the LTC4-induced contractions 
was further investigated. 
Table 1. Effect of salbutamol and sotalol on the contractions and 
TxA2 release, induced by SOOng LTC, in the GPLP strip. •p <0.01 
compared with salbutamol 
Contraction 
TxA2 release 
Response after addition of 
LTC, (%) compared with the 
first addition ( = 100%) 
Salbutamol I pM 25±6.4 
Salbutamol I pM + 
Sotalol 6pM 105 ± 19.2• 
Salbutamol I pM 25± 11.7 
Salbutamol I pM + 
Sotalol 6JlM 91 ± 3!.7• 
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5.1 
/ 
1 
LTC 4 
salbutamol salbutamol + 
sotalol 
LTC 4 
Fig. 1. The effect ofLTC4 (200 ng), salbutamol (I )lM) and sota!ol (3.2)lM) on the GPLP strip. The tissue 
is perfused with salbutamol, followed by salbutamol + sota!ol. The numbers indicate the ng TxB2 formed 
during the perfusion. A representative experiment is given (n = 11). 
When a GPLP strip was superfused with 2 !lM 
sotalol, a contraction occurred. The effect of LTC4 
was increased both in so far as the contraction and 
the TxA2 release are concerned. The sotalol-induced 
contraction was not dependent on the formation of 
TxA2 (Fig. 2). 
8.4 
/ 
sotalol 
The effects of sotalol on the LTC4-induced con-
tractions and TxA. release are represented in Table 2. 
When LTC4 is added for the second time, a tachy-
phylaxis occurs. For this reason, the values obtained 
are lower than those after the first addition. 
The effect of the repeated additions of sotalol to 
18.3 
Fig. 2. The effect of LTC4 (500 ng) and sotalol (2 )lM) on the GPLP strip. The tissue is perfused with 
sotalol. Numbers indicate ng TxB2 (n = 13). 
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sotalol 
J l! Ltamine 
1 propanolol 
Fig. 3. The effect of the repeated addition of 10 p.g sotalol, 
of 10 (1) and 50 p.g (2) propranolol and of 100 ng histamine 
on the GPLP strip (n = 3). 
the GPLP strip was also measured. A contraction 
only occurred after the first addition of 10 p. g, not 
after the second and third one. Propranolol in doses 
of 10 and 50 p. g also induced a contraction in the 
GPLP strip. For comparison, the effect of 100 ng 
histamine is given (Fig. 3). The effect of sotalol was 
not inhibited by the perfusion of the GPLP strip with 
0.14 p.M mepyramine. 
DISCUSSION 
Substances with p,-adrenergic activity induce re-
laxation in bronchial tissue. This effect is used in the 
treatment of a number of respiratory diseases. In the 
experiments represented here, the action of a sub-
stance with P2-adrenergic activity, salbutamol has 
been determined. This compound inhibited both the 
contraction and the TxA2 release, induced by LTC4 
in the GPLP strip. After the addition of sotalol to the 
system, the effect of L TC4 was partly restored to 
normal (Fig. 1 ). With isoprenaline, which has both P1 
and p2 adrenergic activity, a similar effect occurred 
(Zijlstra et al., 1981). 
As has been mentioned before, in some cases the 
effect of LTC4 was increased when, after salbutamol 
perfusion, sotalol was given. This was unexpected as 
a tachyphylaxis occurs in both the contraction and 
the TxA2 release when LTC4 is added repeatedly to 
the GPLP strip (Zijlstra et al., 1983b). For this 
reason, the effect of sotalol on the GPLP strip was 
further investigated. The results indicate, that sotalol 
induces a contraction itself and enhances both this-
effect and the TxA2 release induced by LTC4• The 
latter is not an additive effect as no TxA2 release 
occurs with sotalol alone (Fig. 2). 
After one addition of 10 p. g sotalol, a contraction 
occurs. The second and third additions of the same 
dose only have a small effect. This may indicate that 
the receptors for this substance are nearly completely 
Table 2. Effect of sotalol on the contraction and TxB, release 
induced by 500 ng LTC4 in the GPLP strip. The con~ols are lower 
after the second addition because of the tachyphylws. • P < O.Ql, 
Contraction 
TxB, release 
•• P < 0.001 ~mpared with controls 
Control 
Sotalol2!'M 
Control 
Sotalol 2!'M 
Response after addition of 
LTC4 (%) compared with 
the first addition ( = 100%) 
90±2.2(n = 10) (second add.) 
124 ± 8.2 (n = 13)* 
61 ± 3.6 (n = 6) (second add.) 
178 ± 24.0 (n = 13)** 
occupied after this dose. Propranolol also induces 
contractions. 
Recently, the propranolol-induced broncho-
constriction was ascribed to the release of histamine 
{Terpstra et al., 1981). This cannot explain our 
results, as the superfusion of the system with mepyr-
amine had no influence on the contraction induced by 
sotalol. A potentiating effect of propranolol and 
practolol on the LTC4-induced bronchoconstriction 
was demonstrated in in vivo experiments in the guinea 
pig. There was no effect in vitro. This action was not 
mediated by a serotonergic, cholinergic or 0< -adren-
ergic mechanism (Bongrani et al., 1983). 
The bronchoconstrictive action of P -adreno-
ceptor blockers in vivo is in general attr!buted. to 
the inhibition of the relaxing effect of crrculating 
adrenaline. It is unlikely, that sotalol acts through 
p2-adrenergic blockade in an in vitro system, which is 
constantly superfused. Small amounts of adrenaline, 
with p2 activity which may have been present in the 
beginning of the experiment most probably have been 
removed. 
In the contractions, induced by L TC4, 2 different 
components are present: one is due to the action of 
the released TxA2 and the other one to a direct effect 
of LTC4 (Piper and Sarnhoun, 1982). The release of 
TxA2 only lasts for a few minutes, whereas the direct 
effect has a much longer duration (Zijlstra et al., 
1983a). TxA2 is formed from arachidonic acid, which 
is released from the phospholipids of the tissue, either 
by the action of a phospholipase A2, or by phospho-
lipase C. It has been shown that the action of LTC4 
is inhibited by chloroquine (Zijlstra et al., 1983c). 
This substance is an inhibitor of phospholipases A2 
and C (Matsuzawa and Hostetler, 1980). The relax-
ation, induced by salbutamol can most- probab~y ~ 
ascribed to an activation of the adenylate cyclase m 
the lung parenchymal tissue. An increase in cyclic 
AMP inhibits the release of arachidonic acid in 
platelets (Lapetina et al., 1981). A similar effect may 
occur in lung tissue. 
It is a point of interest to consider, whether the 
effects described here can also occur in asthmatic 
patients as a result of treatment with a p,-adreno-
ceptor blocker. As the conditions in vivo are, of 
course, different from the experiments described and 
also because guinea pig lung tissue is more sensitive 
to the effect of LTC4 than human lung (Zijlstra et al., 
1984), a comparison is difficult to make. It has been 
reported that human alveolar macrophages, when 
activated, form 10 ng LTCJ106 cells (Fels et al., 1982) 
and human mast cells 25 ng/106 cell (Lewis and 
Austen, 1984). 50ng LTC4 induces a contraction in 
human lung strips (Zijlstra et al., 1984). These figures 
indicate that human lungs can produce amounts of 
this substance that have a contractile action on this 
tissue. 
In summary, the results presented here, show that 
sotalol inhibits the effect of salbutamol on the LTC.-
induced contractions in the GPLP strip. Sotalol 
itself also contracts the GPLP strip and potentiates 
the effect of L TC4• These actions are not mediated by 
the release of TxA2 or histamine. 
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3.3 SUMMARY 
The mechanisms of action, the potency in comparison to other biologically 
active sbstances and the effects of antagonists and synthesis inhibitors 
of the leukotriene c4 and D4-induced contractions of the guinea pig lung 
parenchymal (GPLP) strip were investigated. In conclusion it was found 
that 
-the contractions of the GPLP are composed of two parts, one of which is 
due to the immediate effect of the released thromboxane A2 and the other 
one to the slow acting, long lasting direct effect of LT itself [3.2.2]. 
-both the contractile response and the release of thromboxane A2 in the 
GPLP was at least 40 times higher than those obtained in human and 
porcine lung parenchymal strips [3.2.1]. 
-LTC4 and LTD4 are much more active on GPLP than histamine, serotonine or 
acetylcholine [3.2.3 or 3.2.1]. 
-after repeated application of LTs to the GPLP both the contraction and 
the TxA2 release became liable to tachyphylaxis, most pronounced in the 
release reaction [3.2.4 and 3.2.3]. 
-TxA2 generated from aggregated platelets was slightly less potent than 
LTs c4 and D4 . Phospholipase A2 induced contraction and TxA2 release 
were subject to fast tachyphylaxis [3.2.1]. 
-although inhibition of the TxA2 release by indomethacin was complete, 
approximately 80~ of the contractile activity after LT application tc 
the GPLP remained [3.2.2]. 
-physiological antagonism to the LTC4-induced contractions and the TxA2 
release was obtained after the addition of the ~ 1 .~2-adrenoceptor 
agonist isoprenaline [3.2.4] and the ~2-adrenoceptor agonist salbutamol [3.2.5]. 
-sotalol reversed the effect of ~-adrenoceptor agonists. This ~-adrenergic 
antagonist caused a small contraction in the GPLP strip and potentiated 
those induced by LTC4 , in the absence of an agonist [3.2.5]. 
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CHAPTER 4 
MEASUREMENT OF LEUKOTRIENE SYNTHESIS WITH HIGH PERFORMANCE 
LIQUID CHROMATOGRAPHY 
4.1 INTRODUCTION 
In the previous chapter the biological activities of leukotrienes were 
examined on lung parenchymal strips. In this chapter the synthetic 
capacity of lung tissue and macrophages from lungs and other origins to 
generate eicosanoids are described and compared with their occurrence both 
in healthy and diseased tissues or cells. 
The inhibition of eicosanoid production by specific synthesis inhibitors 
was examined. In lung tissue the formation of eicosanoids was measured by 
high performance liquid chromatography and radioimmunoassay. 
In vitro incubation with 14c-arachidonic acid of macrophages, isolated 
from ascitic fluid of patients with alcoholic liver cirrhosis or 
dialysates from patients with kidney insufficiency, made it possible to 
investigate the whole cascade of eicosanoids· synthesized. 
4. 1 • 1 High performance liquid chromatograph'y 
High-performance liquid chromatography (HPLC) is an ideal technique for 
the analysis of small molecules. Despite its high potential demonstrated 
during the last two decades, liquid chromatography frequently confronts us 
with a selectivity or sensitivity of the LC system which is insufficient 
for an accurate and precise quantitation of eicosanoids eluted from the 
column. Pre- or post-column derivatization, sample clean-up and sample 
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concentration improved the result only to a limited degree. One of the 
problems of preconcentration techniques is that not only the compounds of 
interest will be concentrated, but also the interfering compounds. Hence 
the selectivity is reduced. In the area of eicosanoid-research this 
problem can be avoided by using a radiolabelled precursor, which allows 
the radioactive determination of the metabolites in the extract of the 
incubation sample, without interference from non-labelled compounds. 
Elucidation of the pathways of arachidonic acid (AA) metabolism in 
different tissues and cells has been made possible by the separation and 
detection of the metabolites of AA labelled with 14c. HPLC using a single 
25 em x 4.6 mm i.d. column packed with 5~ ODS-silica and a 
tetrahydrofuran/methanol/water or acetonitrile/water solvent system is 
used to separate the major metabolites of 
cyclooxygenase pathways [Tracey,1986]. 
the lipoxygenase and 
Prostaglandins can be separated from thromboxane, leukotrienes and 
hydroxyeicosatetraenoic acids using reversed phase (RP) systems and 
gradient elution. RP chromatography is so named because it behaves in a 
way which is opposite to normal or adsorption chromatography, in which 
interaction occurs between the absorbent and the solute and solvent 
molecules in solution. There is a competition between the solute and 
solvent molecules for adsorption sites on the solid surface. Separation 
is effected since different molecules are absorbed displaced 
differently. Solutes are eluted in the order of increasing polarity and 
retention decreases with increasing solvent polarity. 
In RP chromatography the stationary phase is silica which is chemically 
bounded to an alkylsilyl compound. This results in a non-polar, 
hydrophobic surface. Solute retention is due to hydrophobic interactions 
between the solutes and the hydrocarbonaceous stationary phase surface. 
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Polar mobile phases, usually water-miscible organic solvents, are used for 
elution. Solutes are eluted in the order of decreasing polarity 
(=increasing hydrophobicity), whereas increasing the polar (aqueous) 
component of the mobile phase increases the retention of the solutes. 
Packing material of the RP columns is usually of the c18 type in which 
octadecylsilyl (ODS) groups are bonded to the silica surface. 
Detection of prostaglandins in naturally-occurring concentrations 
presents some problems. The amounts are usually so low that they can not 
be measured without radiolabelling or derivatization with a chromophore 
which will enhance the UV absorption or fluorescence of the compound. 
Detection of amounts in the order of micrograms by UV absorption is 
possible at 192 nm without derivatization. Improved peak shape is 
obtained at low pH (2-3), while the elution order for prostaglandins is 
not pH dependent. The use of methanol instead of acetonitrile reverses 
the elution order of PGF2a and PGE2 , whereas PGE2 and PGD2 are not 
separated In general retention time increases with the number of double 
bonds and hydroxy groups. The longer the column the better the separation 
of cis/trans and diastereoisomers [Green et a1.,1978]. 
Leukotrienes are pH dependent. At higher pH they will have shorter 
retention times, whereas at lower pH LTs are unstable. Measurement of LTs 
by HPLC is much easier than that of PGs, because of the conjugated triple 
bond which makes them detectable at the nanogramlevel using the UV 
absorption at 270 and 280 nm. Separation of LTs is performed on columns 
packed with 5 ~ Nucleosil c18 using solvent systems containing methanol I 
water, at a pH of 5.5. Reducing this pH to 4 considerably enlarges the 
retention times of the sulphidopeptide LTs. Addition of tetrahydrofuran 
to the solvent system allows separation of diastereoisomers of mainly 
LTB4 . Detection down to 2 ng per peak can be obtained. This method is as 
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sensitive as the normally used bioassays with guinea pig lung parenchymal 
strips or guinea pig ileum, and has the advantage that it is a quantitive 
and not merely a qualitative method. 
In fig.11 the basic set-up for on-line and off-line detection of 
radiolabel is presented. The system is controlled by the HP 1084 
computer, which enables the start of both the fraction collector and the 
beta flow detector. By the splitter a certain percentage of the HPLC-
eluent is divided and further examined. After collection of samples by 
the fraction cutter, liquid scintillator is added and samples are counted 
in a tritium-carbon scintillation counter. Data obtained are calculated 
and plotted by the PDP 11/70 computer (the "off-line" method). 
Loss of resolution depends on the fraction volume, whereas the 
sensitivity depends both on the background and the number of counts 
Fig.11 
solvents 
dual pump 
---+----
Basic set-up for on-line and off-line radiometric 
detection in column liquid chromatography. 
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collected. The recently introduced "on-line" method seems to offer some 
promise for low-level radioactivity detection in liquid chromatography 
[Veltkamp et a1,1987]. This dual label system is flexible in storing raw 
data, or entire chromatograms without losing the chromatographic 
properties and the possibility to reintroduce parameters, zones of 
interest and signal smoothing. All these operations enable automation of 
the entire separation and detection process, controlled by a computer. In 
conclusion, this set-up presents an output consisting of chromatograms of 
non-labelled LTs and HETEs, plotted data of dual labelled PGs, LTs and 
HETEs (on-line and/or off-line) and the possibility to collect samples for 
further identification or quantitation (RIA, bioassay, GC-MS). 
4.1 .2 Eicosanoid formation by cells 
Whereas prostaglandins can be synthesized by most cells, the lipoxygenase 
products leukotrienes and hydroxy-eicosatetraenoic acids are formed by a 
limited number of cell types. Producer cells for LTs are mainly 
macrophages, monocytes, neutrophile, eosinophile, and mast cells [table 
3]. In body fluids LTs were demonstrated in bile after endotoxin-induced 
shock and in plasma, sputum and nasal secretions after allergen challenge. 
Various substances and triggers stimulate the generation and release of 
LTC4 and/or LTB4 . These include chemotactic peptides, such as F-Met-Leu-
Phe (FMLP), platelet-activating factor (PAF), IgE directed antigens, a 
ca2+ ionophore such as A23187, phagocytic stimuli such as opsonized 
zymosan, bacterial endotoxin, phospholipase A2 , mechanical or thermal 
tissue injury. In the studies reported in this chapter the ca2+ ionophore 
A23187 was used as a trigger of cells to generate leukotrienes. 
TABLE 3 
CELLULAR SOURCES AND IN VIVO OCCURRENCE 
OF LEUKOTRIENES IN MAN 
(+, ++, +++ relative amounts) 
Stimulated cells/tissues pept. LTs LTB4 
Eosinophils +++ + 
Neutrophils + +++ 
Monocytes ++ +++ 
Macro phages + +++ 
lymphocytes 
Mast cells ++ + 
Basophils + + 
Psoriatic skin + 
Body fluids 
Bile +++ 
Urine + 
Blood plasma asthma + 
Synovial fluid -- + 
Sputum cystic fibrosis + + 
Nasal secretes (allergic) ++ + 
Tear fluid (allergic) + 
Pulmonary fluid (hypertens.) + 
Seminal fluid + 
[Data compilated from Keppler et al., 1985] 
4.1.3 14c-Arachidonic acid labeling oF cells or tissues 
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Lung tissue. Macroscopically normal, tumor free parts of human lung 
tissue were used for incubation with arachidonic acid. The pleura was 
removed and parenchymal tissue dissected free from major blood vessels and 
bronchi. Approx.10 g was chopped with a Mcilwain tissue chopper in slices 
of 0.5x0.5 mm. This fraction was washed and erythrocytes were removed by 
lysation. Incubation was performed in 20 ml of Krebs-Henseleit buffer 
with a pH of 7.45. 1 ~Ci 14c-arachidonic acid per gram tissue was added. 
Macrophages. Dialysis fluid of patients with continuous ambulatory 
peritoneal dialysis was collected at different phases of peritonitis and 
cells were isolated by centrifugation. Ascites from patients with an 
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alcoholic liver cirrhosis was cleaned over a macro gauze and cells 
isolated after centrifugation. Macrophages were separated from 
granulocytes and erythrocytes on LymphoprepR Incubation was performed in 
10 ml buffer with 1 ~Ci 14C-AA per ca. 106 macrophages. 
Incubation and work-up procedure. In fig.12 a flow-sheet is presented 
containing the most important steps in the work-up procedure of the 
analyses of eicosanoid formation by cells. From the 5th step onwards the 
procedure can also be applied with tissue incubations. In short, 
incubations were carried out in a waterbath at 37•c, gassed continuously 
with 95% 02 /5% co2 . Labelled precursor, glutathion and Ca-ionophore A23187 
were added. At the end of the incubation 3H-labelled PGs, LTs and HEs 
were added in known amounts to calculate recoveries (step 7). Eicosanoids 
were extracted from the incubation medium by application to SepPak 
cartridges, and after the evaporation of the eluate and filtration, 
injected into the HPLC column (step 13). 
HPLC. Prostaglandins were separated on a Zorbax c 8 column using a 
solvent system containing acetonitrile /benzene /water /acetic acid, (24 
0.2: 76 : 0.1), with a flow rate of 2 ml/min at 37•c. Lipoxygenase 
products were separated on HPLC by a Nucleosil 5C18 column using as eluens 
tetrahydrofuran /methanol /0.1% EDTA in water /acetic acid, (25 : 30 : 45 
0.1, adjusted to pH 5.5), with a flow rate of 0.9 ml/min at 37•c. 
Materials. Synthetic leukotrienes were generous gifts from Dr. 
J.Rokach (Merck Frosst Canada Inc.). Ethanol soluble Ca-ionophore A23187 
was obtained from Hoechst. Labelled compounds were purchased frcm the 
Radiochemical Centre Amersham (U.K.). Antibodies for determinations of 
the endogenous formation of prostaglandins and thromboxane were obtained 
from l'Institut Pasteur, anti- 6-keto-PGF 1 ~ and anti- HETEs from Seragen 
and anti- LTB4 from Wellcome. Prepacked HPLC columns were from Chrompack. 
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SUMMARY 
A liquid chromatographic method for the determination of 14C-labelled prostaglandins, 
leukotrienes and other lipoxygenase products formed by human lung tissue is described. 
In this paper we report our problems identifying these substances when 3 H- or 14C-labelled 
compbunds are compared with measurements of the mass by absorption or radioimmuno-
assay. Furthermore, some preliminary results of [14C]arachidonic acid labelled human lung 
tissue, stimulated by the Ca-ionophore A23187, show that, of the lipoxygenase products, 
mostly leukotriene B4 like compounds are formed and less leukotriene C4 , E4 and D4 • Rela-
tively large amounts of hydroxyeicosatetraenoic acids are present.' The main cyclooxygenase 
products are thromboxane B2 , 6-ketoprostaglandin F 1a and prostaglandin D2 • 
INTRODUCTION 
The biologically active leukotrienes (LTs) are formed from arachidonic acid 
(AA). Several of these substances induce slow contractions in smooth muscles. 
The effects of the LTs on peripheral and central airway functions of pulmonary 
tissue have also been described [1]. Furthermore, it has been reported that 
the addition of leukotriene C4 (LTC4 ) and D4 (LTD4 ) induces thromboxane 
A2 (TxA2 ) release from guinea pig isolated perfused lungs [2, 3]. Both the 
contraction of lung parenchymal strips and the TxA2 release could be in-
hibited by the ,6-adrenoceptor agonist isoprenaline [ 4]. In previous work, a 
comparison was made between the contractile activities and TxA2 release of 
human, porcine and guinea pig lung parenchymal strips after the application 
of LTC4 and LTD4 [5]. The results indicate that both the contractile activity 
of LTs on human lung strips and the TxA2 release were rather low in com-
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parison with the guinea pig lung strip. In cultured endothelial cells from human 
umbilical vein, however, LTC4 promotes prostacyclin synthesis [6]. Recently, 
it has become evident that human alveolar macrophages produce leukotriene 
B4 (LTB4 ) [7], and it was also shown that human peritoneal macrophages 
synthesize LTB4 and LTC4 [8]. Further, Dahlen et al. [9] showed that allergen 
challenge of chopped human lung tissue elicits contraction that correlates with 
the release of both LTC4, LTD4 and leukotriene E4 (LTE4) and prostaglandins. 
In this paper we describe an extraction procedure and high-performance 
liquid chromatographic (HPLC) techniques for the separation of cyclooxyge-
nase and lipoxygenase products with comparatively high recoveries and discuss 
some of the problems concerned with the identification of these substances 
formed from F4 C] AA-labelled and Ca-ionophore-triggered chopped human 
lung tissue. 
EXPERIMENTAL 
Apparatus 
A 1082B high-performance liquid chromatograph (Hewlett-Packard) was 
used, consisting of double-head pump, temperature-controlled column com-
partment, variable-volume injector and variable-wavelength detector. The 
Superrac fraction collector (LKB, Sweden) was connected to this apparatus 
and used as an automatic sampling system. Radioactivity in the labelled frac-
tions was counted in a 3255 Tricarb liquid scintillation counter (Packard, 
Brussels, Belgium). 
Chemicals 
LTB4, LTC4 and LTD4 were gifts of Dr. J. Rokach (Merck Frosst, Canada). 
Ca-ionophore A23187 was obtained from Hoechst (Calbiochem-Behring, 
U.S.A.), reduced glutathione from ICN (Cleveland, OH, U.S.A.) and prosta-
glandins D2 (PGD2 ), E2 (PGE2 ) and F2a (PGF2a) from Sigma (U.S.A.). 6-Keto-
prostaglandin F la (6-keto-PGF la) and thromboxane B2 (TxB2 ) were gifts of 
Dr. J.B. Smith (Philadelphia, PA, U.S.A.). Siliclad® was obtained from Clay 
Adams (Becton Dickinson, U.S.A.). Tetrahydrofuran, methanol, acetonitrile, 
benzene and acetic acid were all of analytical grade from E. Merck (Darmstadt, 
F.R.G.). Picofluor-15 (Packard) was used as premixed scintillation cocktail. 
Radiochemicals 
[1-14C] AA, 5-D-[ 5,6,8,9,11,12,14,15-3H(n)] hydroxy-6,8,11,14-eicosatetra-
enoic acid (5-HETE), 12-L-[5,6,8,9,11,12,14,15-3H(n)] HETE and 15-L-[5,6, 
8,9,11,12,14,15-3H(n)]HETE were purchased from New England Nuclear. 
All other radiolabelled compounds mentioned below were obtained from the 
Radiochemical Centre (Amersham, U.K.): [5,6,8,9,11,12,14,15-3H(n)] LTB4, 
[14,15-3H(n)] LTC4, [14,15-3H{n )] LTD4, 6-keto-[ 5,8,9,11,12,14,15-3H(n)]-
PGF la, [ 5,6,8,9,11,12,14,15-3H(n )] TxB2 , [ 5,6,8,11,12,14,15-3H(n )] PGE2 , [ 5, 
6,8,11,12,14,15-3H(n)] PGF 2a, [ 5,6,8,9,12,14,15-3H(n )] PGD2 , [1-14C] PGE2 
and [1-14C]PGF2a· The purity of the radiochemicals was shown to be greater 
than 97%. 
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Materials 
Sep-Pak C18 and Sep-Pak silica cartridges and HPLC-solvent filters HA 
(0.45 J,Lm) and FH (0.5 J.Lm) were obtained from Waters Assoc.; prepacked 
HPLC columns Nucleosil 5C18 and Zorbax BPtmC8 (each 250 X 4.6 mm) 
were from Chrompack (Middelburg, The Netherlands). 
Antisera 
Anti-TxB2, anti-PGF2,n anti-PGE2 and anti-PGD2 were obtained from l'In-
stitut Pasteur (Paris, France); anti-6-keto-PGF1a was obtained from Seragen 
(Boston, MA, U.S.A.). Cross-reactivities are given in Table I. 
TABLE I 
CROSS-REACTIVITIES OF COMMERCIALLY OBTAINED ANTIBODIES 
Data are expressed in per cent at 50% B/B0 (B = bound). 
Compound Antiboay 
6-Keto-PGF 1a TxB, PGF2a PGE2 PGD 2 
6-Keto-PGF,a 100 0.04 <0.01 0.01 
PGF1a 7.8 12.0 0.01 0.01 
PGF2a 2.2 0.1 100 0.11 0.04 
6-Keto-PGE, 6.8 0.16 
PGE, 0.7 0.03 10.7 0.01 
PGE2 0.6 0.1 0.03 100 0.01 
PGA1 <0.01 <0.01 0.04 
PGA, <0.01 0.1 <0.01 0.3 
PGD2 <0.01 0.2 3.0 <0.01 100 
PGD, <0.4 <0.01 78 
TxB2 <0.01 100 <0.01 <0.01 1.2 
13 ,14-Dihydro-15-keto-PGE2 <0.01 0.1 0.6 0.01 
13,14-Dihydro-15-keto-PGF 2a <0.01 0.1 <0.01 <0.01 0.01 
13,14-Dihydro-PGE, 2.1 
6-Keto-PGE, 0.1 <0.01 13.2 
Human lung tissue 
Human lung tissues were obtained from adults [5]. Lobectomy was per-
formed on account of tumours. The premedication consisted of 0.25 mg of 
atropine and 10 mg of Opial®. During the operation, the following agents 
were administered: Fentanyl® (0.5 mg), pancuronium bromide (Pavulon®, 
6 mg), thiopental (Pentotal®, 150 mg) and 3 g of cephalothin (Keflin® ). 
Parenchymal tissue of the outer parts was used in our experiments. 
Method 
Human lung tissue (10 g) from which the lung membrane had been removed 
was cut into slices. The slices were chopped in a Mcilwain tissue chopper and 
divided in portions of 0.5 X 0.5 mm. The whole fraction was washed three 
times with Krebs-Henseleit buffer (20 ml of buffer, 5 min, 400 g) in a poly-
propylene 50 ml tube (Falcon® ). Then 20 ml of Krebs-Henseleit buffer were 
added and the tube was placed in a water-bath of 37°C on a magnetic stirrer 
(900 rpm). Through a thin pipette, the sample was continuously gassed with a 
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mixture of 95% 0 2 + 5% C02 • Thereafter, 10 ,uCi of [1-H·c] AA (55 mCi/ 
mmol), glutathione (final concentration 2 mM) and 100 ,ug of Ca-ionophore 
A23187 (dissolved in 100 ,ul of ethanol) were added. At the end of the 10-min 
incubation, [3H] LTs and [3H] PGs were added and the homogenate was cen-
trifuged (10 min, 1400 g, 4°C). The pellet was washed once, and the combined 
supernatant centrifuged (90 min, 30,000 g average, 4°C) to separate the cells 
and small particles. The clear incubation supernatant was then applied to a 
Sep-Pak C18 cartridge and the effluent was placed on a Sep-Pak silica cartridge. 
(The C18 cartridge was prewashed with 10 ml of methanol and 10 ml of 
distilled water; the silica cartridge was prewashed with 10 ml of methanol and 
100 ml of water [10] .) The sample was eluted with 2.5 ml of methanol on 
each column; these eluates were combined and evaporated to dryness with 
a gentle stream of nitrogen at 40°C. Thereafter, the dried sample was dissolved 
in 1 ml of solvent A (tetrahydrofuran-methanol-water-acetic acid, 
25:30:45:0.1, vfv, adjusted to pH 5.5 with ammonium hydroxide), filtered 
and kept in a siliconized micro-vial. 
Chromatographic system 
Reversed-phase HPLC of LTs and other lipoxygenase products was carried 
out on a Nucleosil 5 C18 column, using solvent system A. Mobile phases were 
filtered by vacuum filtering through a Millipore filter and degassed with helium 
[11, 12]. The flow-rate was 0.9 ml/min and the absorption was measured at 
280 nm. Prior to use, the system was washed with approx. 15 ml of water, 
thereafter with approx. 30 ml of a 2% (w/v) EDTA solution in water, andre-
washed with water [10]. The column was equilibrated with the mobile phase 
A at an oven temperature of 37°C. Fractions were collected for scintillation 
counting. After each run (90 min) the column was rinsed for at least 30 min 
because of contamination with Ca-ionophore, which elutes after approx. 115 
min. 
Reversed-phase HPLC of PGs was performed on a Zorbax C8 column. This 
solvent system (B) contained acetonitrile-benzene-water-acetic acid 
(24:0.2:0.1:76, vfv). The flow-rate of this eluent was 2.0 ml/min. From the 
contents of each collected fraction, 50 ,ul were taken and kept at 4 °C for the 
radioimmunoassay (RIA) of the PGs. The main fraction was immediately used 
for 14C and 3H counting. The column was rinsed with acetonitrile for 30 min 
after each sample to elute the lipoxygenase products. 
Radioimmunoassay of prostaglandins 
Reagents were equilibrated to room temperature before use. After the 
addition of standards (range 0-500 pg) and diluted samples, [3H] PG and 
antibody were added. At the end of the incubation (2 h at room temperature 
and 18 h at 4°C), charcoal suspension was added. The tubes were allowed to 
stand for 15 min at 4°C and centrifuged for 10 min at 1400 g. The super-
natants were decanted and mixed with 6 ml of scintillation fluid. The risk of 
cross-reactions was negligible when RIA was performed after HPLC (cross-
reactivities and specifications are given in Tables I and II). 
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TABLE II 
SPECIFICATIONS OF VARIABLE CONDITIONS IN THE RIAs 
Immunogen Amount of added tracer Bound/total(%) Non-specific binding 
dpm pg (%) 
6-Keto-PGF '"' 16,000 18.4 39.7 9.2 
TxB2 15,000 18.5 57.9 1.9 
PGF2a 8,500 9.2 17.0 4.5 
PGE2 12,500 13.0 40.1 3.9 
PGD2 8,500 10.7 34.3 7.4 
Quantitative evaluation 
The settings for double-labelled scintillation counting were such that there 
was no spillover of radioactivity of 3H into the 14C channel. Calculations of 
dpm were carried out using quenched standard sets by a computer (Digital, 
PDP 11/70). For daily analysis, a plotting system was programmed in order 
to obtain data of total counts covering the peak areas. Amounts calculated 
in dpm of both channels were plotted as separate chromatograms. 
The data obtained from the RIAs were linearly plotted as the ln (mass) 
against the negative (-) ln {%B/(100- %B)} (where B=bound). The linearity 
was tested by means of a variance analysis. 
RESULTS AND DISCUSSION 
Fig. 1 shows a representative chromatogram (one of five experiments) of 
LTs and other lipoxygenase products, after F4 C] AA labelling of the lung 
tissue. The upper part of the figure represents the mass, measured by absorp-
tion at 280 nm. It is evident that substances are present with the same reten-
tion times (tR) as LTs, indicated by C, D and B. The major compound is LTB4 , 
whereas LTC4 is hardly detectable because of the strong tailing effect, caused 
by substances with identical chromatographical properties to some of the 
phospholipids, running on the front. Based on the retention time, peak 1 is 
tri-HETE, and peak 2 is 6-trans-LTB4 + 12-epi,6-trans-LTB4 , according to 
Verhagen et al. [12]. 
The lower curve of the HPLC separation gives the plotted 14C-labelled frac-
tions. Peak 1 covers both the above-mentioned tri-HETE and a substance with 
the same tR as LTC4 • Prostaglandins, however, nearly cochromatograph with 
LTC4 , so that a not unimportant part of peak 1 is due to the presence of cyclo-
oxygenase products. The compound indicated by H is most probably HHT 
(12-0H-5,8,10-heptadecatrienoic acid). The identification of this peak was 
based upon the following observation: washed rat platelets were labelled with 
[14 C] AA as described before [13], aggregated with collagen, extracted as 
described above and applied to HPLC for further analysis. Our earlier observa-
tions on platelet aggregation indicate that the main compounds formed are, 
respectively, 12-HETE, HHT and TxB2 • A similar result was obtained by 
Luderer et al. [14]. As in our system, TxB2 cochromatographs with LTC4 and 
the retention time of 12-HETE appeared to be approx. 60 min; the peak at 
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26 min is likely to be HHT. In the example shown in Fig. 1, relatively large 
amounts of HETEs are formed. 
Table III lists the recoveries (mean± S.E.M.) of 3H-labelled standards added 
to tissue samples. It is remarkable that the overall recoveries of HETEs are 
low, especially of 5-HETE. The chromatogram given at the bottom of Fig. 1 
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Fig. 1. Chromatograms of LTs and HETEs, synthesized by chopped human lung tissue, 
after [ 14C]AA loading, in the presence of glutathione (2 mM) and Ca-ionophore A23187 
(approx. 10 ~tM). The incubation medium was processed through Sep-Pak C18 and silica 
cartridges as described in Experimental and the methanol fractions after evaporation to 
dryness were subjected to HPLC in solvent system A. A Chrompack Nucleosil 5C18 column 
(250 X 4.6 mm) was used. Mobile phase: tetrahydrofuran-methanol-water-acetic acid 
(25:30:45:0.1) adjusted to pH 5.5 with ammonium hydroxide. Flow-rate 0.9 ml/min. 
The chromatogram at the bottom, representing radioactivity in fractions of one per min, 
is corrected for delay time between the absorption cell and the fraction collector. Peaks: 
C = LTC4 , D = LTD4 -like, B = LTB4 , 15 = 15-HETE, 12 = 12-HETE and 5 = 5-HETE. Based 
on retention times, 1 = tri-HETE, 2 = 6-trans-LTB4 + 12-epi,6-trans-LTB4 • 
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TABLE III 
RECOVERIES OF TRITIATED LTs, HETEs, AND PGs, MEASURED BY HPLC 
Data were obtained after the extraction procedure as described in the methods section. 
Values are given as the mean± S.E.M. 
Recovery (%) n 
LTC4 59± 5.0 3 
LTD4 -like 86 ± 1.5 3 
LTB4 70 ± 5.7 3 
15-HETE 34 ± 1.1 3 
12-HETE 34 ± 0.9 3 
5~HETE 18 ± 0.6 3 
6-Keto-PGF , 00 64 ± 2.9 8 
TxB2 86 ± 2.7 8 
PGF2 44 ± 1.8 8 
PGE2 73 ± 2.9 8 
PGD2 59± 2.6 8 
is not corrected for recoveries listed in Table III; in this case the plotted quan-
tity of 5-HETE should be three times higher compared to the leukotrienes. 
Furthermore, there is a pronounced difference in recovery of certain PGs 
obtained from HPLC separations as shown in Fig. 2. Fig. 2A shows the internal 
PG standards CH), fig. 2B the 14C-labelled PGs formed from exogenous AA. 
The small peak 2 shows the immunoreactivity of 6-keto-PGF 100 , and the wide 
peak 5 that of TxB2 • However, peak 6 (PGF-immunoreactive), peak 7 (PGE-
immunoreactive) and peak 8 (PGD-immunoreactive) do not have the same tR 
as the added 3H standards. The longer the tR, the greater the delay between 
3H-labelled and unlabelled material. 
Determination of the amounts present in the sample by the different RIAs 
is represented in Fig. 2C. In this case, the immunoreactivities of the PGs men-
tioned before have the same tR as the 14C-labelled compounds. Others have 
noticed that a difference exists between the tR of PGs labelled with 3H or 
14C [15]. This might be due to the isotope effect. Four double bounds are 
labelled with 3H whereas 14C only is labelled on the !-position. Increase of 
the mass plays an unimportant role, because spheric occlusion occurs at molec-
ular weights of 2000 and higher (MWp6 approx. 350). It would appear that 
labelling with 3H makes these substances more hydrophilic. Fig. 3 confirms 
the findings presented in Fig. 2. Commercially available 3H- and 14C-labelled 
PGE2 and PGF 200 have a difference in retention times of approx. 5%. This 
could be a reason of errors in selecting the wrong fractions for RIA when. 3H-
labelled standards are used as markers. 
A second observation that needs further explanation is the difference that 
occurs in the specific activities of the PGs. This can be calculated from the 
data presented in Fig. 2. The pattern of 14C-labelled and RIA-determined 
amounts is not identical. In this case, there is even a difference by a factor 
of 4 between the highest and the lowest specific activity (expressed as dpmjng, 
covering the whole peak area). Peaks 3 and 4 in Fig. 2B are unknown. 13,14-
Dihydro-15-keto-PGs run after 80 min, so that differences are not caused by 
these compounds. · 
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Fig. 2. Reversed-phase HPLC separation of PGs in the same sample as used in Fig. 1. A 
Chrompack Zorbax BP5 column was used; the solvent system contained acetonitrile-ben-
zene-water-acetic acid (24:0.2:76:0.1); the flow-rate was 2 ml/min. One fraction per min 
was collected and divided as described in the text. (A) Chromatogram of [ 3 H]PG standards. 
Peaks: K = 6-keto-PGF "''' T = TxB2 , F = PGF '"'' E = PGE2 and D = PGD2 • (B) Chromato-
gram of 14C-labelled compounds. Identification of peaks 1-8 is discussed in the results 
section. (C) Measurement of the fractions in (A) by RIA. 
Fig. 4 shows the chromatograms of an experiment in which 3H-labelled LTs 
were used as markers, without the addition of [14C] AA to the tissue. Several 
problems arise when the LTs in the tissue are identified with the use of 3H-
labelled substances_ This difficulty is due to the fact that in LTC4 and LTD4 
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Fig. 3. Chromatogram of collected fractions (two per min) after the injection of 3 H- and 
"C-labelled PGF za and PGE,. The chromatographic conditions were the same as described 
in Fig. 2. This chromatogram was plotted by means of a computer-programmed XY printer. 
Peaks: HF = [3H]PGF2 a, CF = [' 4 C]PGF2 a, HE= [3H]PGE., CE = [ 14C]PGE2 • 
one double bound is 3H-labelled, and in LTB4 this amount is four. The latter 
is comparable with the labelled PGs (see section on radiochemicals). In Fig. 
4A, pe~ks 2 and 5 have approximately the same tR as in Fig. 4B. The delay is 
only ± 2%. However, the difference is much greater between peak 6 of Fig. 
4A and peak 8 of Fig. 4B. Batch 9 of the [3H] LTB4 used in the experiment 
as shown in Fig. 4A proved to be a racemic mixture of 6-trans-LTB4 and 12-
epi,6-trans-LTB4. We thereafter injected both batch 9 and the newly prepared 
batch 10 directly into the HPLC system. The tR of the first peak was the same 
as the one obtained in Fig. 4A after extraction procedures. The second peak 
(batch 10) had a delay of approx. 1 min. Compared to Fig. 4B, these two 
peaks were shifted 8% tR. Peaks 3, 5 and 7+8 were collected in order to com-
pare the biological activity of the so far unknown compound 5. The fractions 
were evaporated to dryness, dissolved in Krebs' buffer and added to a guinea 
pig lung parenchymal strip, as described before [5]. Expressed in factors of 
potency, the biological activities were respectively: peak 3 (LTC4 -like), 20; 
peak 5, 5; peak 7+8 (LTB4-like), 1. The unknown peak 5 could be LTE4 on 
the basis of its tR [9, 16] and activity [9, 17, 18]. 
Finally, we determined the presence of glutamine and glycine in the hydro-
lysed fraction, compared to standards of L TC4 (containing cysteine--glycine-
glutamine) and LTD4 (containing cysteine-glycine), following the method as 
described earlier [19]. In this fraction 5, a relatively small amount of glycine 
was present. We concluded from these data that this compound may be LTE4*. 
*During the preparation of the manuscript, synthetic LTE4 was obtained. It shows the same 
tR as the compound described here. 
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Fig. 4. Reversed-phase HPLC separation of LTC4 , LTD4 and LTB4 • (A) 'H-Labelled LTs were 
added to a non-labelled incubation medium of chopped human lung tissue, triggered with 
Ca-ionophore as described in Experimental. The numbers 2, 5 and 6 indicate the 3 H-labelled 
LTC4 , LTD4 and LTB4 (batch 9), respectively. (B) Measurement of the absorbance at 280 
nm of the same tissue extract as mentioned in (A). (C) Chromatogram of synthetic LTC4 (3), 
LTD4 (4) and LTB4 (7, a degradation product?), directly applied to the reversed-phase HPLC 
system. 
When [3H] LTD4 was injected directly onto the HPLC column, the tR was 
the same as peak 4 in Fig. 4A. 
CONCLUSIONS 
Whole human lung tissue, stimulated with Ca-ionophore A23187, produced 
under the conditions described, large amounts of LTB4 -like compounds and 
less LTC4 and LTD4 • The major PG-like substances were immunoreactive with 
TxB2 , 6-keto-PGF 1" and PGD2 • The role of these different compounds has not 
yet been established. The formation of comparatively high amounts of TxB2 
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and PGD2 in antigen-challenged human lung tissue has been observed [20]. 
TxA2 has bronchoconstrictor activity. The differences observed in the specific 
activities of the .PGs may indicate that these substances are not formed from 
the same AA pool. Identification of AA metabolites could give problems when 
tritiated standards are used, due to the decrease of retention times. Whether 
recently available tritiated L Ts are suitable for receptor binding studies and 
other specific interactions is doubtful as long as it remains uncertain that these 
compounds are pure LTs and not chemically degraded products. 
The conversion of LTC4 in LTD4 by -y-glutamyltranspeptidase is inhibited 
by serine--borate complex [21]. Although in receptor binding studies in guinea 
pig lung, [3H] LTD4 was not metabolized to LTE4 [22], this bioconversion 
was demonstrated in experiments with guinea pig ileum. In the presence of 
L-cysteine, the conversion of LTD4 to LTE4 was largely inhibited [23]. In 
future work, the effect of a 5-lipoxygenase inhibitor on the formation of 
PGs will be investigated, as well as the differences in AA metabolism of lung 
tissue obtained from asthmatics and non-asthmatics [24]. 
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4.2.2 
FORMATION OF PROSTAGLANDINS AND LEUKOTRIENES BY HUMAN LUNG TISSUE IN 
VITRO AFTER ACTIVATION BY THE CALCIUM IONOPHORE A23187 
Reproduced from the European Journal of Clinical Investigation, 
1987; 17: 325-329, with permission of 
Blackwell Scientific, Oxford, U.K. 
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Formation of prostaglandins and leukotrienes by 
human lung tissue in vitro after activation 
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Abstract. The formation of metabolites of arachidonic 
acid by the cyclo-oxygenase and lipoxygenase path-
ways were determined in human lung tissue, obtained 
from surgery. In this measurement the chopped tissue 
was incubated with the calcium ionophore A23187. 
Formation of metabolites from [l-14C] arachidonic 
acid was also determined. The metabolites were 
extracted, separated by HPLC and identified by 
measurement of the absorption spectrum at 280 nm, 
radioactivity, biological activity and by radioimmu-
noassay. 
6-keto-prostaglandin F 1• (6-ketoPGF1.), the meta-
bolite of prostacyclin, is the cyclo-oxygenase product 
present in the highest amount (400±49 ng g- 1), 
followed by PGD2 (162±59 ng g- 1) thromboxane B2 
(102±32 ng g- 1) PGE2 (104±46 ng g- 1) and PGF2a 
(58±26 ng g- 1). The amounts of the Iipoxygenase 
products are: leukotriene B4 (LTB4), 163± 100 ngg- 1; 
LTC4, 63±31 ngg- 1 and LTE4 121 ±34ngg-1• From 
[l-14C] arachidonic acid higher amounts of the.cyclo-
oxygenase than of the lipoxygenase products were 
formed, with the exception ofPGE2• 
The effects of several of these substances on the 
contraction of human small airway smooth muscle 
were measured. The contractions, induced by equiva-
lent amounts of L TC4 and a synthetic analogue of 
thromboxane T x A2 were approximately one hundred 
times those induced by PGD2, PGF2• and histamine. 
These results suggest that thromboxane A2 and 
LTC4 are the most important arachidonic acid meta-
bolites that induce bronchoconstriction in the human 
lung. 
Keywords. Prostaglandins, leukotrienes, thromboxane 
A2, human lung tissue, human small airway smooth 
muscle. 
Introduction 
The metabolites formed from arachidonic acid by the 
cyclo-oxygenase and lipoxygenase pathway have 
Correspondence: Dr J. E. Vincent, Department of Pharmacology. 
Faculty of Medicine, Erasmus University Rotterdam, P.O. Box 
1738, 3000 DR Rotterdam, The Netherlands. 
numerous effects on the contractility and other proper-
ties oflung tissue. Some of these actions resemble those 
that occur during asthma and related diseases. For this 
reason the possible role of prostaglandins and leuko-
trienes as mediators of the pathological changes 
occurring in these diseases seems of interest. When 
lung tissue is stimulated by an immunological reaction, 
phospholipase C and A2 are activated, resulting in the 
release of arachidonic acid and the formation of the 
metabolites. Inhalation ofPGE2 induces relaxation of 
bronchial smooth muscle in asthma patients. PGF2• 
induces a bronchoconstriction, both in normal and 
asthmatic patients. The latter are particularly sensitive 
to this compound [1]. Recently, it has been demon-
strated that PGD2 also has a potent bronchoconstric-
tive effect in humans [2]. TxA2 has a similar activity [3]. 
All these compounds are formed by lung tissue after 
the induction of an anaphylactic reaction [4]. 
It is likely that one or more of the substances formed 
through the lipoxygenase pathway also participate in 
the pathogenesis of asthma and related diseases. The 
effects ofL TB4 are the induction of vascular permeabi-
lity and enhanced granulocyte adherence and migra-
tion. This results in peripheral neutropenia and leuco-
cyte accumulation [5]. LTC4 and LTD4 induce 
bronchoconstriction, reduce the clearance of mucus 
and increase vascular permeability [7]. 
The formation of PG and L T by human lung tissue, 
after activation by the calcium ionophore A23187, was 
determined in these experiments. This is a measure of 
the formation from arachidonic acid present in the 
tissues. The formation after labelling the tissue with 
[l-14C] arachidonic acid was also determined. 
Patients and methods 
Patients 
Lung tissue was obtained from ten patients (aged 
53-75) undergoing surgery on account of bronchial 
carcinoma. The following drugs were administered: in 
premedication, atropine and Opial® and during the 
operation, Fentanyl, pancuronium bromide, thiopen-
tal and cephalothin. 
Methods 
Preparation of lung tissue. Immediately after sur-
gery, a macroscopically normal part of the tissue that 
was not connected with the tumour was dissected free 
from major blood vessels and bronchi. Tissue (8-10 g) 
was chopped and erythrocytes removed after lysis by 
washing. After centrifugation, 20 ml Krebs buffer was 
added to the pellet and the mixture gassed with 
carbogen (95% 0 2 +5% C02). One microcurie [I-14C] 
arachidonic acid per gram, 100 Jti glutathione (final 
concentration 1 mM) and IOO pl A23187 (final concen-
tration 10 pM) were added. Mter IO-min incubation, 
100 pi serine (final concentration 0·25 mM) were added 
and after 15-min incubation 50 pi of a mixture of 
[3H]LT and [3H]PG. Thereafter, the suspension was 
centrifuged at 1600 xg. The supernatant was 
decanted. Twenty millilitres Krebs buffer was added to 
the pellet and again centrifuged at 1600 xg. The 
supernatants were centrifuged for I h at 30 000 x g at 
4°C. The clear supernatant was then applied to a SEP-
PAK C18 and a SEP-PAK silica cartridge. The car-
tridges had been prewashed with methanol and water. 
Prior to the elution, the cartridges were washed with 5 
rn1 water and then the samples eluted with 5 ml 
methanol. The elutates were combined and dried in a 
stream of N2 at 40°C. The dried sample was then 
dissolved in I mi of solvent A (tetrahydrofuran-
methanol-0·1% EDTA in water-acetic acid, 
25:30:45:0-I vfv, adjusted to pH 5·5), filtered and 
kept in a polypylene micro vial. Reversed phase HPLC 
of LTs was performed on a Nucleosil 5C18 column 
using solvent system A and for PGs on a Zorbax C8 
column with solvent system B (acetonitrile-benzene-
water-acetic acid, 24:0·2:76:0-I vfv) The separation 
and identification of the fractions have been described 
before [8]. 
In the identification of the substances present in the 
lung extract obtained after separation by HPLC, the 
following methods were used: (i) the absorption at 280, 
270 and 234 nm, (ii) the measurement of the radioacti-
vity, (iii) the determination of the quantity by RIA, (iv) 
the determination of the biological activity, (v) the 
measurement of the absorption spectrum at different 
wave lengths. In this way both the formation from 
endogenous and exogenous arachidonic acid has been 
determined. 
Chemicals. LTB4, LTC4, LTD4 and LTE4 were gifts 
from Dr J. Rokach (Merck Frosst, Canada). PGD2, 
PGE2, PGF2., 6-keto-PGF1• and TxB2 were obtained 
from Sigma, U.S.A., the thromboxane mimetic U-
44069 (9, 11 didioxy, 9, !!-epoxy methano prostaglan-
din F2.) from Upjohn, U.S.A. and· methacholine 
hydrobromide and histamine hydrochloride from 
Janssen Pharmaceuticals, Belgium. Siliclad® was 
obtained from Clay Adams (Beckton Dickinson, 
U.S.A.). Tetrahydrofuran, methanol, acetonitrile, 
benzene and acetic acid were all of analytical grade and 
obtained from E. Merck, F.R.G. Picofluor was used as 
99 
a premixed scintillation cocktail and was obtained 
from Packard, Belgium. 
Radiochemicals. [!-14C] arachidonic acid (specific 
activity 55 mCi mmoi-1) was purchased from New 
England Nuclear. The following compounds were 
obtained from the Radiochemical Centre (Amersham, 
U.K.): [5,6,8,9,11,I2,14,I9H(n)] LTB4 (2IO Ci 
mmoi-1), [I4,I9H(n)] LTC4 (36 Ci mmoi-1), [14,I5-
3H(n)] LID4 (42 Ci mmoi- 1), 6-keto-
[5,8,9,II,I2,I4,I5-3H(n)] PGF1• (150 Ci mmoJ-1), 
[5,6,8,9,11,I2,I4,I5-3H(n)] TxB2 (I77 Ci mmoi- 1), 
[5,6,8,ll,I2,I4,I9H(n)] PGE2 (160 Ci mmoi-1), 
[5,6,8,II,I2,I4,I5-3H] PGF2o (I60 Ci mmoJ-1) and 
[5,6,8,9,I2,I4,15-3H(n)] PGD2 (184 Ci mmol-1). The 
purity of the radiochemicals was shown to be greater 
than 97%. 
Materials. SEP-PAK C18 and silica cartridges and 
HPLC-solvent filters HA (0·45 pm) and FH (0·5 m) 
were obtained from Waters Associated and prepacked 
HPLC columns Nucleosil 5C18 and Zorbax BPtmC18 
(each 250 x 4·6 mm) from Chrompack (Middleburg, 
The Netherlands). HPLC micro vials were obtained 
from Weichmann Plastics, Switzerland. 
Anti-sera. Anti-TxB2, anti-PGF2o, anti-PGE2 and 
anti-PGD2 were obtained from l'Institut Pasteur 
(Paris, France); anti-6-keto-PGF1• from Seragen (Bos-
ton, U.S.A.) and anti-LTB4 from Wellcome. The 
cross-reactivities of the PG have been reported earlier 
[8]. Those of LTB4 are given in Table I. 
Radioimmunoassay. The determination of the PG 
has been described before [8]. The method of Salmon 
was used in the determination of L TB4 [9]. 
Bioassay. Biological activities of Ieukotrienes 
formed by human lung tissue and separated by HPLC 
were measured on a guinea-pig lung parenchymal strip 
[3]. Samples of fractions were dried under nitrogen, 
dissolved in Krebs buffer and applied to a strip. The 
contractile response was measured and compared with 
the amounts calculated by UV-monitoring of the 
HPLC fractions. 
Table 1. Cross-reactivities of the LTB4-antibody. 
Data are expressed in per cent at 50% B/Bo 
(B=bound) 
LTB4 
LTC• 
LTD• 
5-HETE 
12-HETE 
15-HETE 
PG 
Arachidonic acid 
100 
0·03 
0·03 
0·03 
2·0 
<0·03 
<0·03 
<0·03 
100 
Measurement of human small airway smooth muscle 
contractions. This method has been described earlier 
[10]. In brief, bronchioles are dissected free from 
parenchyma and blood vessels and extensively washed 
to remove anaesthetics. Six bronchiolar strips were 
mounted in 10-ml double-jacketed organ baths con-
taining aerated buffer at 37°C. The contractile re-
sponses were measured isotonically using Penny & 
Giles transducers. Cumulative concentration-re-
sponse curves were prepared by adding agonists in 
small volumes. The concentration of the agonist that 
produced 50% of the maximal contraction was deter-
mined (ECso). 
Results 
In the lung tissue, after incubation with A23187, 
extraction and separation of the lipoxygenase pro-
ducts, LTB4, LTC4 and LTE4 were present (see Fig. !.). 
The other two peaks have not yet been identified; they 
may represent hydroxylated derivatives, such as 20-
0H LTB4 • This represents the formation from arachi-
donic acid present in the tissue. In another experiment, 
the tissue was incubated with [l-14C] arachidonic acid 
and A23187 and the lipoxygenase products deter-
mined. In the determination of the PG, the substances 
formed after incubation with either A23187 or [1- 14C] 
arachidonic acid and A23187 were separated. The 
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Figure 1. Chromatogram ofLT, synthesized from chopped human 
lung tissue. after incubation with the calcium ionophore A23187 
(approximately 10 J'M) in the presence of glutathione (I mM). 
Separation was obtained by means of a Nucleosil SC1s column. 
Mobile phase: tetrahydrofuran-methanol-acetic acid-0·1% (w/v) 
EDTA in water, pH 5·5 (25:30:0·1:45). Flow rate 0·9 ml min- 1; 
oven temperature 3TC; absorption: 0·06 A UFS--at t = 0, 280 nm; at 
1= 15, 270 nm; at 1=30. 234 nm. 
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Figure 2. Reversed-phase HPLC separation of[l-14C] PG. A Zorbax 
BP5 column was used; the solvent system contained acetonitrile-
benzene-water-acetic acid (24:0·2:76:0·1); the flow rate was 2 m1 
min - 1• oven temperature 37°C. One fraction per minute was 
collected, counted and plotted. 
Table 2. Formation of arachidonic acid metabolites in human 
lung tissue activated by A23187 
6kPGF, 
TxB, 
PGF,. 
PGE, 
PGD, 
LTB4 
LTC• 
LTE• 
Formation from added 
Formation from arachidonic [l- 14q arachidonic 
acid in the tissue (ngg- 1) acid (ngg- 1) 
400±49 
102±32 
58±26 
104±46 
162±59 
163±100 
63;!:31 
121±34 
44±8·5 
15±1·9 
11±4·0 
6±1·2 
36±15 
10±3-3 
ND 
5±1·4 
The values are expressed as means± SEM . 
Patients were non-smokers and had no chronic obstructive 
pulmonary disease, n = 7. 
result is shown in Fig. 2. The metabolite of prostacyc-
lin (6-keto-PGF1") and PGD2 arepresentin the highest 
amounts. The formation of the eicosanoids is given in 
Table 2. Only the production of LTC4 from arachido-
nic acid present in the tissue is given, not the one from 
the labelled substance. This is due to the overlapping of 
the curves for PG and LTC4 in the chromatogram of 
the labelled compounds in our system. 
In order to compare the bronchoconstrictive activity 
of the substances with the amounts formed by the lung 
tissue, the effects of L TC4, the thromboxane analogue 
U-44069, PGD2, PGF2«, histamine and methacholine 
on the contraction of human small airway smooth 
Table 3. ECso values for LTC,. the throm· 
boxane mimetic U-44069, PGD,, PGF 2, 
histamine and methacholine, obtained 
from the curves of Fig. 3. 
Agonist 
LTC, 
U-44069 
PGD, 
PGF,. 
Methacholine 
Histamine 
ECso SEM 
5·89 x w-• + 0'47 x w-• 
1·23 x w-•± O·I7x to-• 
4·01 x w-• ± 0·42 x to-• 
1·35 x w-'± t·06x to-' 
1·45 x w-• ± 0·30 x w-• 
9·80 x w-7 ± 4·48 x w-7 
Results expressed as means± SEM. 
muscle were compared (Table 3). The contractions are 
expressed as a percentage of the maximum value of 
methacholine. L TC4 and the thromboxane analogue 
U-44069 are one hundred times more potent than 
PGD2, PGF2a and histamine. 
Discussion 
The order of the amounts of the cyclo-oxygenase 
products formed in the lung tissue for the endogenous 
production is: 6-keto-PGF1,, the metabolite ofprosta-
cyclin, PGD2, PGE2, TxB2, PGF2a. It is conceivable 
that, when lungs are activated in vivo by an immunolo-
gical process, the tonus of the bronchial smooth 
muscle depends, insofar as the cyclo-oxygenase pro-
ducts are concerned, on the relative amount ofPGE2, 
with a relaxing effect on one side; and ofPGD2, PGF2a 
and TxB2, which act as bronchoconstrictors on the 
other side. LTC4 and LTE4 also induce bronchocon-
striction and L TB4 to a much lesser extent. The effect 
of L TE4 is lower than that of L TC4, as measured on the 
guinea-pig parenchymal lung strip [11]. In the chroma-
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togram of Fig. I, no peak representing L TD4 is 
present. In guinea-pig lung LTD4 is formed. The 
reason for the absence of the formation in human lung 
is not known. 
The activity of these substances has also been tested 
on human small airway smooth muscle. The TxA2 
mimetic U-44069 and LTC4 have similar effects and 
are approximately one hundred times more potent 
than PGD2, PGF2a and histamine. An example of the 
contractions obtained is shown in Fig. 3. In other 
experiments it has been demonstrated that 115 ng 
TxA2, formed by aggregating blood platelets, contract 
a human lung strip [3]. This is of the same order of 
magnitude as the amount formed per gram of lung 
tissue. These results indicate that the contributions of 
PGD2 and PGF2a are of minor importance. Even-
tually, other activities than bronchoconstriction by 
these substances could play a role. 
The amount of L TC4 formed in the tissue activated 
by the ionophore is sufficient to induce contractions in 
the human lung strip. A 50% contraction is obtained 
with approximately 40 ng (Fig. 3). In this experiment 
the effect of exogenously added compounds is mea-
sured. It was shown that the effect of TxA2 formed 
inside the tissue is considerably higher than that of the 
exogenously added compound [12]. For this reason the 
contractile effects of the PG and L T formed in the lung 
are most probably higher than those indicated in Fig. 
3. 
In the experiments reported here, the overall effect 
of lung tissue on PG and L T synthesis after calcium 
ionophore-induced activation is measured. It has been 
shown that several types of cells contribute to the 
formation of the PG and LT. Activated human lung 
mast cells form mainly PGD2, LTC4 and LTB4 [13]. In 
a fraction containing monocytes and macrophages 
TxB2, PGF2, and immunoreactive PGE were formed 
[14]. Sautebin eta!. consider the macrophages as the 
Concentration agonist (mol 1-1) 
Figure 3. Contraction of human small airway smooth muscle. Mean concentration-response curves for LTC4 (e). the 
thromboxane mimetic U-44069 (0), PGD, ("), PGF, (A), histamine (II) and metacholine (D). The results are expressed as a 
percentage of the maximal contraction induced by metacholine. 
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most important source of L Tin human lung tissue [15]. 
In our own experiments, L TD4 and L TB4 were formed 
in approximately equal amounts in human pulmonary 
macrophages isolated from human lungs after acti-
vation by the A23187 (unpublished). 
A number of observations indicate that a relation-
ship may exist between the formation of L Tin the lung 
and the pathophysiological changes occurring in some 
types of asthma, e.g. the one sensitive to aspirin, and 
related allergic diseases. Dahlen et al. observed long-
lasting contractions induced by L TC4, LTD. and L TE4 
after allergenic challenge in bronchi from asthmatics 
[16]. After an allergic reaction, increased amounts of 
LTC4 were found in the tears of patients with allergic 
conjunctivitis [6]. Furthermore, after allergenic chal-
lenge of patients with rhinitis, L TC4, LTD4 and L TE4 
are present in the nasal fluid [17]. During asthmatic 
attacks the decrease in mucociliary clearance can be 
blocked by the LTantagonist FPL 55712 [18]. LTB4 is 
chemotactic and may induce the accumulation of 
eosinophils occurring in bronchoconstriction [19]. 
These cells can produce comparatively large amounts 
of L TC4 [20]. 
Our results indicate that TxA2 and L TC4 are the 
most important arachidonic acid metabolites in the 
induction of bronchoconstriction of the human lung. 
It would be interesting to compare the formation of 
these compounds in the lungs of normal and asthmatic 
patients. The pharmacological properties, and also 
results of clinical tests of a number of synthesis 
blockers and receptor antagonists of the leukotrienes, 
have been discussed recently [21]. Their role in the 
treatment of asthma is a subject for further investiga-
tion. Other substances with potent bronchoconstric-
tive properties, e.g. the platelet activating factor, could 
also be involved. 
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Pulmonary Alveolar Proteinosis: Determination of 
Prostaglandins and Leukotrienes in Lavage Fluid 
Fred erik J. Zijlstra,l·* J. Eric Vincent ,I Bart van den Berg, 2 
Henk C. Hoogsteden,2 Herman J. Neyens,3 and Jacques J. M. van Dongen4 
Departments of 1Phannacology, 2Pulmonary Medicine, 3Pediatrics, and 4Cell Biology, 
Erasmus University and Academic Hospital Dijkzigt, Rotterdam, The Netherlands 
Abstract. In bronchoalveolar lavage fluid from a patient with pulmonary 
alveolar proteinosis, leukotrienes and prostaglandins were measured on 4 
occasions during 10 months. Large amounts of leukotriene-C4-like sub-
stances (10-25 nmol) and oxygenated products of leukotriene B4 were de-
tected. These substances were characterized by the measurement of absorp-
tion spectra in high-performance liquid chromatography, biological activities 
by means of guinea pig lung parenchymal strips, and immunoreactivities in 
radioimmunoassay. The cyclooxygenase products of arachidonic acid were 
present in lower amounts (40-500 pmol). 
Our results indicate that arachidonic acid metabolites are mainly present 
in the first fraction of the lavage fluid. These substances may have been 
formed by alveolar macrophages. 
Key words: Leukotrienes-Prostaglandins-Pulmonary alveolar proteino-
sis-Lavage fluid. 
Introduction 
In pulmonary alveolar proteinosis (PAP), proteinlike material is accumulated in 
the alveoli. This leads to impaired gas exchange in the alveoli and a decreased 
lung capacity. Surfactant, consisting in part of dipalmitoyl phosphatidylcho-
line, is present in the accumulated material [14]. Several investigators indicate 
that the impaired breakdown of the surfactant is 1 of the main factors in the 
pathologic changes. This effect is attributed in part to a diminished function of 
the pulmonary macrophages [6]. It has been demonstrated that phospholipase 
* To whom offprint requests should be addressed at Department of Pharmacology, Erasmus 
University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands 
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A2 is present in the pulmonary secretion of patients with PAP, [15]. This en-
zyme plays a role both in the formation and breakdown of the surfactant [7]. 
Phospolipase A2 releases arachidonic acid (AA) from phospholipids. AA is 
transformed by both cyclooxygenase and lipoxygenase into prostaglandins and 
leukotrienes, respectively. Several of these substances have effects on lung 
function. Bronchoconstriction is induced by thromboxane Az, prostaglandins 
F2a and D2 [5], and the leukotrienes LTC4 and LTD4 [1]. The latter substances 
also increase mucus secretion [11] and the vasopermeability of the lungs [17]. 
In the experiments presented here, prostaglandins and leukotrienes were mea-
sured in the lavage fluid of a patient with PAP. In the identification of the 
substances the following methods were used [22]: absorption at 280 and 270 nm 
and quantitation with external standards, determination of the quantity by 
radioimmunoassay (RIA), determination of the biological activity, and mea-
surement of the absorption spectrum. 
Case Report 
Case History 
An 11-year-old girl had complained of a dry cough, fatigue, and dyspnea on 
exertion. Auscultation revealed no abnormalities, while respiratory frequency 
was 60 per minute. The chest roentgenogram showed a fine, diffuse infiltrate 
most pronounced in the upper lobes. Lung function tests revealed a forced vital 
capacity (FVC) of 700 mi (26% of expected) at admission, which rapidly de-
creased to 460 ml. The blood gas levels were as follows: Pa02 = 6.8 KPa; Sa02 
= 84%; PaC02 = 5.2 KPa. Treatment with prednisone induced a worsening of 
the symptoms. Lung biopsy revealed a typical picture of alveolar proteinosis. 
Bronchoalveolar Lavage 
The first lavage was performed using cardiopulmonary bypass. With the patient 
under general anesthesia a balloon-cuffed endotracheal tube was inserted 
through the mouth. The lungs were ventilated with 60% oxygen, while both 
femoral veins and the right femoral artery were cannulated and cardiopulmo-
nary bypass established with a 2.5 m2 Kolobow spiral membrane oxygenator 
(Sci-Med. Inc., Minneapolis, MN). When a flow of approximately 2.5 L!min 
was achieved, ventilation of the lungs was stopped. Lavage of both lungs was 
started after establishment of adequate arterial blood gases. The lungs were 
filled with 500 ml saline at 37°C to 40 cmH20 pressure and emptied to a negative 
pressure of 10 cmH20. Each cycle of filling and drainage required approxi-
mately 6 min. The sequence was repeated until lavage with 20 L was accom-
plished. 
The next lavages were performed ventilating llung. A balloon-cuffed endo-
tracheal tube was inserted through the mouth into the right main bronchus and 
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the right lung was ventilated with 60% oxygen. A 10 Fr suction catheter was 
inserted through the mouth into the left main bronchus. Lavage of the left lung 
was performed in the same way using aliquots of 100 ml saline. After 2 weeks 
lavage of the other lung was performed. During each procedure lavage with 7 L 
saline could be accomplished. 
The patient improved symptomatically after the procedures. 
Materials and Methods 
Apparatus 
A 1082 B high-performance liquid chromatograph (HPLC, Hewlett Packard) was used, consisting 
of variable wavelength detector and scanning mode. The Superrac fraction collector (LKB, Swe-
den) was connected to this apparatus. Radioactivity was measured in a 3255 Tricarb scintillation 
counter (Packard, Brussels, Belgium). 
Chemicals 
LTB4, LTC4, LTD4, and LTE4 were gifts of Dr. J. Rokach (Merck Frosst Canada). Standards of20-
0H-LTB4 were not available. Prostaglandins and thromboxane B2 were obtained from Sigma 
(USA). Tetrahydrofuran, methanol, and acetic acid were all of analytical grade and obtained from 
Merck (Darmstadt, FRG). Picofluor-15 (Packard, Brussels) was used as premixed scintillation 
cocktail. 3H-LTB4, 3H-LTD4, 3H-6-keto-PGF1a, 3H-PGE2 , 3H-PGF2a, and 3H-TxB2 were purchased 
from the Radiochemical Centre (Amersham, UK). The purity of the radiochemicals was shown to 
be greater than 97%. PGE2 , PGF2a and TxB2 antibodies were obtained from l'Institut Pasteur 
(Paris, France); anti-6-keto-PGF1a from Seragen (Boston, MA), and anti-LTB4 from the Wellcome 
Foundation Ltd. 
Materials 
Sep-Pak C,8 and Sep-Pak silica cartridges and filters HA (0.45 JLm) and FH (0.5 JLm) were obtained 
from Waters Assoc. and a prepacked Nucleosil 5C 18 HPLC column (250 x 4.6 mm) from Chrom-
pack (Middelburg, The Netherlands). 
Sample Preparation 
Fifty m1 samples of lavage fluid were used. 3H-LTD4 was added as an internal standard (approx. 
10,000 cpm per sample), to calculate the recoveries after extraction. The fluid was applied to a Sep-
'Pak C18 and silica column, pretreated as described before [22], eluted with methanol and evapo-
rated to dryness under nitrogen. The extract was dissolved in 300 JLl HPLC eluent, centrifuged (10 
min, 1400 x g), and portions of 50 JLI were injected on the HPLC column. 
Chromatographic System 
Reversed phase-HPLC (RP-HPLC) of LTs was carried out on a Nucleosi15C18 column, using a 
solvent system consisting oftetrahydrofuran-methanol 0.1% (w/v) EDTA solution in water-acetic 
acid, 25:30:45:0.1 (v/v), adjusted to pH 5.5 with ammonium hydroxide [18, 22]. Mobile phases 
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Table 1. Cross-reactivities for radioimmunoassays of pro-
staglandins (% at 50% B/B0) 
6-keto-PGF1a PGF2a PGE2 TxB2 
6-keto-PGF1a 100 0.04 <0.01 <0.1 
PGF2a 2.2 100 0.11 0.1 
PGE2 0.6 0.03 100 0.1 
TxB2 <0.01 <0.01 <0.01 100 
PGF1a 7.8 12.0 0.01 <0.1 
6-keto-PGE1 6.8 <0.01 0.16 <0.1 
PGEI 0.7 0.03 6.5 <0.1 
PDG2 <0.01 3.0 <0.01 0.2 
PGDI <0.01 0.4 <0.01 <0.1 
Dihydro-PGF2a <0.01 3.0 <0.01 <0.1 
Keto-PGE2 <0.01 <0.01 13.2 <0.1 
Dihydro-PGE2 <0.01 <0.01 2.1 <0.1 
were filtered and degassed with helium. Oven temperature was adjusted to 37°C, the flow rate at 0.9 
ml/min, and the absorption was measured at 280 nm [22]. 
Radioimmunoassay of Prostaglandins 
Ten ml of lavage fluid was applied to a Sep-Pak C18 column and eluted with methanol. A sample of 
200 ,ul was brought into a RIA tube and evaporated to dryness. The extract was dissolved in RIA 
buffer and 3H-PG and antibody were added. At the end of the incubation (2 hat room temperature 
and overnigt at 4°C), charcoal suspension was added. The tubes were allowed to stand for 15 min at 
4°C and centrifuged. The supernatants were decanted and counted. Cross-reactivities of PG-like 
substances are listed in Table I. 
Radioimmunoassay of Leukotriene B4 
RP-HPLC of extracts was performed as described above. Two fractions per minute were collected 
and 25 ,ul portions were used for RIA determination of LTB4 immunoreactive substances. The 
detection range of the LTB4 RIA was 10-1000 pg. Cross-reactivities of LTC4, LTD4, LTE4, and 
other lipoxygenase products were less than 2%. 
Biological Activity 
The biological activity of fractions was tested with a superfused guinea pig lung parenchymalstrip, 
as described before [21]. The detection level of this method was shown to be greater than 0.5 ng 
LTC4 or LTD4. 
Results 
Figure lA shows a representative chromatogram of leukotrienes (LTs) in an 
extract of the first lavage fluid. Portions of 1 L were collected and frozen at 
-20°C without nitrogen for 3 months. The first portion contained large amounts 
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Fig. 1. a Reversed-phase HPLC separation of leukotrienes in an extract of the PAP fluid of the first 
lavage, measured 3 months after BAL. Conditions as mentioned in the methods section. A portion 
of 50 ml of the total volume of 1000 ml was used for further investigations (data in Table 2, 1). b 
Chromatogram ofLTs, measured 2 days after BAL, in the PAP fluid of the second lavage. (volume 
500 ml) The HPLC conditions were the same as in a (data in Table 2, II). c Chromatogram ofLTs, 
measured 2 days after BAL, in the PAP fluid of the third lavage. The fluid was collected in portions 
of 50 ml. This represents the first portion of 50 ml (Fig. 2, fraction 1). d Chromatogram of LTs, 
measured on the day of BAL, of the fourth lavage. This represents the first 100 ml of PAP lavage 
fluid. Peaks: J, 20-hydroxy-LTB.; 2, LP; 3, LTC.; 4, LTh; 5, unknown; 6, LTD4 ; 7, 11-trans-
LTD.; 8, LTE4 ; 9, ll-trans-LTE4 ; 10, 12-epi,6trans-LTB4 + 6-trans-LTB4 ; II, LTB4 • C, D. E, B. 
retention times of synthetic leukotrienes C4 , 0 4 , E4 , and B4 
Table 2. Leukotriene and prostaglandin contents in PAP BALF in 4 collec-
tions (ng of the first L) 
I II III IV 
Date of lavage (d/m) 0402 1305 2305 2810 
Leukotrienes (by HPLC) 
C4, D4 and E4-!ike 12.100 8.000 5.600 32.300 
Day of HPLC after BAL 96 2 2 0 
Prostaglandins (by RIA) 
6-keto-PGF1a 68 68 40 ND 
PGF2a 52 16 21 ND 
PGEz 68 124 30 ND 
TxBz 170 ND 14 ND 
I, lavage of the right and left lungs filled with 500 ml fractions of saline of 
which 1 L was collected for LT/PG determinations (Fig. 1a: 50 ml extracted 
and measured on HPLC) 
II, as I; 2 fractions of 500 ml were collected for experiments (Fig. I b) 
III, lavage of the left lung was performed using aliquots of 100 ml saline. 
50 ml fractions were collected (Figs, 1c and Fig. 2), thereafter, 1 L fractions 
(Fig. 3) 
IV, as III; 100 ml fractions were collected (Fig. 1d) 
ND, not determined 
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of proteins. After centrifugation LTs were measured by HPLC. Relatively 
large amounts were detected, predominantly LTD4-like substances and LTE4. 
The amounts of LTs and PGs in this portion are given in Table 2 (I). 
In a second experiment LTs were determined in fluid obtained from the 
second BAL. In this case HPLC was carried out 2 days after collection. The 
volume of the collected portion was 500 ml. Figure 1B represents a RP-HPLC 
separation of LTs in an extract of this portion. A large unidentified peak is 
present between 6 min and that of synthetic LTC4. The 2 small peaks at reten-
tion time tR 8.5 and tR 9 could be isomers of L TC4 (further indicated as L P and 
LTh). The peak at tR 12 corresponds to the retention time of LTD4. The 
amounts of LTs and PGs are given in Table 2 (II). 
Data from the third BAL, carried out 15 weeks after the first, are shown in 
Figures lC, 2, and 3. HPLC was performed 2 days after collection. For this 
study first portions of 50 ml (Fig. 2) and thereafter of 1000 ml (Fig. 3) were 
collected during lavage. 
The chromatogram of the first 50 ml in Fig. 1 C has nearly the same pattern 
as that of Fig. lB. The only difference is the amount of LTB4-like substance, 
which is not present in Fig. lB. The large peak before LTC4 in Fig. IB (tR 5.5 
min) could be 20-0H-LTB4 [16]. In Figure lC, LTB4 most probably has been 
partially metabolized to this substance. 
In the second portion of 50 ml BALF, the amount of the LTC4-like sub-
stance is decreased, whereas in the third portion only a relatively small amount 
of LTC4-like substance is detected. The LT and PG contents in 6 portions of 50 
ml BALF are shown in Figure 2. In the first and second portion a higher level of 
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ng 
8 
4 
0 
3 5 
50 ml fractions 
ug 
0·8 
E 
6K 
T 
F 
0·4 
0 
Fig. 2. Amounts of LTs (upper part, 
measured by HPLC) and PGs (lower 
part, measured by RIA) of PAP BALF 
from the same collection as in Figure 
lC (third lavage). Lavage fluid was 
collected in portions of 50 mi. LP, 
peak before synthetic LTC4; LTb, peak 
after LTC4; E: PGEz; 6K, 
6-keto-PGF1a; T, thromboxane B2 ; F, 
PGF2a- Leukotrienes were measured by 
HPLC, the prostaglandins and 
thromboxane B2 by radioimmunoassay 
LTa and LTb, 6-keto-PGF1a, and PGF2a is observed. Figure 3 presents these 
arachidonic acid metabolites in the 1 L portions collected after the 50 ml por-
tions. These data indicate that whereas metabolites are present during the 
whole lavage, their amount is enhanced in the first 100 ml of lavage fluid (see 
Fig. 2). The amounts of LTs and PGs are given in Table 2 (III). 
The biological activities of the 2 main LT peaks in Fig. 1 C were investi-
gated by means of a guinea pig lung parenchymal strip. Approximately 10 ng of 
each compound was used, calculated on the basis of synthetic LTC4 • The 
potency ratios proved to be LTC4/LTa/LTb = 1:0.05:0.025. 
In Figure lD the results of the fourth BAL lavage are shown. The first 100 
ml of PAP lavage fluid was taken, extracted, and measured by HPLC on the 
day of BAL. This chromatogram shows 2 main peaks, LP and LTC4 • Further-
more an unknown substance at tR 9.5, a trace of ll-trans-LTE4 and LTB4-
ng 
30 
20 
10 
0 
3 5 7 
1000ml fractions 
ug 
3 
2 
0 
1 1 1 
Fig. 3. Presence of L Ts (upper part, 
by HPLC) and PGs (lower part, by 
RIA) in portions of I L PAP BALF 
collected after the 50 ml portions 
presented in Figure 2. Portion number 
I covers these 50 ml samples 
derivatives (such as 12-epi,6trans-LTB4) were observed. LTB4 was also biolog-
ically converted into 20-0H-LTB4. 
The two LT-peaks at tR 8 in Figure lD proved to have biological activities, 
5-10% of that of synthetic LTC4. Amounts ofLTs and PGs are given in Table 2 
(IV). 
In the PAP fluid LTB4 immunoreactive substances were observed at tR 5.5, 
(20-0H-LTB4), tR 17 (LTB4 isomers), and tR 20 (LTB4). Scans were made of the 
absorption of the LP, LTh, LTC4, and LTE4 peaks. The Emax values were 278, 
272, 270, and 288 nm, respectively. Absorption maxima of synthetic LTC4, 
LTD4 and LTE4 were 280 nm and 272 nm for LTB4-derivatives. The Emax values 
of synthetic 11-trans-LTs and other derivatives could not be determined. 
Discussion 
These results indicate that considerable amounts of L TC4-like substances are 
present in the BALF of a patient with PAP. Two peaks were observed, 1 with a 
slightly shorter and another with a longer retention time of LTC4 (LP and 
LTh). The fact that when the BALF was kept frozen for longer periods mainly 
LTE4 isomers were found indicates that LTa and LTh were most probably 
precursors of this compound. 
An attempt was made to obtain further information on the origin of the LT-
like substances by examining the types of cells in the lavage fluid. Cell differen-
tiations were made of the different portions described in Figure lC. Only the 
first sample contained fragments of macrophages and monocytes. No eosino-
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phils or neutrophils were observed. It has been reported that alveolar macro-
phages produce LTB4 [4]. In human lung parenchyma after allergen challenge, 
LTC~~, D4, and E4 are formed [3]. The origin of the LTs in the experiments 
described here is not yet clear. In Figures 1 and 2, a peak is present with a 
retention time of 5-5.5 min, the same as that of 20-0H-LTB4 , thew-oxidation 
product of LTB4 • LTB4 immunoreactivity was found in the fraction with the 
same tR. This indicates that LTB4 has also been formed, possibly in the alveolar 
macrophages. 
The nature of the substances designated as LTa and L Th has not yet been 
defined. LP is not a tri-HETE because these substances chromatograph at 
elution times between 9 and 10 min. In Figure 1 this could be the peaks indi-
cated by 5. It has been shown that LTC4 is converted spontaneously into the 11-
trans-isomer [9, 19] and that conversion into other oxidation products such as 
15-0H-LTC3 [12] can also occur. During this transformation the biological 
activity may decrease by 90-99% [10]. LTh, with 5% of the activity ofLTC4, is 
possibly 11-trans-LTC4 , according to data provided by Dr. J. Rokach. 
It is of interest to speculate to what extent the substances present in the 
lavage fluid can contribute to the pathologic changes in the disease state. In the 
first liter of lavage fluid, amounts of LTD4 and LTE4-like substances on the 
order of 10-25 nmol were present. It seems likely that these amounts are 
sufficient to induce bronchoconstriction. It has been demonstrated that aero-
sols ofLTD4 induce bronchoconstriction in humans when 10 nmol is inhaled [1]. 
Of this amount, only 5% was deposited in the lungs. A pronounced decrease in 
airflow, mainly in the small airways, was found after inhalation of less than 0.5 
nmol. As the biological activities of LP and LTh are 5% and 2.5% of that of 
LTC4, bronchoconstriction could be induced by the amounts present. 
In comparison with the LTs, the PGs are present in much lower amounts in 
the lavage fluid. Therefore, it is unlikely that these compounds play a role in the 
pathologic effects on the lung described above, since the biological activities of 
PGs and TxA2 are only a few percent of those of the LTs. The PGs present in 
the fluid could be a secondary effect ofLTs, because LTs can release PGs from 
lung tissue [13, 21]. 
The results of HPLC on the BAL in a normal would be of great importance 
in determining the possible significance of these findings, but volunteers for 
BAL under the above described circumstances are not available. A comparison 
can be made with data obtained from BALFs of 6 patients with sarcoidosis 
undergoing lavage for evaluation of the respiratory tract [23 and unpuolished 
data]. In that study BAL was performed with a fiberoptic bronchoscope in 
wedge position in the right middle lobe. Premedication consisted of thiazina-
mium and local anesthesia of the upper respiratory tract with lidocaine spray. 
Fifty ml of 0.9% sterile saline solution at room temperature was inserted in the 
suction part during slow inspiration. The lungs were emptied to a negative 
pressure of 10-15 cmH20 and collected in a specimen trap. This procedure was 
repeated three times. The mean of the total amounts of LT-like substances 
recovered from these BALFs was 260 ± 30 ng. A comparison between the PAP 
BALFs presented in Figure 2 and Table 2 (III) and these data would result in a 
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10-fold increase ofLTs. However, care must be taken because of the different 
techniques used and the absence of real controls. 
Sahu et al. measured fatty acids in the lavage fluid of PAP patients. AA was 
not detectable [14]. It could be that this substances had been released from the 
phospholipids by the phospholipase present in the protein-containing secre-
tions and transformed into the LTs. 
The relationship between the presence of LTs in the lavage fluid and the 
occurrence of symptoms has not yet been established. Although the amounts of 
LTs are large enough to induce bronchoconstriction, there is no evidence that 
this occurs in these patients. It is possible that other biological effects of LTs 
play a role in the pathologic changes. LTC4 and L TD4 induce mucus secretion 
and enhanced vascular permeability [II, 17]. One of or both of these effects 
could lead to the accumulation of proteins in the lung. If this is shown to be the 
case, it would be of interest to investigate the effects of lipoxygenase inhibitors 
[2, 8] or LT antagonists [20] on the course of the disease. 
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ABSTRACT 
Macrophages, isolated from dialysis fluid of three patients with 
continuous ambulatory peritoneal dialysis (CAPD) at different times 
during peritonitis were labelled with 14c-arachidonic acid and stimulated 
with the calcium ionophore A23187. The main metabolites formed by 
5-lipoxygenase activity were leukotriene B4 (LTB4 ) and 
5-hydroxy-6,9,11,14-eicosatetraenoic acid (5-HETE). Smaller amounts of 
cyclooxygenase metabolites were present and also a major compound with an 
elution time between 6-keto-prostaglandin F 1 ~ (6-keto-PGF1 ~) and 
thromboxane B2 (TxB2 ). This substance was isolated, analyzed by GC-MS 
and identified as 20-hydroxy-leukotriene B4 (20-0H-LTB4 ). This indicates 
that human peritoneal macrophages obtained from CAPD not only produce 
leukotrienes and prostaglandins, but also the w-hydroxylase product of 
LTB4 , which has been demonstrated to be present in polymorphonuclear leucocytes. The activity of this enzyme was not correlated with the 
severity of the peritonitis. 
INTRODUCTION 
Continuous ambulatory peritoneal dialysis (CAPD) has become 
increasingly popular in the treatment of end-stage renal disease (ESRD). 
Approx. 15% of all patients in the Netherlands treated for ESRD are on 
CAPD therapy. However, despite this increase in numbers, the major 
complication of this treatment is the frequent development of 
peritonitis. The mean peritonitis incidence still is one episode every 
7.5 patient months (107 patients in 1440 patient months) (1 ). 
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In macrophages (M~) present in different tissues, arachidonic acid 
(AA) is metabolized by both cyclooxygenase and lipoxygenase pathways. It 
has been reported that human peritoneal M~ produce prostacyclin (PGI 2 ), 
thromboxane A2 (TxA2 ), 5-HETE, LTB4 and leukotriene c4 (LTC4 ) after 
activation (2,3). In inflamed tissue, considerable amounts of M~ are 
present and it is likely that the mediators secreted by the M~ contribute 
to the inflammatory changes occurring. Whereas the role of PGE2 in 
several parameters of the inflammatory process such as vasodilatation and 
increased vascular permeability is well documented, much less is known 
about the other PGs, TxA2 and the LTs and HETEs. The in vivo effects of 
LTB4 include chemotaxis for leukocytes and the induction of enhanced granulocyte sticking and-vascular permeability. This makes it likely 
that this substance also participates in the inflammatory process. 
In the experiments described here, the eicosanoid production from 
[1-14c] AA in M~ was determined at different times in the dialysis fluid 
during a peritonitis of three patients with CAPD. The inflammation was 
due to bacterial infection. The production of LTB4 , 20-0H-LTB4 , 5-HETE, 
PG and TxB2 was measured in the course of the peritonitis. The presence 
of 20-0H-LTB4 indicates that metabolism of LTB4 occurs in the M~. It has been shown recently, that the enzyme catalyzing this conversion, 
leukotriene B4 w-hydroxylase is present in human granulocytes (4). 
The results obtained in the present study further demonstrate that during 
the inflammatory process production of AA metabolites by the peritoneal 
M~ is diminished. 
MATERIALS AND METHODS 
Patients 
Peritoneal fluid was obtained from 3 male patients. Peritonitis was 
diagnosed by the presence of cloudy dialysate and a white cell estimate 
in the dialysate of more than 100 per ml. 
Patient R.: age 75, nephrosclerosis; cultures revealed E.coli. Patient 
B.: age 62, diabetic nephropathy; cultures revealed staphylococcus 
epidermialis. Patient deB.: age 67, as patient B. 
Chemicals 
Lymphoprep™ (Ficoll-Isopaque) was obtained from Nyegaard Oslo, 
Norway. Ca-ionophore A23187 was obtained from Hoechst (Calbiochem 
-Behring Inc. U.S.A.), prostaglandins D2 , E2 , F2a, 6-keto-PGF 1 ~, 6-keto-PGE1 and thromboxane B2 from Sigma Chem. Comp. (USA). 
Leukotrienes B4 , c4 , D4 and Ej were gifts of Dr. J. Rokach, Merck 
Frosst Canada Inc. [1-14c arachidonic acid, specific activity 60 
mCi/mmol, 
5 -D- {5,6,8,9,11 ,12,14,15-3H(n)} -hydroxy- 6,9,11 ,14-eicosatetraenoic 
acid (5-HETE), 12-L-{5,6,8,9,11,12,14,15-3H(n)}-HETE, 
15-L-{5,6,8,9,11,12,14,15-3H(n)}-HETE, {5,6,8,9,12,14,15-3H(n)} 
-leukotriene B4 , {14,15-
3H(n)} -leukotriene D4 , 6-keto-{5,8,9,11,12,14,15-3H(n)}· -prostaglandin F 1 , {5,6,8,9,11 ,12,14,15-3H(n)} thromboxane B3, {5,6,8,11 ,12,14,15-
3H(n~} 
prostaglandin E2 ~ {5,6,8,11 ,12,14,15- H(n)} prostaglandin F2a, {5,6,8,11,12,14,15-~H(n)} prostaglandin D2 were obtained from the 
Radiochemical Centre of Amersham (U.K.). Sep-Pak cartridges, 
HPLC-solvent filters and Millex-Sample filters were purchased from 
Millipore. All chemicals were analytical grade (Merck Darmstadt). The 
derivatization reagent, N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) 
was obtained from Pierce Chemical Co., Rockford, Illinois, U.S.A. 
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Fig. 1. RP-HPLC separation of leukotrienes and other lipoxygenase 
products in [1-14c]-A loaded human peritoneal macrophages 
(patient R., the first day of peritonitis, time 12-18). In this 
chromatogram the crude data are shown, not corrected for 
recoveries. A Nucleosil 5C18 column was used. Other conditions 
are described in the section HPLC-analysis (a). 
Identification of peaks: f front, including all 
prostaglandins; D4 = LTD4 ; B4 = LTB4 ; di-HETE 
4 = unknown compound(s); 15-HE = 15-HETE; 12-HE = 
5-HE = 5-HETE. 
5, 12-di-HETE; 
12-HETE and 
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Fig. 2. RP-HPLC separation of prostaglandins in [1-14c]-AA loaded human 
peritoneal maorophages (same sample as separated for LTs and HEs 
in fig.1) , on the first day of peritonitis. A Zorbax BP5 column 
was used. Conditions as mentioned in section HPLC-analysis (b). 
Peaks: f front; k = 6-keto-PGF1a; 1, 2 and 3 unknown 
compounds of which 1 was identified as 20-0H-LTB4 ; T = TxB2 ; F, 
E and D = prostaglandins F2a, E2 and D2 . Arrow indicates tR of 
6-keto-PGE1 (standard). 
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HPLC-analysis 
a. Reversed phase HPLC of leukotrienes and other lipoxygenase 
products was carried out on a Nucleosil 5c18 column (5). The solvent 
system (A) was tetrahydrofuran/methanol/0.1~ EDTA (w/v) in water/acetic 
acid (25:30:45:0.1), adjusted to pH 5.5 with ammonium hydroxyde. The 
flow rate was 0.9 ml/min and UV absorption was measured at 280 nm for 
LTC4 , D4 , and E4 , at 270 nm for LTB4 and di-HETE, at 234 nm for 15-HETE, 
12-HETE and 5-HETE. Prior to use, the column was equilibrated with the 
mobile phase A at 37°C. One minute fractions were collected for 
scintillation counting. After each run (84 min) the column was rinsed 
for 30 min with methanol (flow rate 2 ml/min) to prevent contamination 
with Ca-ionophore and [1- 14c]-AA. 
b. RP-HPLC of prostaglandins and 20-0H-LTB4 was performed on a Zorbax C8 BP5 column (5). The solvent system used for RP-HPLC (B) 
consisted of acetonitrile/benzene/water/acetic acid (24:0.2:0.1 :76). The 
flow rate of this eluent was 2 ml/min. UV absorption of 20-0H-LTB4 was 
monitored at 280 nm. One minute fractions were collected for 
scintillation counting. The column was rinsed with acetonitrile/benzene 
(99:1) for 30 min after each analysis to elute the monohydroxy 
lipoxygenase products. 
Collection or cells, incubation and sample work-up procedures 
The cells were obtained from bags with dialysis fluid starting with 
three fast changing bags. Thereafter a bag was collected every 4 hours 
during daytime and one bag overnight. These collections were performed 
for two days. Thereafter two or three bags were combined daily. The 
patients were followed during the first 4 days of the peritonitis and a 
control was taken approx. 5 weeks after recovery. 
The cells were spun down in 500 ml flasks at 800xg for 10 min. The 
resuspended cells were purified on 20 ml Lymphoprep (650xg, 4°C, 20 min). 
The purity of separated Mr proved to be greater than 90~ on day 2, based 
on Giemsa-May-GrQnwald staining. The other cells were characterized as 
granulocytes (approx. 5%) and lymphocytes (approx. 5%). In the 
incubations 30-40x10 6 M1 were suspended in 10 ml of Krebs-Henseleit 
buffer, using a FalconR tube. The tube was placed in a waterbath of 37°C 
and gassed continuously with a mixture of 95% o2 + 5% CO~ through a thin 
plastic pipette. After 5 min preincubation 2.5 ~Ci [1-14c] arachidonic 
acid (60 mCi/mol), glutathion (final cone. 2 mM) and Ca-ionophore A23187 
(in 50 ~1 of ethanol, final cone. 10 ~M) were added. At the end of the 
10 min incubation, 3H-HETEs, 3H-LTs and 3H-PGs were added (approx. 
50.000 dpm per metabolite, corresponding to 425, 320 and 50 pg resp.) and 
the homogenate centrifuged (10 min, 1400xg, 4°C). Pellets were washed 
once, and supernatants were applied to a couple of Sep-Pak cartridges 
(c18 and Silica)(4). Eluates were dried in a Savant Speed Vac 
concentrator at 40°C. Samples were dissolved in 400 ~l of solvent (A), 
filtered through a Millex 0.2 ~m and kept in plastic HPLC micro vials 
until measurement. An aliquot of 100 ~l was injected into the HPLC 
columns and chromatographed using a 1082 Hewlett Packard HPLC system. 
Fractions were collected with a Superrac fraction collector (LKB, Sweden) 
for further analysis. The chromatographic method and the identification 
of the peaks have been described earlier (5). 
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Fig. 3. Selected ion monitoring analysis obtained on material o~ peak 
(Fig. 2) a~ter derivatization into the methyl ester, 
trimethylsilyl (TMS)-ether. Ions selected ~or the analysis were 
at m/z 203, 217, 293, 383, 448 and 492 (see Materials and 
Methods. 
GC-JYIS. 
The material eluted in peak 1 (as shown in ~ig. 2) during RP-HPLC 
analysis was derivatized into the methyl ester, 'trimethylsilyl ether. 
The methyl ester was prepared with an ethereal diazomethane solution. 
Trimethylsilylation was done with 30 ~1 o~ a mixture o~ BSTFA/pyridine 
(2:1) ~or 1h at room temperature. Immediately be~ore GC/MS analysis, the 
sample was taken to dryness under N2 and redissolved in 10 ~1 o~ 
n-hexane. 
GC/MS analysis was carried out on a Finnigan 4000 instrument, equipped 
with an Incos 2000 data system, using the jet separator as GC/MS. 
inter~ace and with the mass spectrometer operated in the electron impact 
ionization mode and in the selected ion monitoring detection mode. GC 
was per~ormed on a 2m x 2mm internal diameter glass column, packed with 
1% OV-1 coated on Chromosorb WHP 100-200 mesh, which was run isothermally 
at 230°C. Helium was used as carrier gas at a ~low rate o~ 25 ml/min. 
Injector and GC/MS inter~ace temperatures were 250 and 230°C 
respectively. The MS conditions were: electron energy, 70 eV; emission 
current, 0.3 mA; ion source temperature, 230°C. Selected ion monitoring 
was carried out at speci~ic m/z values ~or the 20-0H-LTB4 and 20-COOH-LTB4 derivatives (6), i.e. at m/z 492 
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[M+"(20-0H-LTB4-der.)-TMSOH], m/z 448 [M+"(20-COOH-LTB4-der.)-TMSOH], m/z 383 [M+ .. _CH2-CH=CH(CH2 ) 5-0TMS] or [M+··-cH2-~H=CH-(CH2 ) 5-cooH3 ], m/z 293 [383-TMSOH], m/z 217 [TMSO-CH=CH-CH= OTMS] and m/z 203 
[TMSO+=CH-(CH2 )3-cooH3]. 
This mode of mass spectral analysis was selected because of the small 
amount of material available (± 500 ng) and because of the greater 
sensitivity of this technique compared to the conventional scanning mode. 
RESULTS 
In the M~. isolated from the dialysis fluid of patients with CAPD at 
different times during the peritonitis, the substances formed from 
[1- 14c] AA after activation with Ca-ionophore A23187 have been 
characterized. The main metabolites formed by 5-lipoxygenase activity 
were LTB and 5-HETE (fig.1), less 15-HETE and a compound characterized 
as 5-(s),12-(S)-dihydroxy-6,8,10,14-eicosatetraenoic acid (M.Claeys et 
al, in publication). In the chromatogram of the HPLC analysis aimed at 
detecting cyclooxygenase metabolites TxB2 , PGF2 ~, PGE2 .and PGD2 were 
present and a major peak with an elution time between 6kPGF 1 ~ and TxB2 
was observed (Fig. 2). This substance was isolated and analyzed by 
GC-MS. The peak (1) was identified as 20-0H-LTB4 by selected ion 
monitoring at specific m/z values (Fig. 3). The peak areas obtained for 
the signals at m/z 203, 217, 293 and 383 are comparable, which is in 
agreement with literature data, whereas the signal at m/z 492 confirms 
the presence of 20-0H-LTB4 (6). The RP-HPLC behavior of 20-0H-LTB4 is further in agreement with data reported by Powell for polymorphonuclear 
leukocytes (7). 
The formation of the above mentioned substances was determined in the 
cells in the dialysis fluid at different times during the peritonitis. 
After four days of treatment the symptoms of the disease had disappeared. 
A sample taken at day 39, when the patients were recovered, was 
considered as a control (Fig. 4). Recoveries of the main metabolites 
present were of the same order of magnitude as described earlier (5) and 
approx. 62, 50, 20, 75, 81 and 70 % for LTB4 , 15-HETE, 5-HETE, 6kPGF 1 ~, 
TxB2 and PGE2 respectively. The recovery factor of LTB4 was used for 
calculation of the total amount of 5,12-diHETE and that of 6kPGF 1 ~ for 
20-0H-LTB4 . The final results, corrected for recoveries, indicate that 
the amount of radioactivity incorporated in LTB4 and 5-HETE is 
approximately ten times higher than that in the PG and TxB2 . In the 
course of the peritonitis, the amount of all substances formed diminishes 
60-80% after the first day, when results are expressed per 106 cells. 
There is an increase in the n~ber of M~ in the dialysis fluid, reaching 
a peak at day two (4 ~ 50 x 10 M~/hr). The formation of the metabolites 
has returned to the original level at day 39, with the exception of PGE2 . 
Legend to fig. 4. Representative data of the formation of 
eicosanoids by human peritoneal M~ during and after peritonitis 
Patient R., as fig.1 and fig.2). Sampling times are indicated by 
the number of the day and the duration in hours. Explanation of 
figures: part B. A= 5,12-di-HETE; 4D= LTB4 ; Ill= 20-0H-LTB4 ; 
part C. $= 15-HETE; 1111= 5-HETE; 
part D. 1111 = 6-keto-PGF 1 ~; $ = TxB2 and A= PGE2 . (n=3) 
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DISCUSSION 
The results indicate, that human peritoneal Mr have the capacity to 
metabolize AA by the cyclooxygenase and lipoxygenase pathways. The 
higher incorporation of radioactivity into LTB4 , 5-HETE and 5,12-diHETE (approx. ~5. 30 and 11 ~of total metabolites formed) demonstrates the 
relative importance of 5-lipoxygenase activity. Earlier, we determined 
the eicosanoids produced by human ascites cells, mainly Mr, in patients 
with liver cirrhosis (3). In these cells the main substances formed were 
LTB4 and 5-HETE, each representing approximately 30~. In both cases the PG and TxB2 were produced in smaller quantities. The formation of 20-0H 
LTB4 , which was not observed in cirrhosis, indicates, that the enzyme LTB4 w-hydroxylase which has been demonstrated in polymorphonuclear leucocytes (4), is also present in human CAPD Mr, after activation. 
However, the formation of this substance by the small amounts of 
neutrophils available, or by neutrophil-macrophage interaction can not be 
excluded. The formation of this metabolite of LTB4 is not dependent on 
the inflammation, as it also occurs in the controls, at day 39. 
In Fig. 4, the curves obtained for the different metabolites indicate 
that during the inflammation the amounts produced per 10 6 cells decrease 
considerably and return to normal in the controls, with the exception of 
PGE2 . The amounts produced are inversely proportional to the number of Mr in the dialysis fluid. Several explanations can be given for this 
effect. First, a depletion of precursor pools may occur during 
peritonitis. This is not very likely, as the amounts formed in the 
beginning of the peritonitis are approximately the same as those in the 
controls and as there is no particular reason for depletion. 
Second, the newly formed Mr may have a lower capacity to synthesize 
eicosanoids. The reason for the decrease could be that during the 
peritonitis the production of corticosteroids in the adrenal is probably 
enhanced. This will lead to a higher level of circulating cortisol and a 
diminished eicosanoid production. Glucocorticosteroids induce the 
formation of a peptide, lipocortin with phospholipase A2 inhibitory 
activity in Mr and neutrophils (8). This will in turn result in an 
inhibition of eicosanoid formation. Flower et al. have shown that when 
rats are treated with dexamethasone, lipocortin is formed in the 
peritoneal fluid (9). This result is supported by the observations that 
dexamethason inhibits the TxB2 and LTB4 production in human peritoneal Mr (10). A similar effect could occur in the dialysis fluid of the CAPD 
patients. It is possible, that a relationship exists with the decline in 
cyclic AMP content in peritoneal Mr of the dialysis fluid of CAPD 
patients shown by Adolrs et al. In these experiments, a decrease in PG 
and TxB2 was also observed during the inflammation (11). 
In the Mr, part of the LTB4 (approx. 12 ~) is oxidized to 20-0H-LTB4 , 
which has been shown to contain to a great extent some of the biological 
activities of LTB4 (12). Whether a relationship exists with the peritonitis is unknowm. In order to obtain more complete information on 
the effects of the inflammation, measurements of the endogenous 
eicosanoid production, and of the amounts present in the peritoneal 
fluid, would be of great interest. 
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Rapid Communication 
DIFFERENTIAL EFFECTS OF MALOTILATE ON 5-, 12- AND 
15-LIPOXYGENASE IN HUMAN ASCITES CELLS 
Frederik J. Zijlstra, 
~d 
J.H. Paul Wilson*, 
J. Eric Vincent 
Mario A. Vermeer 
Departments of Pharmacology ~d Internal Medicine II*, 
Erasmus University Rotterdam, PO Box 1738, 
3000 DR Rotterdam, The Netherl~ds. 
Malotilate (diisopropyl-1,3-dithiol-2-ylidene malonate) is a new drug 
which protects against acute liver damage induced by a variety of toxins 
~d reduces hepatic fibrosis in experimental cirrhosis. It is mech~ism 
of action in liver injury is not clearly understood, although in high 
concentrations it suppresses collagen formation by cultured fibroblasts 
[Ryle ~d Dumont,1987]. Macrophages may play a central role in 
inflammation ~d their products are thought to be involved in liver damage 
~d fibrosis in experimental hepatitis. Hum~ peritoneal macrophages 
produce mainly lipoxygenase ~d smaller amounts of cyclooxygenase products 
after stimulation by the calcium ionophore A23187 [Ouwendijk et al.,1985], 
~d are suitable target cells to test the effects of ~tiinflammatory 
agents on eicos~oid production. 
Macrophages were isolated from ascitic fluid of patients with alcoholic 
liver cirrhosis by centrifugation ~d sedimentation on Lymphoprep 
(Nycomed, Norway), ~d labelled with [1-14c] arachidonic acid (AA, 
60mCilmmol, Amersham) to determine ex
20
og.e
1
n
0
gusmacfroorpmhaagtieons of110emic1 osK~reobisd-s [Zijlstra et al.,1987]. Approximately 
Henseleit buffer per sample were preincubated with malotilate for 2 min. 
at 37°C while stirring gently, glutathione ~d 14c AA were added ~d after 
3 min the cells stimulated with calcium ionophore A23187. After a further 
10 min incubation [ 3H]-labelled st~dards were added, ~d the incubation 
fluids passed through SepPak cartridges. Eluates were separated on HPLC 
using a Chromsep Nucleosil 5C18 column ~d a solvent system consisting of 
tetrahydrofur~ I meth~ol I 0.1~ EDTA in water I acetic acid 
(25:30:45:0.1, pH 5.5) for determination of lipoxygenase products 
(Leukotrienes (LTs) ~d monohydroxy eicosatetraenoic acids (HETEs) ). 
Prostagl~dins (PGs) were measured on a Zorbax c8 column (Dupont) ~d the 
solvent system acetonitrile I benzene I water I acetic acid 
(2~:0.2:76:0.1). Endogenous formation was measured in samples containing 
10 macrophages l1ml Krebs-Henseleit buffer, without addition of AA 
following the same incubation procedure. Radioimmunoassay of PGs, HETEs 
~d LTB4 was performed in 503 25 ~d 10 ul resp., using specific ~tisera from Seragen ~d Amersham. H-Labelled eicos~oids were obtained from 
Amersham. 
The main subst~ces formed by untreated macrophages in vitro after 
stimulation were 5-HETE ~d LTB4 , ~d smaller amounts of 6kPGF1 ~, TxB2 , 15- ~d 12-HETE (table 1). After incubation with malotilate, a concen-
tration dependent decrease occurred in the 5-lipoxygenase products 5-HETE 
~d LTB4 , both in the formation of exogenous ~d endogenous metabolites. 
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The mean rc50 of malotilate on the 5-lipoxygenase was 4.7 ~M. 15- and 12-HETE were not inhibited and these products tended to increase. There 
was a decrease in the cyclooxygenase products 6-keto-PGF1a•· TxB2 and PGD2 , 
which could possibly be related to the increase of 15-HPETE and 12-HPETE 
respectively [Vanderhoek et al.,1982]. The formation of prostaglandins 
F2a and E2 was not significantly influenced by malotilate. This finding 
was confirmed with data obtained a£ter labelling of sheep seminal vesicles 
with 14c-AA, a source of predominantly PGs E2 , F2a' D2 and 6-keto-F1a. 
Formation of HPETEs was inhibited by addition of ascorbic acid, to 
eliminate the inhibitory effects of these metabolites. Malotilate did not 
decrease the PG-formation, in contrast to indomethacin. 
These effects of malotilate on eicosanoid formation differ from those of 
known lipoxygenase inhibitors such as BW 7550 (weak 5-lipoxygenase and 
cyclooxygenase inhibitor, strong 15-lipoxygenase inhibitor), nordihydro-
guiaretic acid (not specific lipoxygenase inhibitor, weak cyclooxygenase 
inhibitor) and ketoconazole (weak 5-l~poxygenase inhibitor, 12-
lipoxygenase not affected and 15-lipoxygenase increased) [data summarized 
in table 2 ; Beetens et al.,1986]. The differential effects of malotilate 
on the 5-, 12- and 15-lipoxygenases and also on the formation of the 
comp0unds of the cycloxygenase, have not previously been reported. The 
suppression of leukotriene production in vitro occurred at concentrations 
found following normal therapeutic doses in vivo. Inhibition of the 
production of the chemotactic substance LTB4 and the vasoconstrictive TxA2 
provide a possible explanation for the beneficial effects of this drug on 
liver necrosis and liver fibrosis. 
Acknowledgement. Malotilate was kindly supplied by Dr. J.-M. Dumont 
(Zyma, Nyon, Switzerland). 
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TABLE 1 THE EFFECT OF MALOTI LATE ON THE METABOLISM OF ARACHIDONIC ACID 
BY HUMAN PERITONEAL MACROPHAGE$ 
EXOGENOUS FORMATION 
controls percentage change vs. controls controls 
dpm. 1 00/2.1 07 MCD 0.85JLM 8.5JLM 85JLM pg/108 MCD 
LT84 1290 -23 - 79 - 99 59700 
±155 ±4 ±6 ±1 ±6800 
5-HETE 2170 - 1 - 73 - 94 74700 
±83 ±8 ±7 ±3 ±950 
15-HETE 775 +15 +125 +172 2050 
±190 ±11 ±56 ±99 ±575 
12-HETE 114 + 1 + 59 +133 520 
±26 ±19 ±43 ±66 ±101 
6-keto-PGF,a 232 -12 - 34 - 70 2960 
±67 ±5 ±4 ±13 ±820 
TxB2 300 - 2 - 24 - 75 2600 
±118 ±10 ±8 ±7 ±400 
PGFza 72 - 6 + 21 + 17 340 
±30 ±11 ±3 ±18 ±120 
PGD2 72 - 4 - 34 - 48 260 
±41 ±11 ±3 ±5 ±60 
PGE2 88 +32 - 11 8 N.D. 
±52 ±15 ±7 ±18 
Each value represents the mean ± SEM of 4 separate determinations. N.D.= not detectable. 
Table 2. Summary of the inhibition of the 
oxygenation reactions in several in vitro 
systems by different drugs (ICsoi'MI 
5-LO 12-LO 15-LO co 
NDGA 1 26 
Malotilate 5 + 
Nafazatrom 10 + 
Phenidone 16 + 
Ketoconazole 28 ni 
BW755C 36 >100 
LO: lipoxygenase CO: cyclooxygenase 
+ ++: stimulation ni: not inhibited 
1 15 
++ 90 
9 >100 
3 >100 
+ ni 
1 21 
· Beetens et al. 
ENDOGENOUS FORMATION 
percentage change vs. controls 
3.4JLM 34JLM 340JLM 
-21 -77 - 98 
±2 ±18 ±1 
-47 -80 - 99 
±5 ±9 ±1 
+45 +68 +209 
±8 ±26 ±60 
-14 +14 + 111 
±8 ±43 ±61 
-24 -56 - 62 
±6 ±8 ±9 
- 6 -31 - 80 
±6 ±13 ±3 
+ 8 +28 + 40 
±17 ±17 ±5 
-15 -37 - 87 
±27 ±12 ±8 
N.D. N.D. N.D. 
4.3 COMPARISON OF EICOSANOID FORMATION IN MACROPHAGES OF HUMAN, RAT 
AND GUINEA PIG FROM DIFFERENT ORIGIN. 
131 
In this paragraph results ~rom incubations o~ macrophages with labelled 
arachidonic acid ~rom di~~erent species and origin will be summarized. 
Data were obtained ~rom investigations by research institutes both in the 
Erasmus University o~ Rotterdam and abroad. 
The labelling o~ cells, measurements by HPLC and the calculation and 
interpretation o~ data were per~ormed as described in section 4.1.3. 
Di~~erences exist in the methods o~ separation and puri~ication o~ the 
cells. 
Liver Kup~~er cells (KC) were isolated by per~usion and incubation o~ 
tissue with pronase and collagenase and kept ~or 24 h at 37°C in Eagles 
medium to recover ~rom the isolation procedure [Kuiper et al.,1987]. 
Peritoneal rat macrophages (Per.M¢) were obtained ~rom animals that had 
been injected with 50 ml o~ sterile physiological saline [Vincent et al., 
1986]. 
Human peritoneal macrophages were isolated ~rom ascitic ~luid o~ 
patients with alcoholic liver cirrhosis by centri~ugation and 
sedimentation on Ficoll-Paque [Ouwendijk et al.,1985]. 
Human alveolar macrophages (Alv.M¢) were obtained by lavage o~ one side 
o~ the lungs with 200 ml o~ saline [Schenkelaars et al.,1987]. 
Guinea pig and rat alveolar macrophages were harvested with 100 ml 
saline injected via an incision in the trachea [Bachelet et al.,1987; 
Klein et al.,1987]. 
Rat testis macrophages (TM¢) were obtained after leakage o~ the 
interstitial ~luid and adherence on petri dishes [Dreteler et al.,1987]. 
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In table 4 the formation of exogenous arachidonic acid metabolites is 
given as means in percent of total formation. In this summary the 
distribution of metabolites is reviewed, considering that Kupffer cells 
represent liver macrophages. 
The data show that the capacity to generate products of the lipoxygenase 
pathway or the cyclooxygenase pathway (the lip/cycle ratio) is dependent 
on the origin of the macrophage. 
Alveolar macrophages. In the guinea pig only the production of 
eicosanoids by alveolar macrophages was investigated. It is clearly shown 
that thromboxane synthetase is the most common enzyme activated after 
stimulation by Ca-ionophore A23187. The marked formation of TxB2 (and 
HHT) in contrast to the absence of lipoxygenase products could be related 
to the TxA2-induced contractions of parenchymal strips of this species. 
Alveolar macrophages of rat and human origin predominantly formed 5-
lipoxygenase products and less 12-HETE. A small amount of thromboxane as 
the most important cyclooxygenase product was measured. A marked 
difference between these species was the formation of LTC4-like substances 
in human alveolar macrophages. This is in agreement with findings by 
other investigators [Fels et a1.,1982]. 
Peritoneal macrophages. A significant difference between rat and human 
peritoneal macrophages was observed. The profile of eicosanoid formation 
in human peritoneal macrophages was almost identical with that of human 
alveolar macrophages, with the exception of the formation of LTC4 . In 
comparison with these findings, rat peritoneal macrophages preferentially 
formed 6kPGF 1 ~ and TxB2 [Schenkelaars and Bonta,1983], as well as mono-
and di-hydroxy-eicosatetraenoic acids. 
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Kupffer cells. In rat Kupffer cells the formation of large amounts of 
PGD2 was noticable. The importance of this finding in view of its further 
metabolism to the vasoactive substance 9a,11~-PGF2 has already been 
discussed in paragraph 2.6. The lack of production of 5-lipoxygenase 
substances is comparable with that of the rat peritoneal macrophages. In 
human Kupffer cells a large PGD2 production was not present. A base-line 
level of cyclooxygenase products was seen, with the exception of TxB2 . 
Lipoxygenase products were formed, however these cells failed to produce 
leukotrienes. 
Testis macrophages. Finally one would expect that macrophages obtained 
from interstitial fluid would preferentially generate prostaglandins, as 
interstitial fluid generally contains these substances. Surprising 
however was that the substance formed in the largest amount was 12-HETE. 
In macrophages of other origin, except rat Kupffer cells, the 5- and 15-
HETE were dominant. 
Table 4-. Eicosanoid formation from A23187 stimulated 14C-AA loaded cells 
Rat Guinea Pig Human 
Alv. M<Jl Per. M<!l KC TM<Jl Alv. M<Jl Alv. M<Jl Per. M<!l KC 
LTC4fD4 7 
LTB4 26 3 2 44 40 
15·HETE 5 3 5 7 < 1 5 25 
12·HETE 20 14 10 40 8 2 14 
5·HETE 34 2 4 14 30 14 
di·HETE 8 22 3 3 
HHT 2 13 10 7 54 8 8 7 
6kPGF1a 21 < 1 10 < 1 4 7 
TxB2 2 17 10 5 40 7 6 16 
PGF2a < 1 3 5 12 5 2 5 
PGE2 < 1 1 2 6 < 1 7 
PGD2 < 1 3 55 5 < 1 4 
lip./cyclo 13/1 1/1.4 1/4.9 1.2/1 1/24 3.4/1 3.5/1 1.2/1 
ratio 
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4.4 SUMMARY 
The formation of prostaglandins, leukotrienes and other lipoxygenase 
products was determined in human lung tissue and in human peritoneal 
macrophages after prelabelling with 14o-arachidonic acid. Separation was 
performed by HPLO and further quantitation by RIA. A comparison was made 
between macrophages of different origin and from different species. 
Eicosanoid levels were measured in human alveolar lavage fluid. In 
conclusion 'it was found that: 
-in chopped human lung tissue after stimulation with Oa-ionophore A23187 
eicosanoids are present in nanogram amounts per gram tissue [4.2.1]. 
-after stimulation with A23187 mostly LTB4-like compounds were generated 
and also leukotrienes 04 , D4 and E4 • Large amounts of HETEs were also present [4.2.1] and [4.2.2]. 
-the main cyclooxygenase products were 6-keto-PGF1a, TxB2 and PGD2 [4.2.2]. 
-specific activities (dpm/ng) derived from data of 7 non smokers varied 
both in cyclooxygenase and lipoxygenase products [4.2.2]. 
-eicosanoid production by macrophages isolated from dialysis fluid of 
patients decreased considerably during inflammation (peritonitis) and 
returned to normal in clinically stable periods [4.2.4]. 
-LTB4 was further metabolized in these macrophages by the enzyme omega-
hydroxylase to 20-0H-LTB4 [4.2.4]. 
-malotilate, an anti-fibrotic substance, inhibited the 5-lipoxygenase, 
whereas both the 12- and the 15-lipoxygenase pathways were stimulated, 
followed by a possible inhibition of two main cycloxygenase products, 
TxB2 and 6-keto-PGF1a [4.2.5]. 
-large amounts of LT04-like substances and oxygenated products of LTB4 
were detected in lung lavage fluids of a patient with pulmonary alveolar 
proteinosis [4.2.3]. 
-the ratio lipoxygenasefcyclooxygenase products, generated 
arachidonic acid labelled macrophages after stimulation by 
ionophore A23187, is origin and species dependent [4.3]. 
from 
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CHAPTER 5 
GENERAL PISCUSSION 
The purpose of the experiments described in chapter 3 of this thesis was 
to study the biological effects of leukotrienes on lung parenchyma, and 
the influence here upon of pharmacological substances. Secondly the 
profile of eicosanoids generated by different cells and different tissues 
was determined (chapter 4). Furthermore the role of synthesis inhibitors 
and blockers in inflammatory processes and diseases was studied 
5.1 ACTIONS ON LUNG PARENCHYMA 
In this part the bronchoconstrictive effects of eicosanoids and other 
agents on human and guinea pig lung parenchyma and airway smooth muscle 
are discussed. 
5.1.1 Human lung. 
Both the contractile response of human lung parenchymal strips after the 
application of LTs and the release of TxA2 were shown to be considerably 
lower than those obtained on the GPLP [3.2.1]. From our studies on the 
contractile effect of several substances on human small airway smooth 
muscle, we concluded that on an equimolar base this tissue tended to be 
less sensitive. 
The thromboxane mimetic U-44069 and LTC4 were still 100-times more 
active than histamine or methacholine on human smooth muscle [4.2.2]. 
Measurements of AA-metabolites in chopped human lung tissue after 
stimulation with the calcium ionophore A23187 suggested that PGD2 was 
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formed in larger amounts than TxB2 . Recently it was shown, that this PG 
is metabolized to 9a,11$-PGF2 in the lungs after one passage [Seibert et 
a1.,1987]. The substance proved to be equipotent to PGD2 and PGF2a in 
bronchoconstrictive effect. However the results presented in table 3 of 
paragraph 4.2.2 indicate a minor role for these PGs in the contraction of 
the lung, having an Ec50 one thousend times higher than that of LTC4 . The 
contractile activity of TxA2 is of the same order of magnitude as that of 
LTC4 or LTD4 in guinea pig lung strips [3.2.3] and human lung parenchyma 
[4.2.2]. A comparison of the amounts produced by chopped human lung 
tissue and the effects on the lung strips indicates that it could play a 
role in the induction of bronchoconstriction in vivo. 
In guinea pig isolated trachea, application of PGF2a to the segments 
stimulated the generation of lipoxygenase products. The release of 
lipoxygenase-mediated LT-like substances differed in the mode of action 
from that of histamine and LTD4 [Shikada et a1.,1987]. A comparison of 
the responses of isolated human airways, obtained from a single asthmatic 
patient at thoracotomy, was made to the responses of airways of non-
asthmatics in vitro. In asthma bronchiolar strips exhibited an increased 
airway smooth muscle contractility in response to histamine, methacholine 
and LTC4 [de Jongste et al., 1987a]. In bronchiolar strips of controls 
the contractile responses after repeated exposure to LTC4 did not induce 
tachyphylaxis [de Jongste et al., 1987b]. It was hypothesized that a high 
endogenous LT synthesis would lead to desensitisation of airway smooth 
muscle. It was however found that the sensitivity and contractility of 
airway smooth muscle to LTC4 were not diminished in lungs in which large 
amounts of LTs are synthesized. 
5.1 .2 Guinea pig lung parenchyma (GPLP). 
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In the experiments presented in chapter 3 the mechanisms of leukotriene-
induced contractions of lung parenchyma were scrutinized. The most 
important finding was the thromboxane-release related action of 
leukotrienes [3.2.4 and 3.2.3]. The release of TxA2 through LTC4 and 
LTD4-induced contractions of guinea pig lung parenchymal tissue was 
observed by others in the same year [Piper and Samhoun, 1981]. 
Our first results of thromboxane Ag formation were obtained by using a 
superfused rabbit mesenteric artery, measuring the release on a system by 
which contraction-inducing substances released from lung parenchymal 
strips or platelets were identified. Usually this method proved to be 
sufficiently sensitive [Zijlstra and Vincent, 1981]. When specific 
antisera against TxB2 became available, a comparison was made between the 
results of the bioassay and the radioimmunoassay. It turned out that the 
latter method allowed a better separation of the two components of the 
contractile activity of LTC4 on the guinea pig lung parenchymal strip. 
It was shown that the release of TxA2 occurred during the initial pe~iod 
of the contractions [3.2.2]. Both this finding and the contraction 
obtained after addition of the cyclooxygenase inhibitor indomethacin 
indicated that the direct action of LTC4 represents the long-lasting slow-
acting component in the contraction. 
Tachyphylaxis. Repeated applications of the same dose of LTC4 or LTD4 to 
the GPLP lead to a marked diminution of the thromboxane release. There 
was only a slight decline in the contractile activity. After 8 or more 
applications of the same dose LTC4 or D4 approximately SO% of the initial 
contractile activity was still present but no more TxA2 was formed. This 
is in agreement with experiments in which the thromboxane synthesis was 
totally inhibited [Zijlstra at a1.,1983a]. 
The rapid loss of effect upon repeated applications of LTs was reported 
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by a number of authors [Leitch, 1984; Feuerstein, 1985; Bach, 1984], but 
only observed in human cerebral arteries in vitro [Tagari et a1.,1983]. In 
vivo, however, frequent injection of LTD4 into the intact pig coronary 
circulation did not result in tachyphylaxis [Feuerstein, 1985]. 
The fact that other investigators did not observe the phenomenon of 
tachyphylaxis in LT-induced contractions of the GPLP [Piper and Samhoun, 
1982], can possibly be explained by the fact that they did not use a 
radioimmunoassay and failed to standardize the superfused artery model 
before and after the experiment with angiotensin II or the thromboxane A2 
mimetic U-44069. Using the contraction of the mesenteric artery as a 
measure of TxA2 released from the GPLP, the area under the contraction 
curve should be taken for calculations. From other observations it was 
proven that an adequate relationship existed between the area and the quan 
tity of TxB2 obtained by radioimmunoassay [Zijlstra and Vincent, 1983]. 
Application of TxA2 generated by aggregated rat platelets to a GPLP 
caused a pronounced contraction [Zijlstra and Vincent,1984]. The amounts 
of added TxA2 were measured by RIA of TxB2 . The amount of TxA2 released 
from the GPLP due to LT-induced contraction was about 5-times lower than 
that of externally applied TxA2 required to induce a contraction of the 
same order of magnitude. The same occurred when phosphol~pase A2 was 
administered to the GPLP in the superfusion bath. Other experiments 
indicate that TxA2 , released by either PLA2 or LTC4 tn4 originates from 
different sources of arachidonic acid [Zijlstra et al., 1983a]. After the 
depletion of TxA2 , induced by repeated applications of LTC4 a pronounced 
formation of TxB2 was still seen after the administration of a single dose 
of PLA2 and which gave also a contraction. Inverse application of the two 
contraction inducing substances resulted in the same phenomenon [Zijlstra 
and Vincent, 1985a]. 
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5.2 EICOSANOIDS IN BODY FLUIDS 
Besides the determination of the profiles of eicosanoid synthesis of cells 
involved in inflammatory processes and chronic diseases, measurements of 
the concentration of eicosanoids in tissue fluids could give more insight 
in the relative contribution of these substances to their ultimate effect. 
In the next paragraph results of measurements of eicosanoids in lung 
lavage fluid and in mucus of ulcerative colitis are discussed. 
5.2.1 Lung lavage Fluid. 
In chapter 4, table 3, it was summarized that LTs are present in body 
fluids after allergen challenge or in inflammatory processes. These data 
indicate the importance of specific inhibitors of leukotriene synthesis. 
In paragraph 4.2.3 the results of measurements of LTs in broncho- alveolar 
lavage fluid of a patient with pulmonary alveolar proteinosis were 
discussed. In view of the relatively large amount of sulphidopeptide LTs 
present, we expected smooth muscle constriction. This was however not the 
case. We have no explanation for this finding. The capacity of LTC4 and 
LTD4 to increase vascular permeability could be the reason of the 
accumulation of proteins in the lung. 
5.2.2 Eicosanoid production in inflammatory diseases. 
To determine the influence of inflammation and topical treatment with 5-
aminosalicylic acid or prednisolone on arachidonic acid metabolism in 
vivo, a study on the release of PGE2 and LTB4 from the rectal lumen in 
patients with distally located ulcerative colitis was performed [Lauritsen 
et al., 1986]. Luminal concentrations of these eicosanoids were 
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positively correlated to disease activity ~d decreased in the 
prednisolone treated patients [Lauritsen et a1., 1987]. 
In our laboratory PGs, LTs and HETEs were measured in mucus of freshly 
recovered morning stools of a patient with an exacerbation of ulcerative 
proctocolitis who was not treated with drugs [Zijlstra and van 
Bl~kenstein, 1987]. 15-HETE was present in extremely high amounts 
compared to those of LTB4 , TxB2 ~d 6-keto-PGF1a (1070, 20, 9 ~d 4 ng/g 
mucus resp.). Comparatively small amounts of sulphidopeptide LTs were 
measured ( < 1 ng/g mucus ). 
Also incubates with 3H-labelled AA from jejunal mucosal biopsies from 
patients with gluten-sensitive enteropathy, generated extremely high 
amounts of 15-HETE [Krilis et a1., 1986]. 
Studies in experimental colitis established a relationship between LTB4 
~d LTC4 ~d the severity of the inflammation [Zipser et a1., 1986]. The 
pro-ulcerogenic action of LTC4 has been demonstrated in dogs [Whittle et 
a1., 1986]. Furthermore LTC4 increases mucus secretion [Johnson et al., 
1983]. 
Both the LTs ~d HETEs are synthesized by macrophages, eosinophile ~d 
neutrophile. In our studies mucus samples contained small numbers of these 
cells. Normally considerable amounts of macrophages are present in 
inflamed tissue ~d it is likely that the mediators secreted contribute to 
the ch~ges occurring. 
The presence of LTB4 was demonstrated in synovial fluids ~d tissue of 
patients with rheumatoid arthritis [Keppler et al.,1985]. This indicates 
that LTB4 is a likely stimulator of cellular infiltration in acute phase 
of the inflammatory process in rheuma. Interactions between PGs, LTs and 
HETEs occur after the initial activation of the process by immunological 
or chemical triggers. 
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5.3 EICOSANOID PRODUCTION BY MACROPHAGES 
In this part of the discussion the formation of eicosanoids by cells in 
human lung and macrophages during peritoneal inflammation and the 
differences between species and origin in the profile of eicosanoid 
formation of macrophages, are described. 
5.3.1 Cells in human lung. 
Human mast cells predominantly form PGD2 (55~) and the leukotrienes c4 
(20~) and B4-isomers (14~) after labelling with 14C-AA and activation with 
anti-IgE or ionophore A23187 [Peters et al., 1984]. 
Macrophages (M~) were considered as the most important source of LT in 
human lung tissue. In our own experiments human alveolar macrophages 
generated mainly LTB4 (44%) whereas LTC4 tn4 and TxB2 were synthetized in 
limited quantities (7%) [4.3]. 
Accumulation of eosinophile after application of the chemotactic agents 
LTB4 and 5-HETE could lead to a comparatively large production of LTC4 
[Verhagen et al., 1984; Weller et al., 1983]. The formation of LTC4 could 
in turn result in the release of TxA2 . 
In asthmatics the eosinophil count is significantly higher [Godard et 
al., 1982]. Accumulation of these cells and stimulation of the LTC4 
production and subsequent generation of thromboxane and prostaglandins 
could in combination result in an excessive bronchoconstriction. 
Eosinophile from patients with eosinophilia, including asthmatics, have an 
increased capacity to release PAF (platelet activating factor), as 
compared to those from normal individuals [Lee et al., 1984]. PAF 
stimulates leukotriene and prostaglandin formation in lungs and various 
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cell systems [Rola-Pleszczynski, 1985]. Recently it was found that PAF 
induces LTC4 synthesis in purified human eosinophile as well [Bruynzeel et 
al., 1987]. 
5.3.2 Peritoneal macrophages. 
The generation of arachidonic acid metabolites by peritoneal macrophages 
was studied in patients with end-stage renal disease undergoing continuous 
ambulatory peritoneal dialysis (CAPD) during infection-free periods and 
during bacterial peritonitis [4.2.4]. The most important metabolites 
generated by macrophages isolated from the CAPD fluid were LTB4 and 5-HETE 
(each 30~). 15-HETE and 20-0H-LTB4 were synthetized in small amounts (each 
5~). Approximately 20~ of the metabolized AA yielded cyclooxygenase 
products. 
During inflammation the amounts produced diminish considerably but 
return to baseline after cure in the control period. A likely explanation 
is, that the production of corticosteroids in the adrenal might be 
enhanced during peritonitis, which leads to a higher level of circulating 
cortisol and hence a diminished eicosanoid production. Also the induction 
of lipocortin with its phospholipase A2 inhibitory activity will result in 
an inhibition of the eicosanoid formation. Furthermore it has been shown 
that during peritonitis a decline in cAMP content of peritoneal 
macrophages correlates with a decrease in PGs and TxB2 synthesis [Adolfs 
et al., 1985]. 
The prostacyclin metabolite 6-keto-PGF 1 ~ was found to be the major 
prostanoid generated by human peritoneal mesothelium. The ratio of the 
vasodilating PGs and their metabolites to the vasoconstricting PGs and 
their metabolites increased considerably during peritoneal inflammation 
[Steinhauer et al., 1985]. This may be responsible for the increased 
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peritoneal blood flow during peritonitis. The loss of proteins in 
peritonitis was also considered to be caused by eicosanoids. 
The results of our studies [4.2.4] indicate that, although the formation 
of eicosanoids per unit of macrophages decreased during peritonitis, the 
extremely high influx of cells induced an inbalance between the 
chemotactic, vasoconstrictive and vasodilator agents and their 
interactions. In all probability the losses of proteins are caused by 
lipoxygenase products [Marom et a1.,1982], [4.2.3]. In vivo inhibition of 
these products by specific synthesis inhibitors could give more insight in 
this problem. 
In human peritoneal macrophages obtained from ascites of patients with 
liver cirrhosis, the amounts of exogenous TxB2 are six times higher than 
those of the classic PGs [Ouwendijk et al., 1985; paragraph 4.2.5]. 
In elicited populations of rat peritoneal macrophages an increase of 
prostaglandin E2 production was observed after stimulation by LTC4 
[Schenkelaars and Bonta, 1983]. In these experiments approximately equal 
amounts of endogenous PGE2 and TxB2 were measured. In resident rat 
peritoneal macrophages the amounts of exogenous TxB2 were approx. 15 times 
higher than those of PGE2 [Vincent and Zijlstra, 1986]. 
5.3.3 Macrophages ~rom several species and origin. 
In paragraph 4.3 a summary is given of the synthetic properties of 
macrophages obtained from several species and origin to generate 
eicosanoids. The lipoxygenasefcyclooxygenase ratio presents in one view 
the contribution of LTs, considering human macrophages. 
Differences were present in the synthesis of peptide LTs. In the rat 
the testis macrophages formed mainly 12-HETE, but this was not true in 
macrophages from other origin. Peritoneal macrophages differ from 
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alveolar macrophages with regard to the formation of cyclooxygenase 
products [5.3.1]. Remarkable is the generation of PGD2 by rat liver 
macrophages or Kupffer cells. This was in contrast to findings in man in 
whom 54% of AA was metabolized to mono-HETEs. 
Considering the origin of peritoneal macrophages in liver cirrhosis the 
diversion of 12- and 15-HETE formation into LTB4 formation is of interest. 
Moreover, a marked difference between peritoneal macrophages from ascites 
fluid of liver cirrhosis and those from CAPD was not observed in our 
results. 
The noticable generation of TxB2 (and HHT) in alveolar macrophages of 
the guinea pig could be related to the TxA2 related bronchoconstriction in 
these animals. In conclusion all types of macrophages have the capacity 
to produce eicosanoids, but the profile of eicosanoid production is 
dependent both on the tissue and on the species from which the macrophage 
is derived. 
Changing profiles of eicosanoids may be produced by human macrophages in 
different diseases. As discussed in paragraph 5.3.1 peritoneal macrophages 
from patients undergoing continuous ambulatory peritoneal dialysis, 
synthetize almost the same pattern of eicosanoids as peritoneal 
macrophages derived from patients with ascites due to liver disease. 
5.4 PRECURSORS. 
It was hypothetized that deficiencies of precursors or enzymes or an 
inbalance in phospholipid composition, could lead to subpopulations of 
macrophages which generate either less or more different types of 
eicosanoids in different amounts. In view of our findings that possibly 
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two pools of arachidonic acid are involved in the LT- or PLA2- induced 
contractions of the guinea pig lung parenchyma [Zijlstra and Vincent, 
1985a], and taking into account the differences in the generation of PGs, 
LTs or HETEs in macrophages of different species and origin, one would 
expect that the phospholipid metabolism is the rate-limiting factor. 
Incorporation of 14c-AA into alveolar macrophages from healthy subjects 
(HS), allergic asthmatics (AS) and chronic bronchitis patients (CB) 
revealed more labelling of phospholipids in macrophages from AS and CB 
than in those from HS [Damon et al, 1987]. An increase in the 
incorporation into PI and PE was seen, from which the authors conclude to 
the existence of two different sources of AA release, one for inflammatory 
macrophages and another for quiescent cells. 
In guinea pig lungs linoleic acid-derived products can also be 
synthesized by non-stimulated alveolar macrophages [Engels et al, 1986]. 
These compounds, 9-hydroxy-10,12-octadecadienoic acid (9-HODE) and 13-
hydroxy-9,11-octadecadienoic acid (13-HODE) are not synthesi~ed via 
exogenous arachidonic acid, or when a stimulus is used to liberate AA from 
membrane lipids. The role of these substances as mediators in 
inflammatory processes has not yet been established. 
Recently it was shown that during inflammation the arachidonic acid 
composition of phospholipids in colonic mucosa is increased in patients 
with active ulcerative oolites [Nishida et al.,1987]. Furthermore a 
positive relationship existed between the cell density of the inflammatory 
infiltrate and the arachidonic acid composition. Unfortunately the 
investigators failed to measure the endogenous formation of eicosanoids by 
inflammatory cells. 
Incorporation into the tissues and metabolism of 14C-AA after i.v. 
administration to rats was investigated [Zijlstra and Vincent, 1985b]. A 
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r.onsiderable incorporation occurred into perispinal fat, liver, heart 
muscle, kidney and adrenal. In the heart the composition of the 
phospholipids was determined. 44~ of the radioactivity was incorporated 
into phosphatidylcholine (PC) and 7 and 10~ into phosphatidylinositol (PI) 
and phosphatidylethanolamine (PE). 
In aggregated rat platelets it was observed that the rapid formation of 
TxA2 was correlated with a decline in PI and PE. The slow formation of 
12-HETE, on the contrary, was inversely proportional to a decline in PC. 
A preliminary conclusion based on these data would be that cyclooxygenase 
products are generated from PI and PE, whereas PC is the precursor of 
lipoxygenase products. This could imply that the rate-limiting factor was 
the incorporation of the exogenous AA into the phospholipids [Vincent and 
Zijlstra, unpublished]. 
In platelets of patients indicated as deficient in 12-lipoxygenase, 
incubations in the presence of 14C-AA lead to the rapid formation of TxB2 
only. Administration of aspirin in vivo, however, resulted in a total 
inhibition of TxB2 , and the formation of 12-HETE [de Vetten et al, 1987]. 
Recently results of investigations on PG synthesis and release by 
subpopulations of rat alveolar macrophages were published [Chandler and 
Fulmer, 1987]. The results demonstrated that density-defined alveolar 
macrophages are heterogenous in ability to synthesize and release PGs, 
which is dependent on the stimuli applied. These findings suggest that 
there may be a specific role for individual macrophage subpopulations in 
the control and/or modulation of the pulmonary inflammatory and immune 
processes. Investigations with subpopulations of macrophages obtained 
from CAPD before and during peritonitis could confirm this hypothesis. 
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5.5 PHARMACOLOGICAL INTERVENTION 
In the last part of the general discussion the influence of ~-adrenoceptor 
agonists and antagonists, the role of cyclic AMP, leukotriene antagonists 
and synthesis inhibitors are subjects of discussion. 
5.5.1 Beta-adrenergic agonists. 
Adrenergic substances stimulate the ~2-receptor of smooth muscle cells. 
This leads to an increase in cyclic-AMP and subsequently to relaxation. 
In experiments described in paragraphs 3.2.4, 3.2.3 and 3.2.5 the effects 
of ~-adrenoceptor agonists and antagonists in LT-induced contractions of 
the guinea pig lung parenchyma were investigated. Isoprenaline reversed 
the LTC4-induced contraction of the GPLP and inhibited the release of TxA2 
from the GPLP. The ~-adrenoceptor antagonist sotalol counteracted these 
effects. The specific ~2-agonist salbutamol mimicked the results obtained 
by isoprenaline, whereas the phosphodiesterase inhibitor isobutyl-methyl-
xanthine (IBMX) had an identical activity [Zijlstra et al., 1983a]. 
In platelets, activation of adenylate cyclase and subsequent enhancement 
of intracellular cyclic-AMP results in a decrease in the release of TxA2 
[Minkes et al., 1977]. Adrenergic substances stimulate the ~2-receptor of 
the smooth muscle cells. This leads to an increase in cyclic AMP, 
inhibition of the secretion of mediators and consequently relaxation of 
smooth muscle. 
5.5.2 Leukotriene antagonists. 
The anti-bronchoconstrictive effect of corticosteroids can possibly be 
attributed to the inhibition of phospholipase A2 and the subsequent 
decrease in formation of eicosanoids. Inhibition of the release of 
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mediators from the mast cell by cromoglycate can also result in a 
reduction of smooth muscle constriction upon challenge with triggers. The 
limited effects of histamine antagonists indicated that histamine might 
not play a dominant role in many processes leading to bronchoconstriction. 
Therefore studies on the effect of LT synthesis inhibitors and antagonists 
became interesting. 
In paragraph 3.2.1 the effect of FPL 55712, an antagonist of SRS-A, on 
the LT-induced contraction of the GPLP is described. The remaining direct 
contractile effect of LTC4 after the addition of indomethacin to the 
superfusion buffer, was almost completely abolished. The clinical and 
therapeutic usefulness of FPL 55712 in naturally occurring diseases of 
man, e.g. allergic asthma, will depend upon the final results arising from 
the use of FPL 55712 as an aerosol in experimental models. The short 
biological half-life (T~ = 0.6 min in guinea pig i.v.) is one of the 
problems to be solved [Chand, 1979]. 
Another recently introduced pharmacological antagonist of LT-induced 
bronchoconstriction is SKF 88046 [Weichmann et al., 1984]. The results 
obtained by the administration of this compound demonstrated that its 
effect is based on an indirect, Tx-dependent inhibition of LTD4 in the 
guinea pig, presumably via thromboxane antagonism. 
5.5.3 Lipoxygenase inhibitors. 
Much effort was made to obtain a specific 5-lipoxygenase inhibitor. If 
leukotrienes are ultimately established as major mediators of distinct 
disorders, selective leukotriene synthesis inhibitors may offer an 
advantage as a therapy in major aspects of allergic airway disease and 
inflammatory processes. 
The ability of retinoids to inhibit the generation of chemotactic LTB4 
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can be considered as an explanation of the activity of such compounds as 
inhibitors of inflammatory cell accumulation in diseases such as psoriasis 
[Bray, 1984]. Another non-specific lipoxygenase inhibitor is caffeic 
acid. It inhibits both the leukotriene synthesis and the 12-HPETE 
synthesis, whereas platelet aggregation and the biosynthesis of 
thromboxane tended to decrease [Koshihara et al., 1984]. 
During the last few years a number of drugs were described which inhibit 
lipoxygenase pathways. A summary is given by Beetens et al. [1986], who 
tested the inhibition of the oxygenation reactions in several in-vitro 
systems. The relative potency of the various compounds is nor-dihydro-
guaiaretic acid (NDGA) > nafazatrom > phenidone > ketoconazole > BW-755C, 
for the 5-lipoxygenase pathway. However, none of these compounds 
specifically inhibited this particular pathway. Differences occurred in 
the dosages necessary to obtain inhibition of the 12- and 15-lipoxygenase 
pathways, and in the ability to influence parts of the cyclooxygenase 
pathway. 
Recently more selective inhibitors of 5-lipoxygenase were introduced. 
AA-861 dose-dependently inhibited LTB4 and LTC4 generation by human 
polymorphonuclear leukocytes with rc50 values of 0.3 ~and 0.01 ~M 
respectively, being about 1000 times more potent than BW-755C [Mita et 
a1.,1986]. Auranofin (AF) is a newly introduced oral gold compound, having 
antirheumatic properties, with differential inhibitory effects on LTB4 and 
LTC4 formation by human leukocytes [Honda et a1.,1987]. rc50 values of 
this compound are extremely higher than those of AF,_ being 100 ~M and 14 
~ respectively. 
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5.5.4 Malotilate. 
As presented in paragraph 4.2.5, our results with malotilate suggest a 
new mechanism of action for this compound as a specific 5-lipoxygenase 
inhibitor. Malotilate has been shown to protect against injury of the 
liver, chronic hepatitis, alcohol intoxi~ation and fibrotic liver. It 
inhibits collagenous fibre formation under ordinary cell culture 
conditions. Because macrophages are involved in liver damage and 
fibrosis, the effect of malotilate on the synthesis of arachidonic acid 
metabolites was investigated. The scope of the initial study was to 
establish whether the in vivo effects of malotilate are related to the 
modulation of inflammatory modulators, such as the eicosanoids. 
In the in vitro set-up macrophages isolated from ascitic fluid of 
patients with alcoholic liver cirrhosis were incubated with 14c-AA and 
triggered with calcium ionophore A23187. Separation and quantitation was 
performed on HPLC. In a second series of experiments the endogenous 
formation of eicosanoids, triggered with ionophore, was measured with RIA. 
Both the exogenous and endogenous formation of the 5-lipoxygenase products 
LTB4 and 5-HETE was inhibited, whereas the 12- and' 15-HETE tended to 
increase. The formation of the cyclooxygenase products TxB2 , 6-keto-PGF1a 
and PGD2 was also inhibited, but at a Ic50 being 10 times higher than that 
of 5-lipoxygenase. 
As mentioned before the inhibitory effect of the hydroperoxides on the 
thromboxane synthetase and prostacyclin synthetase was described by 
Vanderhoek. This finding was confirmed by experiments performed with 
sheep seminal vesicles, in the presence of 14C-AA and malotilate, in which 
only cyclooxygenase compounds were synthetized. The formation of 
hydroperoxides was inhibited by the addition of ascorbic acid to the 
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medium. No inhibitory effect of malotilate was observed, in contrast to 
the inhibition of cyclooxygenase products by indomethacin (Ic50 6 pM). 
Malotilate was less potent than NDGA (rc50 resp. 4.8 and 1.4 pM) on 5-
lipoxygenase, but appeared to have no direct inhibitory effect on the 
other lipoxygenase pathways. This behaviour was more or less identical to 
that of ketoconazole. 
The development of specific 5-lipoxygenase inhibitors opens new perspec-
tives for the study of the role of leukotrienes in disease processes. 
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SUMMARY 
Since the discovery of the leukotrienes it has become clear that these 
substances, and in particular the sulphidopeptide leukotrienes, are 
involved in asthmatic and inflammatory processes. The aim of the 
investigations described in this thesis was to gain more insight into the 
biological effects of leukotrienes on lung parenchymal tissue and the 
formation of these substances by (inflammatory) cells and tissues. The 
mechanism of action and metabolism was investigated in the presence of 
agonists, antagonists, blockers and synthes~s inhibitors. 
Contractions of the guinea pig lung parenchymal strip (GPLP), induced by 
the leukotrienes c4 or D4 are biphasic. The initial part is due to the 
fast release of thromboxane A2 (TxA2 ), whereas the slow long-lasting 
effect is caused by the direct action of LT itself. Repeated application 
of LTC4 to parenchymal tissue results in the development of tachyphylaxis. 
It was found, however, that the tachyphylaxis to the induced formation of 
TxA2 was greater than that to the contractile response. The addition of 
a-adrenoceptor 
preferentially 
agonists, 
inhibited 
such as isoprenaline and salbutamol, 
TxA2 production with less effect on the 
contraction of this tissue. Indications that this effect was initiated 
via an increase of cellular cAMP were obtained by an investigation in 
which the phosphodiesterase inhibitor IBMX was used, with identical 
effects as the a-adrenoceptor agonists. Addition of a ~-adrenoceptor 
antagonist, such as sotalol and propranolol, to the superfusion system 
reversed both the inhibition of the contraction and the release of TxA2 . 
There was no marked difference observed between the ~ 1 , 2 -agonist and the 
specific a2-agonist. 
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The release of TxA2 and the contractile effects induced after 
application of LTs or phospholipase A2 (PLA2 ) to human and porcine lung 
parenchymal strips were considerably less than found with the GPLP. 
Application of LTs and PLA2 to the GPLP in distinct order indicated that 
two or more pools of arachidonic acid are present which generate TxA2 • 
Addition of indomethacin, a specific cyclooxygenase inhibitor, to the 
superfusion system, totally inhibited the LT-induced TxA2 release, whereas 
only a small part of the contraction was abolished. FPL 55712, a SRS-A 
antagonist nearly completely counteracted the LT-induced contraction of 
the GPLP. The constrictive activities of LTC4 and a thromboxane A2 
mimetic appeared to be much more potent than those induced by other 
eicosanoids and bronchoconstrictive agents (histamine, acetylcholine and 
5-hydroxytryptamine) in both the GPLP and human small airway smooth 
muscle. 
The introduction of high performance liquid chromatography increased the 
possibilities to measure prostaglandins, leukotrienes and other 
arachidonic acid metabolites in body fluids or cell incubates. In addition 
the availability of specific antisera for these substances made it 
possible to characterize and quantitize these metabolites in femtomoles. 
Work-up procedures for fluids and extracts were considerably simplified by 
the introduction of disposable cartridge systems. Finally the enormous 
development in computing controlled systems contributed for a large part 
to the progress of these measurements. 
Levels of sulphidopeptide LTs were measured in lung lavage fluids and 
LTB4 and 15- and 12-HETE in mucus of a patient with ulcerative procto 
colitis. In 14c-arachidonic acid loaded chopped human lung tissue mostly 
LTB4-like substances were formed and less leukotrienes c 4 ,n4 and E4 , 
whereas large amounts of mono hydroxy eicosatetraenoic acids were 
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generated. PGD2 appeared to be the most common cyclooxygenase product. 
Differences were observed between the amounts formed from endogenous and 
exogenous by applied arachidonic acid. 
Macrophages isolated from fluids of patients with peritonitis and liver 
cirrhosis generated mainly the 5-lipoxygenase products LTB4 and 5-HETE, 
depending on the severity of the inflammation. The cyclooxygenase 
products 6-keto-PGF 1 ~ and TxB2 were the most important prostaglandin-like 
substances. Malotilate, an anti-fibrotic substance, selectively inhibited 
the 5-lipoxygenase, whereas both the 12- and the 15-lipoxygenase pathways 
were stimulated. The e~~ects o~ malotilate on eicosanoid production 
di~~er ~rom those o~ known lipoxygenase inhibitors. Such di~~erential 
e~~ects have not previously been reported. The inhibition o~ the 5-
lipoxygenase pathway, and thus o~ the production o~ LTB4 , which plays a 
major role in the regulation o~ the immune response through numerous and 
varied e~~ects on several cell types, and the inhibition 0~ the ~ormation 
o~ vasoconstrictive TxA2 , provide possibilities ~or the bene~icial e~~ects 
o~ this drug in in~lammatory diseases. 
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SAMENVATTING 
Sinds de ontdekking van leukotrienen is het duidelijk geworden dat deze 
stoffen, en met name de sulfido peptide houdende leukotrienen, zijn 
betrokken bij asthmatische en ontstekingsprocessen. De onderzoekingen die 
in dit proefschrift zijn gebundeld omvatten twee hoofdonderwerpen, 
namelijk de biologische effekten van leukotrienen op long parenchym 
weefsel en voorts de vorming van deze stoffen door (ontstekings) cellen 
en weefsel. Het werkingsmechanisme en de omzetting naar andere produkten 
werden bestudeerd in tegenwoordigheid van farmaca die de effekten 
blokkeren of de synthese remmen. 
Contracties van de cavia long parenchym strip (GPLP), opgewekt door de 
leukotrienen c4 en D4 zijn bifasisch in de wijze waarop ze tot stand 
komen. Het eerste traject van de contractie wordt veroorzaakt door de 
snelle afgifte van thromboxane A2 (TxA2 ), terwijl het langzame 
aanhoudende effekt teweeg wordt gebracht door de direkte werking van LT 
zelf. Herhaalde toediening van LTC4 aan parenchym weefsel heeft een 
uitputting van het systeem tot gevolg. Er werd echter gevonden dat er een 
grotere uitputting van het gevormde TxA2 optrad dan wat werd waargenomen 
aan teruglopende respons van de contractie. Toevoeging van de ~-adrenerge 
stoffen isoprenaline en salbutamol aan de superfusiebuffer hadden met 
name een grote remmende invloed op de TxA2 synthese terwijl het 
samentrekkende effekt van LT slechts ten dele werd gereduceerd. 
Aanwijzingen dat dit effekt tot stand werd gebracht via een toename van 
het cellulaire cyclisch AMP werden ondermeer bevestigd door experimenten 
waarin de fosfodiesterase remmer IBMX werd gebruikt, waarbij 
vergelijkbare resultaten werden verkregen. Als vervolgens een ~-
169 
adrenoceptor antagonist aan het systeem werd toegevoegd, zoals sotalol en 
propranolol, dan bleken zowel het TxA2 vormend als het contractieve 
effekt reversibel te zijn. Opmerkelijke verschillen tussen een 
agonist en een specifieke 82-agonist werden niet waargenomen. 
Het vrijkomen van TxA2 en de contractie geinduceerd door toediening van 
LTs of fosfolipase A2 (PLA2 ) aan humane en varkens long strips vertoonden 
reakties die slechts een paar procent bedroegen ten opzichte van de 
verkregen effekten met de cavia long strip. Toediening van LTs en PLA2 
aan de GPLP in verschillende volgorde gaven aan dat er sprake kan zijn 
van twee of meer opslagplaatsen van arachidonzuur in de eel waaruit de 
vorming van TxA2 tot stand komt na aktivatie. Onder invloed van aan het 
superfusiesysteem toegevoegd indomethacine, een cyclooxygenase remmer, 
wordt een totale inhibitie van de LT geinduceerde TxA2 vorming 
bewerkstelligd, hoewel slechts een gedeeltelijke afname van de 
longstripcontractie verkregen wordt. De SRS-A antagonist FPL 55712 bleek 
de contractie van de GPLP door LT totaal te blokkeren. De constrictieve 
aktiviteiten van LTC4 en een op thromboxane A2 lijkende stof vertoonden 
een veel grotere aktiviteit dan andere aracnidonzuur metabolieten en in 
het lichaam voorkomende bronchoconstrictieve stoffen, bij zowel de GPLP 
als stripjes van humane luchtwegen. 
De introduktie van de hoge druk vloeistof chromatografie vergrootte de 
mogelijkheden om prostaglandinen, leukotrienen en andere arachidonzuur 
metabolieten te meten in lichaamsvloeistoffen of inkubatiemedia van 
cellen. Bovendien maakte de beschikbaarheid van specifieke antisera voor 
deze substanties het mogelijk om ze te karakterizeren en hoeveelheden te 
bepalen in de femtomolen range. Opwerkingsprocedures voor vloeistoffen en 
extracten werden aanzienlijk vereenvoudigd door de invoering van wergwerp 
zuiveringssystemen. Tot slot heeft de enorme ontwikkeling in de 
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computergestuurde systemen voor een belangrijk deel bijgedragen in de 
voortgang van meetmethoden. 
Zodoende konden sulfidopeptide houdende leukotrienen ook gemeten worden 
in long spoelingen van patienten en was het technisch uitvoerbaar LTB4 en 
15- en 12-HETE in darmslijm van een patient met een ulceratieve procto 
colitis te meten. Het vormend vermogen van cellen om na het verzadigen 
met 14c-arachidonzuur metabolieten ~e vormen werd zo eenvoudig vast te 
stellen. Humaan long weefsel bleek voornamelijk LTB4-achtige 
verbindingen te vormen en beduidend minder van de leukotrienen c 4 , n4 en 
E4 , hoewel niet onaanzienlijke hoeveelheden monohydroxy verbindingen van 
arachidonzuur werden gevormd. 
cyclooxygenase component 
Het prostaglandine n2 bleek de voornaamste 
te zijn. Duidelijke verschillen werden 
vastgesteld tussen de endogene en exogene gevormde hoeveelheden. 
Macrofagen verkregen na isolatie uit vloeistoffen van patienten met een 
buikontsteking en leveraandoeningen zijn in staat voornamelijk en in 
grote mate verbindingen van de 5-lipoxygenase ·,route te vo.rmen, .de 
produkten LTB4 en 5-HETE, afhankelijk van de ernst van de ontsteking. De 
cyclooxygenase produkten 6-keto-PGF1a en TxB2 waren daarnaast de meest 
voorkomende prostaglandine achtige metabolieten. Malotilate, een stof met 
anti fibrotische werking, blijkt zeer selektief de 5-lipoxygenase route 
te remmen, terwijl zowel de 12- als de 15-lipoxygenase routes niet geremd 
doch gestimuleerd worden, resulterend in een neveneffekt waarbij de 
vorming van genoemde cyclooxygenase verbindingen licht geremd'worden. 
Deze effekten van Malotilate op de arachidonzuur produkten verschillen 
van die welke bekend zijn van als zodanig aangeduide lipoxygenase 
remmers. Dergelijke verschillen in effekten zijn nog niet eerder 
waargenomen. De remming van de 5-lipoxygenase route, en daarmee de 
vorming van bijvoorbeeld LTB4 , welke een belangrijke rol vervult in de 
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regulering van het immuunsysteem via talrijke en gevarieerde effekten op 
verschillende cellen, en bovendien de remming van de bloedvatvernauwende 
stof TxA2 , geven mogelijkheden om dit farmacon op termijn te gebruiken 
ala substantie bij allerlei onstekingsprocessen. 
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Tot slot wil ik mijn sponsors danken voor de financi~le ondersteuning, 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd geboren op 2 januari 1953 te 
Rotterdam-Overschie. Na ter plaatse de lagere- en middelbare school 
doorlopen te hebben, werd aanvankelijk een opleiding gevolgd aan de HTS 
(studierichting elektronica) te Rotterdam, doch wegens langdurige ziekte 
afgebroken en omgezet in een HBO-opleiding tot chemisch analist aan het 
Van 't Hoff Instituut te Rotterdam, van 1971 tot 1975. Op 23 oktober 1973 
werd een aanstelling als analist verkregen aan de Medische Faculteit te 
Rotterdam binnen het instituut Farmacologie (beheerder: prof. dr. I.L. 
Bonta) en toegevoegd als assistent aan dr. J.E. Vincent. 
Diverse cursussen op het gebied van de radiochemie werden gevolgd, 
afgesloten met de C-akte stralingsbescherming in 1978. 
In de zeventiger jaren werd onderzoek gedaan naar mediatoren bij de 
aggregatie van bloedplaatjes en ontstekingsprocessen. Hierbij werd 
gebruik gemaakt van de superfusie cascade methode en in later stadium van 
radioimmunoassays (RIA's). 
Het vormingspatroon van radioaktieve arachidonzuurmetabolieten werd 
onderzocht in verschillende organen van proefdieren, gebruik makend van 
dunnelaagchromatografie, toegespitst op essenti~le vetzuurdefici~ntie. 
Na de ontdekking van leukotri~nen werd in 1980 begonnen met een in vitro 
model van de cavia long strip waarbij biologische aktiviteiten 
geregistreerd en gevormde metabolieten gemeten konden worden, in 
samenwerking met prof.dr. I.L. Bonta. 
De snelle opkomst van de HPLC leidde in 1983 tot het ontwikkelen van 
geschikte scheidingsmethoden van alle mogelijke produkten van 
arachidonzuur. In combinatie met de reeds genoemde RIA's en superfusie 
methode werd zo de mogelijkheid gecre~erd een compleet beeld te krijgen 
van in het lichaam aanwezige hoeveelheden, vormingspatronen en biologische 
aktiviteiten van eicosanoiden. 
Deze ongekende mogelijkheden hebben geleid tot vele vruchtbare 
samenwerkingsverbanden binnen de facultaire gemeenschap, met andere 
universiteiten en op internationaal nivo met de farmaceutische industrie. 
Het totaal aantal publikaties waarvan hij (mede)auteur is hebben de 60 
reeds overschreden. Een 10-tal presentaties van eigen werk werd gehouden. 
Enkele onderzoeken hebben een bijdrage geleverd in het tot stand komen 
van dissertaties 
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stagiaires begeleid 
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